Adalimumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Adalimumab comprises 1,025 peer-reviewed publications across 15 journals, 175 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Arthritis, Rheumatoid, Crohn Disease, Psoriasis, and Colitis, Ulcerative. Most recent publication: Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year., Dermatol Ther (Heidelb), 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
    Thaçi D, Vender R, de Rie MA, et al. · Br J Dermatol · 2023
    PubMed: PMID 36689515 · NCT03412747 (BE SURE) · Psoriasis
  2. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
    Ritchlin CT, Coates LC, McInnes IB, et al. · Ann Rheum Dis · 2023
    PubMed: PMID 37696588 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  3. Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial.
    Nanchahal J, Ball C, Rombach I, et al. · Lancet Rheumatol · 2025
    PubMed: PMID 35949922 · NCT03180957 (RIDD) · Dupuytren Contracture
  4. Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis.
    Moulin D, Millard M, Taïeb M, et al. · Ann Rheum Dis · 2024
    PubMed: PMID 38049981 · NCT01382160 (AFORA) · Arthritis, Rheumatoid
  5. Activated Peripheral Blood B Cells in Rheumatoid Arthritis and Their Relationship to Anti-Tumor Necrosis Factor Treatment and Response: A Randomized Clinical Trial of the Effects of Anti-Tumor Necrosis Factor on B Cells.
    Meednu N, Barnard J, Callahan K, et al. · Arthritis Rheumatol · 2022
    PubMed: PMID 34347945 · NCT00837434 · Arthritis, Rheumatoid
  6. Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial.
    Gottenberg JE, Brocq O, Perdriger A, et al. · JAMA · 2022
    PubMed: PMID 27654603 · NCT01000441 (ROC) · Arthritis, Rheumatoid
  7. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
    Gordon KB, Langley RG, Warren RB, et al. · Br J Dermatol · 2024
    PubMed: PMID 37950894 · NCT03412747 (BE SURE) · Psoriasis
  8. Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.
    Acharya NR, Ramanan AV, Coyne AB, et al. · Lancet · 2025
    PubMed: PMID 39863370 · NCT03816397 (ADJUST) · Uveitis

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT00048542Arthritis, JuvenileNumber of Subjects in the Non-MTX Stratum With Disease Flare During the Double-Blind Phase
Week 16 to Week 48 (32 weeks)
Double-Blind Adalimumab13 Participants
Double-Blind Placebo20 Participants
NCT00055497
CLASSICII
Crohn DiseaseNumber of Randomized Participants Achieving Clinical Remission at Week 56 - Last Observation Carried Forward (LOCF)
Week 56
DB Adalimumab 40 mg Every Other Week (Eow)15 Participants
DB Adalimumab 40 mg Every Week (ew)15 Participants
DB Placebo8 Participants
NCT00055497
CLASSICII
Crohn DiseaseNumber of Randomized Participants Achieving Clinical Remission at Week 56 - Non-Responder Imputation (NRI)
Week 56
DB Adalimumab 40 mg Every Other Week (Eow)9 Participants
DB Adalimumab 40 mg Every Week (ew)12 Participants
Placebo6 Participants
NCT00085644
ATLAS
Spondylitis, AnkylosingMean Change in the Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) Compared Against a Historical Control Group (Outcomes in Ankylosing Spondylitis International Study [OASIS]) Using the ANCOVA Model Adjusting for Baseline mSASSS Score
Week 104
Any Adalimumab0.9 score on a scale (±0.19 Standard Error)
Any Adalimumab0.9 score on a scale (±0.23 Standard Error)
NCT00085644
ATLAS
Spondylitis, AnkylosingNumber of Responders With a Reduction of Signs and Symptoms of Ankylosing Spondylitis (AS) as Measured With ASAS International Working Group Response Criteria (ASAS 20).
Week 12
Adalimumab83 Participants (responders, nonresponders)
Adalimumab121 Participants (responders, nonresponders)
Adalimumab4 Participants (responders, nonresponders)
Placebo22 Participants (responders, nonresponders)
Placebo3 Participants (responders, nonresponders)
Placebo82 Participants (responders, nonresponders)
NCT00195650Arthritis, RheumatoidChange From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 260
Baseline of prior Phase 1, 2, or 3 adalimumab study and Week 260
Adalimumab-0.59 units on a scale (±0.628 Standard Deviation)
NCT00195650Arthritis, RheumatoidChange From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 520
Baseline of prior Phase 1, 2, or 3 adalimumab study and Week 520
Adalimumab-0.52 units on a scale (±0.662 Standard Deviation)
NCT00195650Arthritis, RheumatoidNumber of Participants in Clinical Remission (Based on Modified Disease Activity Score) at Week 260
Week 260
Adalimumab243 participants
NCT00195650Arthritis, RheumatoidNumber of Participants in Clinical Remission (Based on Modified Disease Activity Score) at Week 520
Week 520
Adalimumab135 participants
NCT00195650Arthritis, RheumatoidNumber of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 260
Week 260
Adalimumab402 participants
NCT00195650Arthritis, RheumatoidNumber of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 520
Week 520
Adalimumab187 participants
NCT00195650Arthritis, RheumatoidNumber of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 260
Week 260
Adalimumab279 participants
NCT00195650Arthritis, RheumatoidNumber of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 520
Week 520
Adalimumab132 participants
NCT00195650Arthritis, RheumatoidNumber of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 260
Week 260
Adalimumab179 participants
NCT00195650Arthritis, RheumatoidNumber of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 520
Week 520
Adalimumab78 participants
NCT00195663
PREMIER
Arthritis, RheumatoidChange From Baseline in Modified Total Sharp Score (mTSS) at Week 52
Baseline and Week 52
Adalimumab3.0 units on a scale (±11.2 Standard Deviation)
Adalimumab + Methotrexate1.3 units on a scale (±6.5 Standard Deviation)
Methotrexate5.7 units on a scale (±12.7 Standard Deviation)
NCT00195663
PREMIER
Arthritis, RheumatoidNumber of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 52
Baseline and 52 Weeks
Adalimumab113 participants
Adalimumab + Methotrexate165 participants
Methotrexate118 participants
NCT00195676PsoriasisPercentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R
Week 16 of Period R
Period R Modified Intent-to-Treat Population76.5 percentage of participants
NCT00195702Arthritis, RheumatoidChange From Baseline in Modified Total Sharp X-ray Score at Week 52
Baseline and Week 52
DB Adalimumab 20 mg ew0.8 Units on a scale (±4.9 Standard Deviation)
DB Adalimumab 40 mg Eow0.1 Units on a scale (±4.8 Standard Deviation)
DB Placebo ew2.7 Units on a scale (±6.8 Standard Deviation)
NCT00195702Arthritis, RheumatoidChange From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52
Baseline and Week 52
DB Adalimumab 20 mg ew-0.61 Units on a scale (±0.55 Standard Deviation)
DB Adalimumab 40 mg Eow-0.59 Units on a scale (±0.57 Standard Deviation)
DB Placebo ew-0.25 Units on a scale (±0.56 Standard Deviation)
NCT00195702Arthritis, RheumatoidNumber of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24
Week 24
DB Adalimumab 20 mg ew129 Participants
DB Adalimumab 40 mg Eow131 Participants
DB Placebo ew59 Participants
NCT00195715Crohn DiseasePercentage of Subjects Achieving Clinical Remission
Week 156
Open-label Adalimumab69.5 Percentage of participants
Open-label Adalimumab46.7 Percentage of participants
Open-label Adalimumab68.8 Percentage of participants
Open-label Adalimumab59.4 Percentage of participants
NCT00195819Spondylitis, AnkylosingMean Change in the Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) Compared Against a Historical Control Group (Outcomes in Ankylosing Spondylitis International Study [OASIS]) Using the ANCOVA Model Adjusting for Baseline mSASSS Score
Baseline and Week 104
Any Adalimumab0.5 score on a scale (±0.36 Standard Error)
Any Adalimumab0.9 score on a scale (±0.23 Standard Error)
NCT00195819Spondylitis, AnkylosingNumber of Subjects With a Reduction in Signs and Symptoms as Measured by Assessments of Ankylosing Spondylitis (ASAS) 20 Response at Week 12
Week 12
Adalimumab20 participants
Adalimumab0 participants
Adalimumab18 participants
Placebo0 participants
Placebo12 participants
Placebo32 participants
NCT00235872Arthritis, RheumatoidNumber of Subjects With American College of Rheumatology (ACR) Criteria Improvement Consisting of 20%, 50%, and 70% (ACR20/50/70 Responders, Respectively)
Every 4 weeks up to Week 24 and every 12 weeks thereafter until Study completion or discontinuation (final value)
Adalimumab 40 mg Eow155 participants
Adalimumab 40 mg Eow58 participants
Adalimumab 40 mg Eow104 participants
Adalimumab 40 mg Eow166 participants
Adalimumab 40 mg Eow0 participants
Adalimumab 40 mg Eow1 participants
Adalimumab 40 mg Eow1 participants
Adalimumab 40 mg Eow4 participants
Adalimumab 40 mg Eow7 participants
Adalimumab 40 mg Eow8 participants
Adalimumab 40 mg Eow8 participants
Adalimumab 40 mg Eow16 participants
Adalimumab 40 mg Eow24 participants
Adalimumab 40 mg Eow16 participants
Adalimumab 40 mg Eow33 participants
Adalimumab 40 mg Eow47 participants
Adalimumab 40 mg Eow28 participants
Adalimumab 40 mg Eow42 participants
Adalimumab 40 mg Eow27 participants
Adalimumab 40 mg Eow47 participants
Adalimumab 40 mg Eow25 participants
Adalimumab 40 mg Eow47 participants
Adalimumab 40 mg Eow63 participants
Adalimumab 40 mg Eow27 participants
Adalimumab 40 mg Eow49 participants
Adalimumab 40 mg Eow68 participants
Adalimumab 40 mg Eow23 participants
Adalimumab 40 mg Eow41 participants
Adalimumab 40 mg Eow63 participants
Adalimumab 40 mg Eow43 participants
Adalimumab 40 mg Eow72 participants
Adalimumab 40 mg Eow27 participants
Adalimumab 40 mg Eow61 participants
Adalimumab 40 mg Eow62 participants
Adalimumab 40 mg Eow104 participants
Adalimumab 40 mg Eow22 participants
Adalimumab 40 mg Eow157 participants
Adalimumab 40 mg Eow74 participants
Adalimumab 40 mg Eow30 participants
Adalimumab 40 mg Eow154 participants
Adalimumab 40 mg Eow74 participants
Adalimumab 40 mg Eow40 participants
Adalimumab 40 mg Eow154 participants
Adalimumab 40 mg Eow83 participants
Adalimumab 40 mg Eow39 participants
Adalimumab 40 mg Eow148 participants
Adalimumab 40 mg Eow81 participants
Adalimumab 40 mg Eow46 participants
Adalimumab 40 mg Eow155 participants
Adalimumab 40 mg Eow77 participants
Adalimumab 40 mg Eow46 participants
Adalimumab 40 mg Eow91 participants
Adalimumab 40 mg Eow49 participants
Adalimumab 40 mg Eow81 participants
Adalimumab 40 mg Eow33 participants
Adalimumab 40 mg Eow63 participants
Adalimumab 40 mg Eow92 participants
Adalimumab 40 mg Eow45 participants
Adalimumab 40 mg Eow75 participants
Adalimumab 40 mg Eow118 participants
Adalimumab 40 mg Eow47 participants
Adalimumab 40 mg Eow86 participants
Adalimumab 40 mg Eow141 participants
Adalimumab 40 mg Eow52 participants
Adalimumab 40 mg Eow99 participants
Adalimumab 40 mg Eow158 participants
Adalimumab 40 mg Eow50 participants
Adalimumab 40 mg Eow99 participants
Adalimumab 40 mg Eow163 participants
Adalimumab 40 mg Eow46 participants
Adalimumab 40 mg Eow52 participants
Adalimumab 40 mg Eow24 participants
NCT00348283Crohn DiseaseNumber of Subjects Without Mucosal Ulceration at Week 12
Week 12
Adalimumab17 Subjects
Placebo8 Subjects
NCT00385736Colitis, UlcerativeProportion of Participants With Clinical Remission Per Mayo Score at Week 8
Week 8
Adalimumab 160/80/4018.5 Proportion of participants
Adalimumab 80/4010.0 Proportion of participants
Placebo9.2 Proportion of participants
NCT00408629Colitis, UlcerativeProportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52
Week 52
Adalimumab 160/80/4017.3 Percentage of Participants
Placebo8.5 Percentage of Participants
NCT00408629Colitis, UlcerativeProportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8
Week 8
Adalimumab 160/80/4016.5 Percentage of Participants
Placebo9.3 Percentage of Participants
NCT00409617Crohn DiseaseNumber of Participants in Clinical Remission at Treatment Week 20. Clinical Remission Defined as Harvey Bradshaw Index (HBI) Score Less Than 5.
Week 20 of treatment
Open Label Adalimumab 40 mg Every Other Week or Every Week492 Participants
NCT00409682Crohn DiseasePercent of Participants With Clinical Remission as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤ 10 at Week 26
Week 26
High-Dose Adalimumab: 40 mg or 20 mg Eow (Week 4 to Week 52)38.7 percent of participants
Low-Dose Adalimumab: 20 mg or 10 mg Eow (Week 4 to Week 52)28.4 percent of participants
NCT00427921
ACCESS
Crohn DiseaseCompliance With Number of Injections of Adalimumab. Compliance Corresponds to Patients Who Received Their Injections.
Up to 24 weeks
40 mg Adalimumab Every Other Week98.85 Percentage of injections (±4.207 Standard Deviation)
NCT00427921
ACCESS
Crohn DiseaseMean Extent of Exposure - Duration in Days
Up to 24 weeks
40 mg Adalimumab Every Other Week159.2 days (±34.78 Standard Deviation)
NCT00427921
ACCESS
Crohn DiseaseTotal Number of Injections of Adalimumab
Up to 24 weeks
40 mg Adalimumab Every Other Week2 injections (±0.1 Standard Deviation)
40 mg Adalimumab Every Other Week11.8 injections (±4.24 Standard Deviation)
NCT00445432Crohn DiseaseNumber of Participants Who Had Clinical Remission at Week 52 of Double-blind Treatment
Week 52 of double-blind treatment
DB Adalimumab 40 mg Eow8 Participants
Placebo Eow2 Participants
NCT00445939Crohn DiseaseThe Number of Subjects With a Clinical Remission (Crohn's Disease Activity Index [CDAI] < 150) at Week 4
4 Weeks
Adalimumab 160 mg/80 mg11 Particpants
Adalimumab 80 mg/40 mg6 Particpants
Placebo3 Particpants
NCT00513370
PRIDE
PsoriasisNumber of Subjects With Psoriasis Area and Severity Index (PASI) 75 Response at 16 Weeks
16 weeks
Adalimumab 40 mg Eow - 16 Weeks144 participants
Adalimumab 40 mg Eow - 16 Weeks47 participants
NCT00538902Arthritis, RheumatoidNumber of Participants With American College of Rheumatology (ACR)20 at Week 12 of the Double-Blind Period
Week 12
Adalimumab 40 mg69 Participants
Adalimumab 80 mg62 Participants
Placebo21 Participants
NCT00566722PsoriasisNumber of Participants Who Achieved a Physician's Global Assessment (PGA) of Clear (0) or Minimal (1) at Week 16
Week 16
Sub-optimal Response to Etanercept40 Participants
Sub-optimal Response to MTX25 Participants
Sub-optimal Response to Narrow-band Ultraviolet-B14 Participants
NCT00573794Colitis, UlcerativeMayo Score: Change From Baseline Over Time
Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Adalimumab 40 mg EOW/EW3.5 units on a scale (±2.72 Standard Deviation)
Adalimumab 40 mg EOW/EW-0.5 units on a scale (±2.49 Standard Deviation)
Adalimumab 40 mg EOW/EW-0.3 units on a scale (±2.64 Standard Deviation)
Adalimumab 40 mg EOW/EW-0.8 units on a scale (±2.73 Standard Deviation)
Adalimumab 40 mg EOW/EW-2.0 units on a scale (±1.73 Standard Deviation)
Adalimumab 40 mg EOW/EW-1.3 units on a scale (±2.87 Standard Deviation)
Adalimumab 40 mg EOW/EW-0.9 units on a scale (±2.84 Standard Deviation)
Adalimumab 40 mg EOW/EW-1.0 units on a scale (±2.40 Standard Deviation)
Adalimumab 40 mg EOW/EW-0.8 units on a scale (±2.52 Standard Deviation)
NCT00573794Colitis, UlcerativePartial Mayo Score: Change From Baseline Over Time
Baseline (Week 0), Weeks 48, 96, 144, 192, 240, 292, 340, 388
Adalimumab 40 mg EOW/EW-2.0 units on a scale (±1.00 Standard Deviation)
Adalimumab 40 mg EOW/EW-0.6 units on a scale (±1.84 Standard Deviation)
Adalimumab 40 mg EOW/EW-0.5 units on a scale (±2.06 Standard Deviation)
Adalimumab 40 mg EOW/EW-0.4 units on a scale (±1.78 Standard Deviation)
Adalimumab 40 mg EOW/EW-0.2 units on a scale (±2.04 Standard Deviation)
Adalimumab 40 mg EOW/EW2.5 units on a scale (±2.02 Standard Deviation)
Adalimumab 40 mg EOW/EW-1.0 units on a scale (±1.97 Standard Deviation)
Adalimumab 40 mg EOW/EW-0.7 units on a scale (±2.05 Standard Deviation)
Adalimumab 40 mg EOW/EW-0.8 units on a scale (±1.79 Standard Deviation)
NCT00574249
BELIEVE
PsoriasisPercentage of Participants Who Achieve a PASI75 Response at Week 16 Compared With Baseline (Week 0)
Week 0 and Week 16
Adalimumab + Calcipotriol/Betamethasone64.8 percentage of participants
Adalimumab + Placebo70.9 percentage of participants
NCT00603993Arthritis, RheumatoidNumber of Subjects With American College of Rheumatology (ACR) Criteria Improvement of at Least 20%, 50%, and 70% (ACR20/50/70 Responders, Respectively)
Every 4 weeks up to Week 24 and every 12 weeks thereafter until study completion or discontinuation (Final value)
Adalimumab 40 mg or 80 mg Every Other Week (Eow)57 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)35 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)49 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)62 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)3 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)3 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)7 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)16 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)24 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)28 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)29 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)45 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)54 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)27 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)43 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)56 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)29 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)42 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)32 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)47 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)57 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)28 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)44 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)56 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)27 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)46 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)62 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)32 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)45 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)64 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)29 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)48 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)63 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)31 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)49 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)68 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)30 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)49 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)67 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)30 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)50 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)68 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)32 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)45 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)69 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)27 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)44 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)64 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)28 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)48 participants
Adalimumab 40 mg or 80 mg Every Other Week (Eow)66 participants
NCT00647270Arthritis, RheumatoidThe Number of Responders According to the American College of Rheumatology (ACR) 20 Response Criteria at Week 12 Involving the Comparison of Adalimumab 80 mg Monthly Dose Versus Placebo and Adalimumab 40 mg Every Other Week (Eow)
Week 12
Adalimumab 40 mg Eow80 participants
Adalimumab 40 mg Eow79 participants
Adalimumab 80 mg Monthly97 participants
Adalimumab 80 mg Monthly108 participants
Placebo19 participants
Placebo37 participants
NCT00647400PsoriasisNumber of Participants With a 50% Reduction in PASI (Psoriasis Area and Severity Index) Score Compared With Baseline PASI Score (PASI50 Response)
Baseline and 12, 24, 36, 52, 76, 100, 160, and 208 weeks after the first dose of adalimumab
Adalimumab 40 mg Every Other Week80 Participants
Adalimumab 40 mg Every Other Week78 Participants
Adalimumab 40 mg Every Other Week29 Participants
Adalimumab 40 mg Every Other Week76 Participants
Adalimumab 40 mg Every Other Week80 Participants
Adalimumab 40 mg Every Other Week75 Participants
Adalimumab 40 mg Every Other Week71 Participants
Adalimumab 40 mg Every Other Week79 Participants
Adalimumab 80 mg Every Other Week49 Participants
Adalimumab 80 mg Every Other Week51 Participants
Adalimumab 80 mg Every Other Week52 Participants
Adalimumab 80 mg Every Other Week55 Participants
Adalimumab 80 mg Every Other Week52 Participants
Adalimumab 80 mg Every Other Week54 Participants
Adalimumab 80 mg Every Other Week14 Participants
Adalimumab 80 mg Every Other Week47 Participants
NCT00667355Spondylitis, AnkylosingNumber of Subjects Achieving Assessment in Ankylosing Spondylitis 20 (ASAS 20) at Week 12
Week 12
Adalimumab30 Subjects
Adalimumab30 Subjects
Adalimumab30 Subjects
NCT00686374Crohn DiseaseNumber of Participants Who Achieved Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission Over Time
Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408
Any Adalimumab67 Participants
Any Adalimumab60 Participants
Any Adalimumab8 Participants
Any Adalimumab14 Participants
Any Adalimumab59 Participants
Any Adalimumab60 Participants
Any Adalimumab54 Participants
Any Adalimumab60 Participants
Any Adalimumab49 Participants
Any Adalimumab54 Participants
Any Adalimumab54 Participants
Any Adalimumab54 Participants
Any Adalimumab52 Participants
Any Adalimumab51 Participants
Any Adalimumab44 Participants
Any Adalimumab44 Participants
Any Adalimumab36 Participants
Any Adalimumab37 Participants
Any Adalimumab31 Participants
Any Adalimumab24 Participants
Any Adalimumab2 Participants
Any Adalimumab7 Participants
Any Adalimumab67 Participants
Any Adalimumab65 Participants
NCT00686374Crohn DiseaseNumber of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score Over Time
Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408
Any Adalimumab52 Participants
Any Adalimumab53 Participants
Any Adalimumab64 Participants
Any Adalimumab65 Participants
Any Adalimumab70 Participants
Any Adalimumab72 Participants
Any Adalimumab95 Participants
Any Adalimumab72 Participants
Any Adalimumab76 Participants
Any Adalimumab87 Participants
Any Adalimumab92 Participants
Any Adalimumab90 Participants
Any Adalimumab35 Participants
Any Adalimumab43 Participants
Any Adalimumab46 Participants
Any Adalimumab69 Participants
Any Adalimumab28 Participants
Any Adalimumab15 Participants
Any Adalimumab10 Participants
Any Adalimumab8 Participants
Any Adalimumab2 Participants
Any Adalimumab74 Participants
Any Adalimumab82 Participants
Any Adalimumab88 Participants
NCT00690573Arthritis, JuvenileNumber of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 16
Week 16
Adalimumab23 Participants
NCT00775437Arthritis, JuvenileNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)
TEAEs were collected from first dose of study drug until 70 days after the last dose of study drug and before start of commercial adalimumab or other biologics (32.5 months).
Adalimumab29 participants
Adalimumab5 participants
NCT00853099Colitis, UlcerativePercentage of Participants With Clinical Remission at 52 Weeks
Week 52
Adalimumab 160 mg/80 mg20.0 percentage of participants
Adalimumab 80 mg/40 mg26.4 percentage of participants
Placebo7.3 percentage of participants
NCT00853099Colitis, UlcerativePercentage of Participants With Clinical Remission at 8 Weeks
Week 8
Adalimumab 160 mg/80 mg10.0 percentage of participants
Adalimumab 80 mg/40 mg13.8 percentage of participants
Placebo11.5 percentage of participants
NCT00870467Arthritis, RheumatoidChange From Baseline in Modified Total Sharp X-Ray Score at Week 26
Baseline, Week 26
DB Adalimumab1.5 units on a scale (±6.07 Standard Deviation)
DB Placebo2.4 units on a scale (±3.20 Standard Deviation)
NCT00927069—Number of Patients From Group B Who Achieve a Physician's Global Assessment (PGA) of Clear or Almost Clear at Week 12.
12 weeks
Group B11 Participants
NCT00929864Arthritis, RheumatoidThe Proportion of Participants Meeting the American College of Rheumatology (ACR) Criteria of 20% Improvement (ACR20) After 12 Months of Treatment - Intent to Treat Population
Day 1 to Day 365
Abatacept64.8 percentage of participants
Adalimumab63.4 percentage of participants
NCT00939003Axial SpondyloarthritisNumber of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 40 Response
Baseline and Week 12
Double-blind Adalimumab33 participants
Double-blind Placebo14 participants
NCT01064856—Number of Participants With Adverse Events
Baseline (day of first study drug administration) through Week 156 plus 70 days
Double-blind (DB) Adalimumab47 participants
Double-blind (DB) Adalimumab4 participants
Double-blind (DB) Adalimumab21 participants
Double-blind (DB) Adalimumab3 participants
Double-blind (DB) Adalimumab0 participants
Double-blind (DB) Adalimumab18 participants
Double-blind (DB) Adalimumab1 participants
Double-blind Placebo0 participants
Double-blind Placebo0 participants
Double-blind Placebo24 participants
Double-blind Placebo1 participants
Double-blind Placebo45 participants
Double-blind Placebo15 participants
Double-blind Placebo2 participants
NCT01064856—Percentage of Responders According to the Composite Peripheral SpA Response Criteria (PSpARC 40) at Week 12
Week 12
Double-blind (DB) Adalimumab60.7 percentage of participants
Double-blind (DB) Adalimumab39.3 percentage of participants
Double-blind Placebo80.2 percentage of participants
Double-blind Placebo19.8 percentage of participants
NCT01070303
CLASSICII
Crohn DiseaseNumber of Participants Achieving Clinical Remission (Crohn's Disease Activity Index[CDAI] <150 Points) at Week 104 of Study M02-433 (Starting From Week 0 of NCT00055497) (Through 1 Year of Participation in NCT01070303).
Week 104
Non-Remitters71 Participants
Remitters29 Participants
NCT01114880Spondylitis, AnkylosingNumber of Participants Meeting the Assessment of Spondyloarthritis International Society (ASAS) ASAS20 Response Criteria
Week 12
Adalimumab/Adalimumab154 participants
Placebo/Adalimumab35 participants
NCT01124838
Visual II
UveitisTime to Treatment Failure on or After Week 2
From Baseline until end of study (up to 80 weeks)
Integrated Study (Main + Japan Sub-study): AdalimumabNA months
Integrated Study (Main + Japan Sub-study): Placebo5.6 months
Main Study: AdalimumabNA months
Main Study: Placebo8.3 months
NCT01138657
VISUAL l
UveitisTime to Treatment Failure on or After Week 6
From Baseline until end of study (up to 80 weeks)
Integrated Study (Main + Japan Sub-study): Adalimumab4.8 months
Integrated Study (Main + Japan Sub-study): Placebo3.0 months
Main Study: Adalimumab5.6 months
Main Study: Placebo3.0 months
NCT01148225
VISUAL III
UveitisChemistry: Number of Participants With PCS Values
Baseline to Final Visit (Up to 366 weeks)
Adalimumab5 participants
Adalimumab1 participants
Adalimumab2 participants
Adalimumab2 participants
Adalimumab18 participants
Adalimumab7 participants
Adalimumab4 participants
Adalimumab3 participants
Adalimumab2 participants
Adalimumab8 participants
Adalimumab3 participants
NCT01148225
VISUAL III
UveitisDiastolic and Systolic Blood Pressure (Sitting): Mean Change (mmHg) From Baseline To Final Visit
Baseline to Final Visit (Up to 366 weeks)
Adalimumab1.443 mmHg (±10.4373 Standard Deviation)
Adalimumab1.955 mmHg (±14.6281 Standard Deviation)
NCT01148225
VISUAL III
UveitisHematology: Number of Participants With Potentially Clinically Significant (PCS) Values
Baseline to Final Visit (Up to 366 weeks)
Adalimumab6 participants
Adalimumab7 participants
Adalimumab3 participants
NCT01148225
VISUAL III
UveitisNumber of Participants With Adverse Events
Baseline to Final Visit (up to 366 weeks)
Adalimumab398 participants
Adalimumab101 participants
NCT01148225
VISUAL III
UveitisPulse (Sitting): Mean Change (Beats Per Minute) From Baseline To Final Visit
Baseline to Final Visit (Up to 366 weeks)
Adalimumab-1.0 beats per minute (±11.92 Standard Deviation)
NCT01148225
VISUAL III
UveitisRespiratory Rate (Sitting): Mean Change (Respirations Per Minute) From Baseline To Final Visit
Baseline to Final Visit (Up to 366 weeks)
Adalimumab-0.1 respirations per minute (±2.94 Standard Deviation)
NCT01148225
VISUAL III
UveitisTemperature (Sitting): Mean Change (Centigrade) From Baseline To Final Visit
Baseline to Final Visit (Up to 366 weeks)
Adalimumab-0.03 Centigrade (±0.516 Standard Deviation)
NCT01166282Spondylitis, AnkylosingPercent Change in Number of Active Joints With Arthritis From Baseline to Week 12
Baseline and Week 12
Double-blind Adalimumab EOW-62.6 percent change (±59.53 Standard Deviation)
Double-blind Placebo EOW-11.6 percent change (±100.5 Standard Deviation)
NCT01185301
CONCERTO
Arthritis, RheumatoidPercentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26
Week 26
ADA + 10 mg MTX56.6 percentage of participants
ADA + 2.5 mg MTX42.9 percentage of participants
ADA + 20 mg MTX60.2 percentage of participants
ADA + 5 mg MTX44.0 percentage of participants
NCT01231321Arthritis, RheumatoidChanges of Physical Examination
Baseline and 24 weeks
Change From Abnormal to Normal0 participants
Change From Abnormal to Normal0 participants
Change From Abnormal to Normal0 participants
Change From Abnormal to Normal0 participants
Change From Abnormal to Normal0 participants
Change From Abnormal to Normal0 participants
Change From Abnormal to Normal0 participants
Change From Abnormal to Normal0 participants
Change From Abnormal to Normal1 participants
Change From Abnormal to Normal1 participants
Change From Abnormal to Normal0 participants
Change From Abnormal to Normal0 participants
Change From Abnormal to Normal0 participants
Change From Abnormal to Normal0 participants
Change From Abnormal to Normal0 participants
Change From Abnormal to Normal0 participants
Change From Abnormal to Normal0 participants
Change From Abnormal to Normal0 participants
Change From Normal to Abnormal0 participants
Change From Normal to Abnormal0 participants
Change From Normal to Abnormal0 participants
Change From Normal to Abnormal0 participants
Change From Normal to Abnormal0 participants
Change From Normal to Abnormal1 participants
Change From Normal to Abnormal0 participants
Change From Normal to Abnormal0 participants
Change From Normal to Abnormal0 participants
Change From Normal to Abnormal0 participants
Change From Normal to Abnormal1 participants
Change From Normal to Abnormal0 participants
Change From Normal to Abnormal0 participants
Change From Normal to Abnormal0 participants
Change From Normal to Abnormal0 participants
Change From Normal to Abnormal1 participants
Change From Normal to Abnormal0 participants
Change From Normal to Abnormal0 participants
NCT01231321Arthritis, RheumatoidDeviation From Normal Laboratory Ranges
24 weeks
Above Reference Range6 participants
Above Reference Range1 participants
Above Reference Range11 participants
Above Reference Range2 participants
Above Reference Range30 participants
Above Reference Range2 participants
Above Reference Range14 participants
Above Reference Range9 participants
Above Reference Range0 participants
Above Reference Range11 participants
Above Reference Range0 participants
Above Reference Range0 participants
Above Reference Range9 participants
Above Reference Range24 participants
Above Reference Range6 participants
Above Reference Range12 participants
Above Reference Range6 participants
Above Reference Range6 participants
Above Reference Range3 participants
Above Reference Range14 participants
Above Reference Range2 participants
Above Reference Range9 participants
Above Reference Range6 participants
Above Reference Range0 participants
Above Reference Range0 participants
Above Reference Range2 participants
Above Reference Range1 participants
Above Reference Range45 participants
Above Reference Range10 participants
Above Reference Range0 participants
Above Reference Range0 participants
Above Reference Range5 participants
Above Reference Range4 participants
Above Reference Range1 participants
Above Reference Range10 participants
Below Reference Range0 participants
Below Reference Range3 participants
Below Reference Range15 participants
Below Reference Range0 participants
Below Reference Range11 participants
Below Reference Range0 participants
Below Reference Range0 participants
Below Reference Range3 participants
Below Reference Range5 participants
Below Reference Range0 participants
Below Reference Range2 participants
Below Reference Range21 participants
Below Reference Range4 participants
Below Reference Range0 participants
Below Reference Range1 participants
Below Reference Range0 participants
Below Reference Range33 participants
Below Reference Range0 participants
Below Reference Range0 participants
Below Reference Range1 participants
Below Reference Range0 participants
Below Reference Range0 participants
Below Reference Range5 participants
Below Reference Range20 participants
Below Reference Range0 participants
Below Reference Range1 participants
Below Reference Range44 participants
Below Reference Range1 participants
Below Reference Range0 participants
Below Reference Range0 participants
Below Reference Range17 participants
Below Reference Range0 participants
Below Reference Range15 participants
Below Reference Range0 participants
Below Reference Range15 participants
NCT01231321Arthritis, RheumatoidFrequency of Adverse Events
Up to 34 weeks (24 week study treatment plus 70-day follow-up period)
Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL24 participants
Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL3 participants
Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL0 participants
Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL38 participants
Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL1 participants
Adalimumab/ Pre-filled Syringe 40 mg/0.8 mL1 participants
NCT01231321Arthritis, RheumatoidVital Sign Values
24 weeks
Above Reference Range0 participants
Above Reference Range0 participants
Above Reference Range0 participants
Above Reference Range2 participants
Below Reference Range1 participants
Below Reference Range1 participants
Below Reference Range0 participants
Below Reference Range0 participants
NCT01235689
CALM
Crohn DiseasePercentage of Participants With Mucosal Healing and No Deep Ulcerations
48 weeks after Randomization
Clinically Driven Management30.3 percentage of participants
Tight Control Management45.9 percentage of participants
NCT01243671—Number of Participants With Marked Improvement at Week 24
24 weeks
Adalimumab9 participants
NCT01251614—Percentage of Participants Achieving a Physician's Global Assessment of Disease Activity (PGA) of "Cleared" (0) or "Minimal" (1) at Week 16
Week 16
Adalimumab 0.4 mg/kg41.0 percentage of participants
Adalimumab 0.8 mg/kg60.5 percentage of participants
Methotrexate40.5 percentage of participants
NCT01251614—Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 75 Response at Week 16
Baseline and Week 16
Adalimumab 0.4 mg/kg43.6 percentage of participants
Adalimumab 0.8 mg/kg57.9 percentage of participants
Methotrexate32.4 percentage of participants
NCT01295814Cystitis, InterstitialO'Leary-Santa Interstitial Cystitis Symptom Index and Problem Index (OSPI) Score
Baseline/12 Weeks
Adalimumab19.9 units on a scale (±7.5 Standard Deviation)
Adalimumab27.8 units on a scale (±3.9 Standard Deviation)
Inactive Drug19.6 units on a scale (±10.7 Standard Deviation)
Inactive Drug27.7 units on a scale (±4.9 Standard Deviation)
NCT01468207
PIONEER I
PsoriasisPercentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12
Baseline (Week 0) up to Week 12
Adalimumab Every Week (EW)41.8 percentage of participants
Adalimumab Every Week (EW) - Baseline Hurley Stage II44.6 percentage of participants
Adalimumab Every Week (ew) - Baseline Hurley Stage III38.6 percentage of participants
Placebo26.0 percentage of participants
Placebo - Baseline Hurley Stage II29.8 percentage of participants
Placebo - Baseline Hurley Stage III21.4 percentage of participants
NCT01468233
PIONEER II
PsoriasisPercentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12
Baseline (Week 0) up to Week 12
Adalimumab Every Week (EW)58.9 percentage of participants
Adalimumab Every Week (EW) - Baseline Hurley Stage II62.4 percentage of participants
Adalimumab Every Week (EW) - Baseline Hurley Stage III55.1 percentage of participants
Placebo27.6 percentage of participants
Placebo - Baseline Hurley Stage II36.8 percentage of participants
Placebo - Baseline Hurley Stage III17.1 percentage of participants
NCT01550965
InspirAda
Colitis, UlcerativeMean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ): Total Score
Week 0 (baseline) and Week 26
Participants Receiving Adalimumab17.4 units on a scale (±14.48 Standard Deviation)
NCT01550965
InspirAda
Colitis, UlcerativeMean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in Costs of UC-related Medical Care Excluding Adalimumab Costs
6 months prior to treatment start (Week 0 [baseline]) and 6 months after treatment start (total 12 months)
Participants Receiving Adalimumab-1383.8 Pound Sterling (GBP) (±2213.06 Standard Deviation)
NCT01635764
PIONEER (OLE)
Hidradenitis SuppurativaModified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations
Baseline (in prior phase 3 study) to Entry of M12-555 and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
EW/EOW/EW-34.9 units on a scale (±47.42 Standard Deviation)
EW/EOW/EW-23.1 units on a scale (±56.94 Standard Deviation)
EW/EOW/EW-36.6 units on a scale (±51.33 Standard Deviation)
EW/EOW/EW-35.6 units on a scale (±53.64 Standard Deviation)
EW/EOW/EW-34.0 units on a scale (±49.42 Standard Deviation)
EW/EOW/EW-34.0 units on a scale (±54.41 Standard Deviation)
EW/EOW/EW-35.6 units on a scale (±53.72 Standard Deviation)
EW/EOW/EW-34.8 units on a scale (±55.71 Standard Deviation)
EW/EOW/EW-35.1 units on a scale (±53.94 Standard Deviation)
EW/EOW/EW-35.1 units on a scale (±53.01 Standard Deviation)
EW/EOW/EW-34.7 units on a scale (±53.95 Standard Deviation)
EW/EOW/EW-37.1 units on a scale (±46.07 Standard Deviation)
EW/EOW/EW-35.6 units on a scale (±53.64 Standard Deviation)
EW/EOW/EW-37.5 units on a scale (±47.94 Standard Deviation)
EW/EOW/EW-37.1 units on a scale (±47.39 Standard Deviation)
EW/EOW/EW-31.8 units on a scale (±60.85 Standard Deviation)
EW/EOW/EW-34.8 units on a scale (±50.17 Standard Deviation)
EW/EOW/EW-35.9 units on a scale (±47.92 Standard Deviation)
EW/EOW/EW-30.2 units on a scale (±48.99 Standard Deviation)
EW/EOW/EW-35.4 units on a scale (±55.22 Standard Deviation)
EW/PBO/EW-16.7 units on a scale (±66.87 Standard Deviation)
EW/PBO/EW-15.4 units on a scale (±67.39 Standard Deviation)
EW/PBO/EW-15.4 units on a scale (±67.39 Standard Deviation)
EW/PBO/EW-15.5 units on a scale (±67.40 Standard Deviation)
EW/PBO/EW-15.7 units on a scale (±67.09 Standard Deviation)
EW/PBO/EW-16.6 units on a scale (±67.30 Standard Deviation)
EW/PBO/EW-18.3 units on a scale (±65.14 Standard Deviation)
EW/PBO/EW-20.0 units on a scale (±66.02 Standard Deviation)
EW/PBO/EW-20.1 units on a scale (±64.52 Standard Deviation)
EW/PBO/EW-22.6 units on a scale (±65.06 Standard Deviation)
EW/PBO/EW-24.8 units on a scale (±63.21 Standard Deviation)
EW/PBO/EW-24.7 units on a scale (±63.81 Standard Deviation)
EW/PBO/EW-24.1 units on a scale (±61.52 Standard Deviation)
EW/PBO/EW-26.2 units on a scale (±60.59 Standard Deviation)
EW/PBO/EW-25.5 units on a scale (±57.92 Standard Deviation)
EW/PBO/EW-21.2 units on a scale (±63.26 Standard Deviation)
EW/PBO/EW-18.8 units on a scale (±56.52 Standard Deviation)
EW/PBO/EW-10.5 units on a scale (±56.74 Standard Deviation)
EW/PBO/EW-16.2 units on a scale (±66.82 Standard Deviation)
EW/PBO/EW-18.3 units on a scale (±66.88 Standard Deviation)
PBO/PBO/EW-26.2 units on a scale (±54.58 Standard Deviation)
PBO/PBO/EW-33.5 units on a scale (±50.20 Standard Deviation)
PBO/PBO/EW0.2 units on a scale (±51.35 Standard Deviation)
PBO/PBO/EW-24.8 units on a scale (±51.55 Standard Deviation)
PBO/PBO/EW-16.2 units on a scale (±56.16 Standard Deviation)
PBO/PBO/EW-30.2 units on a scale (±64.84 Standard Deviation)
PBO/PBO/EW-28.4 units on a scale (±71.52 Standard Deviation)
PBO/PBO/EW-32.3 units on a scale (±48.60 Standard Deviation)
PBO/PBO/EW-28.7 units on a scale (±69.81 Standard Deviation)
PBO/PBO/EW-28.7 units on a scale (±69.81 Standard Deviation)
PBO/PBO/EW-28.3 units on a scale (±70.37 Standard Deviation)
PBO/PBO/EW-28.8 units on a scale (±69.79 Standard Deviation)
PBO/PBO/EW-31.7 units on a scale (±66.33 Standard Deviation)
PBO/PBO/EW-33.6 units on a scale (±57.58 Standard Deviation)
PBO/PBO/EW-31.8 units on a scale (±65.26 Standard Deviation)
PBO/PBO/EW-29.5 units on a scale (±65.79 Standard Deviation)
PBO/PBO/EW-29.0 units on a scale (±68.85 Standard Deviation)
PBO/PBO/EW-28.6 units on a scale (±70.03 Standard Deviation)
PBO/PBO/EW-28.0 units on a scale (±69.11 Standard Deviation)
PBO/PBO/EW-28.7 units on a scale (±69.81 Standard Deviation)
NCT01635764
PIONEER (OLE)
Hidradenitis SuppurativaModified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EW/EW Analysis Population
Baseline (in prior phase 3 study) to Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
EW/EW/EW-41.8 units on a scale (±129.89 Standard Deviation)
EW/EW/EW-41.6 units on a scale (±93.11 Standard Deviation)
EW/EW/EW-41.4 units on a scale (±130.94 Standard Deviation)
EW/EW/EW-42.2 units on a scale (±115.22 Standard Deviation)
EW/EW/EW-26.6 units on a scale (±54.63 Standard Deviation)
EW/EW/EW-41.9 units on a scale (±119.98 Standard Deviation)
EW/EW/EW-43.2 units on a scale (±122.30 Standard Deviation)
EW/EW/EW-22.8 units on a scale (±35.45 Standard Deviation)
EW/EW/EW-42.8 units on a scale (±123.18 Standard Deviation)
EW/EW/EW-43.2 units on a scale (±126.21 Standard Deviation)
EW/EW/EW-18.0 units on a scale (±25.27 Standard Deviation)
EW/EW/EW-43.2 units on a scale (±124.92 Standard Deviation)
EW/EW/EW-43.4 units on a scale (±127.65 Standard Deviation)
EW/EW/EW-21.0 units on a scale (±31.81 Standard Deviation)
EW/EW/EW-42.5 units on a scale (±128.45 Standard Deviation)
EW/EW/EW-42.4 units on a scale (±129.37 Standard Deviation)
EW/EW/EW-32.1 units on a scale (±73.69 Standard Deviation)
EW/EW/EW-36.6 units on a scale (±74.99 Standard Deviation)
EW/EW/EW-23.9 units on a scale (±48.30 Standard Deviation)
EW/EW/EW-40.7 units on a scale (±130.30 Standard Deviation)
EW/EW/EW-41.5 units on a scale (±130.40 Standard Deviation)
EW/EW/EW-41.9 units on a scale (±130.46 Standard Deviation)
EW/EW/EW-41.4 units on a scale (±130.72 Standard Deviation)
NCT01635764
PIONEER (OLE)
Hidradenitis SuppurativaModified Sartorius Score: Change From Baseline to Each Visit for Participants in the PBO/EW/EW Analysis Population
Baseline (in prior phase 3 study) to Entry of Period B in prior phase 3 study and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204
PBO/EW/EW-45.8 units on a scale (±75.89 Standard Deviation)
PBO/EW/EW-45.9 units on a scale (±75.30 Standard Deviation)
PBO/EW/EW-44.4 units on a scale (±78.09 Standard Deviation)
PBO/EW/EW-47.1 units on a scale (±61.95 Standard Deviation)
PBO/EW/EW-45.8 units on a scale (±75.96 Standard Deviation)
PBO/EW/EW-45.4 units on a scale (±76.53 Standard Deviation)
PBO/EW/EW-49.5 units on a scale (±57.05 Standard Deviation)
PBO/EW/EW-45.9 units on a scale (±75.96 Standard Deviation)
PBO/EW/EW-46.0 units on a scale (±76.17 Standard Deviation)
PBO/EW/EW-43.0 units on a scale (±53.08 Standard Deviation)
PBO/EW/EW-43.2 units on a scale (±48.07 Standard Deviation)
PBO/EW/EW-46.1 units on a scale (±75.84 Standard Deviation)
PBO/EW/EW-18.0 units on a scale (±38.32 Standard Deviation)
PBO/EW/EW-44.5 units on a scale (±67.13 Standard Deviation)
PBO/EW/EW-46.8 units on a scale (±64.57 Standard Deviation)
PBO/EW/EW-45.5 units on a scale (±70.63 Standard Deviation)
PBO/EW/EW-45.0 units on a scale (±74.15 Standard Deviation)
PBO/EW/EW-46.2 units on a scale (±60.94 Standard Deviation)
NCT01635764
PIONEER (OLE)
Hidradenitis SuppurativaPercentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3
Entry of M12-555, and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
EW/EOW/EW41.3 percentage of participants
EW/EOW/EW49.2 percentage of participants
EW/EOW/EW42.9 percentage of participants
EW/EOW/EW47.6 percentage of participants
EW/EOW/EW41.3 percentage of participants
EW/EOW/EW45.2 percentage of participants
EW/EOW/EW47.5 percentage of participants
EW/EOW/EW40.0 percentage of participants
EW/EOW/EW41.3 percentage of participants
EW/EOW/EW42.9 percentage of participants
EW/EOW/EW41.3 percentage of participants
EW/EOW/EW39.7 percentage of participants
EW/EOW/EW47.6 percentage of participants
EW/EOW/EW41.3 percentage of participants
EW/EOW/EW47.6 percentage of participants
EW/EOW/EW41.3 percentage of participants
EW/EOW/EW50.8 percentage of participants
EW/EOW/EW50.8 percentage of participants
EW/EOW/EW50.8 percentage of participants
EW/EOW/EW47.6 percentage of participants
EW/PBO/EW49.2 percentage of participants
EW/PBO/EW47.6 percentage of participants
EW/PBO/EW50.8 percentage of participants
EW/PBO/EW46.0 percentage of participants
EW/PBO/EW42.9 percentage of participants
EW/PBO/EW50.8 percentage of participants
EW/PBO/EW49.2 percentage of participants
EW/PBO/EW46.0 percentage of participants
EW/PBO/EW49.2 percentage of participants
EW/PBO/EW47.6 percentage of participants
EW/PBO/EW21.9 percentage of participants
EW/PBO/EW47.6 percentage of participants
EW/PBO/EW43.1 percentage of participants
EW/PBO/EW50.8 percentage of participants
EW/PBO/EW47.6 percentage of participants
EW/PBO/EW42.9 percentage of participants
EW/PBO/EW54.0 percentage of participants
EW/PBO/EW55.6 percentage of participants
EW/PBO/EW50.8 percentage of participants
EW/PBO/EW47.6 percentage of participants
PBO/PBO/EW55.4 percentage of participants
PBO/PBO/EW54.2 percentage of participants
PBO/PBO/EW48.2 percentage of participants
PBO/PBO/EW48.2 percentage of participants
PBO/PBO/EW48.2 percentage of participants
PBO/PBO/EW50.6 percentage of participants
PBO/PBO/EW50.6 percentage of participants
PBO/PBO/EW48.2 percentage of participants
PBO/PBO/EW45.8 percentage of participants
PBO/PBO/EW50.6 percentage of participants
PBO/PBO/EW56.6 percentage of participants
PBO/PBO/EW47.0 percentage of participants
PBO/PBO/EW49.4 percentage of participants
PBO/PBO/EW55.4 percentage of participants
PBO/PBO/EW48.2 percentage of participants
PBO/PBO/EW48.2 percentage of participants
PBO/PBO/EW22.6 percentage of participants
PBO/PBO/EW44.6 percentage of participants
PBO/PBO/EW51.8 percentage of participants
PBO/PBO/EW51.8 percentage of participants
NCT01635764
PIONEER (OLE)
Hidradenitis SuppurativaPercentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3
Entry of M12-555, and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
EW/EOW/EW43.4 percentage of participants
EW/EOW/EW47.2 percentage of participants
EW/EOW/EW39.6 percentage of participants
EW/EOW/EW49.1 percentage of participants
EW/EOW/EW47.2 percentage of participants
EW/EOW/EW49.1 percentage of participants
EW/EOW/EW47.2 percentage of participants
EW/EOW/EW43.4 percentage of participants
EW/EOW/EW43.4 percentage of participants
EW/EOW/EW43.4 percentage of participants
EW/EOW/EW46.2 percentage of participants
EW/EOW/EW43.4 percentage of participants
EW/EOW/EW39.6 percentage of participants
EW/EOW/EW45.3 percentage of participants
EW/EOW/EW49.0 percentage of participants
EW/EOW/EW39.6 percentage of participants
EW/EOW/EW43.6 percentage of participants
EW/EOW/EW45.3 percentage of participants
EW/EOW/EW43.4 percentage of participants
EW/EOW/EW43.4 percentage of participants
EW/PBO/EW46.8 percentage of participants
EW/PBO/EW48.1 percentage of participants
EW/PBO/EW48.1 percentage of participants
EW/PBO/EW37.7 percentage of participants
EW/PBO/EW55.8 percentage of participants
EW/PBO/EW59.6 percentage of participants
EW/PBO/EW59.6 percentage of participants
EW/PBO/EW53.8 percentage of participants
EW/PBO/EW48.1 percentage of participants
EW/PBO/EW51.9 percentage of participants
EW/PBO/EW53.8 percentage of participants
EW/PBO/EW59.6 percentage of participants
EW/PBO/EW48.1 percentage of participants
EW/PBO/EW57.7 percentage of participants
EW/PBO/EW44.2 percentage of participants
EW/PBO/EW48.1 percentage of participants
EW/PBO/EW50.0 percentage of participants
EW/PBO/EW50.0 percentage of participants
EW/PBO/EW46.2 percentage of participants
EW/PBO/EW48.1 percentage of participants
PBO/PBO/EW58.8 percentage of participants
PBO/PBO/EW58.8 percentage of participants
PBO/PBO/EW54.4 percentage of participants
PBO/PBO/EW55.9 percentage of participants
PBO/PBO/EW61.8 percentage of participants
PBO/PBO/EW54.4 percentage of participants
PBO/PBO/EW63.2 percentage of participants
PBO/PBO/EW55.9 percentage of participants
PBO/PBO/EW61.8 percentage of participants
PBO/PBO/EW31.9 percentage of participants
PBO/PBO/EW52.9 percentage of participants
PBO/PBO/EW54.4 percentage of participants
PBO/PBO/EW54.4 percentage of participants
PBO/PBO/EW54.4 percentage of participants
PBO/PBO/EW55.9 percentage of participants
PBO/PBO/EW54.4 percentage of participants
PBO/PBO/EW57.4 percentage of participants
PBO/PBO/EW54.4 percentage of participants
PBO/PBO/EW58.8 percentage of participants
PBO/PBO/EW54.4 percentage of participants
NCT01635764
PIONEER (OLE)
Hidradenitis SuppurativaPercentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Who Achieved AN Count of 0, 1, or 2 at Each Visit
Entry of M12-555, Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
EW/EOW/EW51.1 percentage of participants
EW/EOW/EW31.1 percentage of participants
EW/EOW/EW35.6 percentage of participants
EW/EOW/EW43.2 percentage of participants
EW/EOW/EW45.5 percentage of participants
EW/EOW/EW50.0 percentage of participants
EW/EOW/EW43.2 percentage of participants
EW/EOW/EW54.5 percentage of participants
EW/EOW/EW50.0 percentage of participants
EW/EOW/EW48.9 percentage of participants
EW/EOW/EW50.0 percentage of participants
EW/EOW/EW53.4 percentage of participants
EW/EOW/EW51.1 percentage of participants
EW/EOW/EW51.1 percentage of participants
EW/EOW/EW46.6 percentage of participants
EW/EOW/EW51.1 percentage of participants
EW/EOW/EW48.9 percentage of participants
EW/EOW/EW47.7 percentage of participants
EW/EOW/EW51.1 percentage of participants
EW/EOW/EW51.1 percentage of participants
EW/PBO/EW43.5 percentage of participants
EW/PBO/EW35.9 percentage of participants
EW/PBO/EW35.9 percentage of participants
EW/PBO/EW35.9 percentage of participants
EW/PBO/EW39.1 percentage of participants
EW/PBO/EW41.3 percentage of participants
EW/PBO/EW37.0 percentage of participants
EW/PBO/EW37.0 percentage of participants
EW/PBO/EW40.2 percentage of participants
EW/PBO/EW40.2 percentage of participants
EW/PBO/EW44.6 percentage of participants
EW/PBO/EW43.5 percentage of participants
EW/PBO/EW42.4 percentage of participants
EW/PBO/EW45.7 percentage of participants
EW/PBO/EW46.7 percentage of participants
EW/PBO/EW41.3 percentage of participants
EW/PBO/EW44.6 percentage of participants
EW/PBO/EW42.4 percentage of participants
EW/PBO/EW34.8 percentage of participants
EW/PBO/EW22.8 percentage of participants
PBO/PBO/EW51.6 percentage of participants
PBO/PBO/EW57.4 percentage of participants
PBO/PBO/EW52.5 percentage of participants
PBO/PBO/EW21.1 percentage of participants
PBO/PBO/EW57.4 percentage of participants
PBO/PBO/EW50.8 percentage of participants
PBO/PBO/EW44.3 percentage of participants
PBO/PBO/EW50.0 percentage of participants
PBO/PBO/EW53.3 percentage of participants
PBO/PBO/EW53.3 percentage of participants
PBO/PBO/EW45.1 percentage of participants
PBO/PBO/EW52.5 percentage of participants
PBO/PBO/EW54.1 percentage of participants
PBO/PBO/EW52.5 percentage of participants
PBO/PBO/EW51.6 percentage of participants
PBO/PBO/EW51.6 percentage of participants
PBO/PBO/EW51.6 percentage of participants
PBO/PBO/EW51.6 percentage of participants
PBO/PBO/EW52.5 percentage of participants
PBO/PBO/EW51.6 percentage of participants
NCT01635764
PIONEER (OLE)
Hidradenitis SuppurativaPercentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3
Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
EW/EW/EW46.0 percentage of participants
EW/EW/EW58.7 percentage of participants
EW/EW/EW52.4 percentage of participants
EW/EW/EW54.0 percentage of participants
EW/EW/EW52.4 percentage of participants
EW/EW/EW54.0 percentage of participants
EW/EW/EW52.4 percentage of participants
EW/EW/EW49.2 percentage of participants
EW/EW/EW54.0 percentage of participants
EW/EW/EW50.8 percentage of participants
EW/EW/EW46.0 percentage of participants
EW/EW/EW54.0 percentage of participants
EW/EW/EW52.4 percentage of participants
EW/EW/EW47.6 percentage of participants
EW/EW/EW46.0 percentage of participants
EW/EW/EW52.4 percentage of participants
EW/EW/EW44.4 percentage of participants
EW/EW/EW52.4 percentage of participants
EW/EW/EW42.9 percentage of participants
EW/EW/EW50.8 percentage of participants
EW/EW/EW54.0 percentage of participants
NCT01635764
PIONEER (OLE)
Hidradenitis SuppurativaPercentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3
Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
EW/EW/EW56.0 percentage of participants
EW/EW/EW52.0 percentage of participants
EW/EW/EW46.0 percentage of participants
EW/EW/EW48.0 percentage of participants
EW/EW/EW56.0 percentage of participants
EW/EW/EW50.0 percentage of participants
EW/EW/EW50.0 percentage of participants
EW/EW/EW56.0 percentage of participants
EW/EW/EW40.0 percentage of participants
EW/EW/EW54.0 percentage of participants
EW/EW/EW56.0 percentage of participants
EW/EW/EW46.0 percentage of participants
EW/EW/EW56.0 percentage of participants
EW/EW/EW58.0 percentage of participants
EW/EW/EW56.0 percentage of participants
EW/EW/EW56.0 percentage of participants
EW/EW/EW56.0 percentage of participants
EW/EW/EW58.0 percentage of participants
EW/EW/EW48.0 percentage of participants
EW/EW/EW56.0 percentage of participants
EW/EW/EW56.0 percentage of participants
NCT01635764
PIONEER (OLE)
Hidradenitis SuppurativaPercentage of Participants in the EW/EW/EW Analysis Population Who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Each Visit
Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
EW/EW/EW42.0 percentage of participants
EW/EW/EW22.7 percentage of participants
EW/EW/EW28.4 percentage of participants
EW/EW/EW38.6 percentage of participants
EW/EW/EW35.2 percentage of participants
EW/EW/EW37.5 percentage of participants
EW/EW/EW36.4 percentage of participants
EW/EW/EW48.9 percentage of participants
EW/EW/EW46.6 percentage of participants
EW/EW/EW43.2 percentage of participants
EW/EW/EW50.0 percentage of participants
EW/EW/EW45.5 percentage of participants
EW/EW/EW44.3 percentage of participants
EW/EW/EW46.6 percentage of participants
EW/EW/EW44.3 percentage of participants
EW/EW/EW44.3 percentage of participants
EW/EW/EW43.2 percentage of participants
EW/EW/EW45.5 percentage of participants
EW/EW/EW46.6 percentage of participants
EW/EW/EW46.6 percentage of participants
EW/EW/EW47.7 percentage of participants
EW/EW/EW47.7 percentage of participants
EW/EW/EW46.6 percentage of participants
NCT01635764
PIONEER (OLE)
Hidradenitis SuppurativaPercentage of Participants in the EW/EW/EW, EW/EOW/EW, and EW/PBO/EW Analysis Populations Achieving Clinical Response Per Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit
Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
EW/EOW/EW55.6 percentage of participants
EW/EOW/EW56.7 percentage of participants
EW/EOW/EW55.6 percentage of participants
EW/EOW/EW45.6 percentage of participants
EW/EOW/EW52.2 percentage of participants
EW/EOW/EW54.4 percentage of participants
EW/EOW/EW55.6 percentage of participants
EW/EOW/EW52.2 percentage of participants
EW/EOW/EW53.3 percentage of participants
EW/EOW/EW57.8 percentage of participants
EW/EOW/EW54.4 percentage of participants
EW/EOW/EW52.2 percentage of participants
EW/EOW/EW41.1 percentage of participants
EW/EOW/EW56.7 percentage of participants
EW/EOW/EW61.1 percentage of participants
EW/EOW/EW54.4 percentage of participants
EW/EOW/EW39.8 percentage of participants
EW/EOW/EW47.8 percentage of participants
EW/EOW/EW56.7 percentage of participants
EW/EOW/EW54.4 percentage of participants
EW/EOW/EW48.9 percentage of participants
EW/EOW/EW54.4 percentage of participants
EW/EOW/EW54.4 percentage of participants
EW/EW/EW48.9 percentage of participants
EW/EW/EW38.6 percentage of participants
EW/EW/EW51.1 percentage of participants
EW/EW/EW52.3 percentage of participants
EW/EW/EW50.0 percentage of participants
EW/EW/EW34.1 percentage of participants
EW/EW/EW56.8 percentage of participants
EW/EW/EW50.0 percentage of participants
EW/EW/EW50.0 percentage of participants
EW/EW/EW51.1 percentage of participants
EW/EW/EW51.1 percentage of participants
EW/EW/EW52.3 percentage of participants
EW/EW/EW48.9 percentage of participants
EW/EW/EW51.1 percentage of participants
EW/EW/EW52.3 percentage of participants
EW/EW/EW56.8 percentage of participants
EW/EW/EW60.2 percentage of participants
EW/EW/EW56.8 percentage of participants
EW/EW/EW56.8 percentage of participants
EW/EW/EW59.1 percentage of participants
EW/EW/EW62.5 percentage of participants
EW/EW/EW58.0 percentage of participants
EW/EW/EW62.5 percentage of participants
EW/PBO/EW46.7 percentage of participants
EW/PBO/EW34.1 percentage of participants
EW/PBO/EW53.3 percentage of participants
EW/PBO/EW46.7 percentage of participants
EW/PBO/EW52.2 percentage of participants
EW/PBO/EW55.4 percentage of participants
EW/PBO/EW46.7 percentage of participants
EW/PBO/EW40.2 percentage of participants
EW/PBO/EW53.3 percentage of participants
EW/PBO/EW45.7 percentage of participants
EW/PBO/EW45.7 percentage of participants
EW/PBO/EW58.7 percentage of participants
EW/PBO/EW51.1 percentage of participants
EW/PBO/EW52.2 percentage of participants
EW/PBO/EW50.0 percentage of participants
EW/PBO/EW42.4 percentage of participants
EW/PBO/EW50.0 percentage of participants
EW/PBO/EW46.7 percentage of participants
EW/PBO/EW58.7 percentage of participants
EW/PBO/EW45.7 percentage of participants
EW/PBO/EW46.7 percentage of participants
EW/PBO/EW47.8 percentage of participants
EW/PBO/EW53.3 percentage of participants
NCT01635764
PIONEER (OLE)
Hidradenitis SuppurativaPercentage of Participants in the PBO/EW/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit
Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204
PBO/EW/EW26.1 percentage of participants
PBO/EW/EW54.4 percentage of participants
PBO/EW/EW53.5 percentage of participants
PBO/EW/EW53.5 percentage of participants
PBO/EW/EW54.4 percentage of participants
PBO/EW/EW55.3 percentage of participants
PBO/EW/EW52.6 percentage of participants
PBO/EW/EW51.8 percentage of participants
PBO/EW/EW56.1 percentage of participants
PBO/EW/EW53.5 percentage of participants
PBO/EW/EW52.6 percentage of participants
PBO/EW/EW53.5 percentage of participants
PBO/EW/EW50.0 percentage of participants
PBO/EW/EW50.0 percentage of participants
PBO/EW/EW57.0 percentage of participants
PBO/EW/EW60.5 percentage of participants
PBO/EW/EW57.0 percentage of participants
PBO/EW/EW57.9 percentage of participants
NCT01635764
PIONEER (OLE)
Hidradenitis SuppurativaPercentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3
Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204
PBO/EW/EW51.3 percentage of participants
PBO/EW/EW55.1 percentage of participants
PBO/EW/EW53.8 percentage of participants
PBO/EW/EW56.4 percentage of participants
PBO/EW/EW55.1 percentage of participants
PBO/EW/EW62.3 percentage of participants
PBO/EW/EW63.6 percentage of participants
PBO/EW/EW64.9 percentage of participants
PBO/EW/EW58.4 percentage of participants
PBO/EW/EW53.2 percentage of participants
PBO/EW/EW55.8 percentage of participants
PBO/EW/EW55.3 percentage of participants
PBO/EW/EW51.6 percentage of participants
PBO/EW/EW31.6 percentage of participants
PBO/EW/EW57.7 percentage of participants
PBO/EW/EW56.4 percentage of participants
PBO/EW/EW57.7 percentage of participants
PBO/EW/EW57.7 percentage of participants
NCT01635764
PIONEER (OLE)
Hidradenitis SuppurativaPercentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3
Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204
PBO/EW/EW59.0 percentage of participants
PBO/EW/EW62.3 percentage of participants
PBO/EW/EW61.7 percentage of participants
PBO/EW/EW60.0 percentage of participants
PBO/EW/EW53.3 percentage of participants
PBO/EW/EW61.7 percentage of participants
PBO/EW/EW61.0 percentage of participants
PBO/EW/EW59.2 percentage of participants
PBO/EW/EW62.3 percentage of participants
PBO/EW/EW60.7 percentage of participants
PBO/EW/EW62.3 percentage of participants
PBO/EW/EW62.3 percentage of participants
PBO/EW/EW55.7 percentage of participants
PBO/EW/EW60.7 percentage of participants
PBO/EW/EW30.6 percentage of participants
PBO/EW/EW58.3 percentage of participants
PBO/EW/EW60.0 percentage of participants
PBO/EW/EW62.3 percentage of participants
NCT01635764
PIONEER (OLE)
Hidradenitis SuppurativaPercentage of Participants in the PBO/EW/EW Analysis Population Who Achieved AN Count of 0, 1, or 2 at Each Visit
Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204
PBO/EW/EW45.6 percentage of participants
PBO/EW/EW49.1 percentage of participants
PBO/EW/EW45.6 percentage of participants
PBO/EW/EW46.5 percentage of participants
PBO/EW/EW45.6 percentage of participants
PBO/EW/EW45.6 percentage of participants
PBO/EW/EW45.6 percentage of participants
PBO/EW/EW43.9 percentage of participants
PBO/EW/EW20.0 percentage of participants
PBO/EW/EW38.6 percentage of participants
PBO/EW/EW43.0 percentage of participants
PBO/EW/EW42.1 percentage of participants
PBO/EW/EW45.6 percentage of participants
PBO/EW/EW43.9 percentage of participants
PBO/EW/EW43.9 percentage of participants
PBO/EW/EW46.5 percentage of participants
PBO/EW/EW42.1 percentage of participants
PBO/EW/EW46.5 percentage of participants
NCT01635764
PIONEER (OLE)
Hidradenitis SuppurativaPercentage of Participants in the PBO/PBO/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit
Entry of M12-555, Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
PBO/PBO/EW51.6 percentage of participants
PBO/PBO/EW19.5 percentage of participants
PBO/PBO/EW46.7 percentage of participants
PBO/PBO/EW48.4 percentage of participants
PBO/PBO/EW57.4 percentage of participants
PBO/PBO/EW55.7 percentage of participants
PBO/PBO/EW60.7 percentage of participants
PBO/PBO/EW54.9 percentage of participants
PBO/PBO/EW55.7 percentage of participants
PBO/PBO/EW54.9 percentage of participants
PBO/PBO/EW54.9 percentage of participants
PBO/PBO/EW57.4 percentage of participants
PBO/PBO/EW54.9 percentage of participants
PBO/PBO/EW52.5 percentage of participants
PBO/PBO/EW54.1 percentage of participants
PBO/PBO/EW51.6 percentage of participants
PBO/PBO/EW50.8 percentage of participants
PBO/PBO/EW51.6 percentage of participants
PBO/PBO/EW51.6 percentage of participants
PBO/PBO/EW51.6 percentage of participants
NCT01646073PsoriasisPercentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12
Week 12
Adalimumab Eow77.8 percentage of participants
Placebo11.5 percentage of participants
NCT01695239
SPIRIT-P1
Arthritis, PsoriaticPercentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24 (Efficacy of Ixekizumab in Participants With Active Psoriatic Arthritis. Measure: American College of Rheumatology 20 Index [ACR20])
Week 24
Adalimumab Q2W57.4 percentage of participants
Ixekizumab Q2W62.1 percentage of participants
Ixekizumab Q4W57.9 percentage of participants
Placebo30.2 percentage of participants
NCT01710358
RA-BEAM
Arthritis, RheumatoidPercentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20)
Week 12
Adalimumab61.2 percentage of participants
Baricitinib69.6 percentage of participants
Placebo40.2 percentage of participants
NCT01808118Spondylitis, AnkylosingNumber of Participants Who Did Not Experience a Flare During Period 2 by Week 68
From Week 28 through 68
Double-blind Adalimumab (Period 2)107 Participants
Placebo (Period 2)72 Participants
NCT01877668
OPAL BROADEN
Arthritis, PsoriaticChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
From Baseline to Month 3
Adalimumab, 40 mg, Every 2 Weeks-0.3808 Units on a scale (±0.04767 Standard Error)
Adalimumab, 40 mg, Every 2 Weeks-0.3028 Units on a scale (±0.04465 Standard Error)
Adalimumab, 40 mg, Every 2 Weeks-0.4304 Units on a scale (±0.05143 Standard Error)
Adalimumab, 40 mg, Every 2 Weeks-0.4478 Units on a scale (±0.05426 Standard Error)
Adalimumab, 40 mg, Every 2 Weeks-0.4259 Units on a scale (±0.05227 Standard Error)
Adalimumab, 40 mg, Every 2 Weeks-0.2129 Units on a scale (±0.04246 Standard Error)
Adalimumab, 40 mg, Every 2 Weeks-0.3643 Units on a scale (±0.05069 Standard Error)
Adalimumab, 40 mg, Every 2 Weeks-0.3736 Units on a scale (±0.04719 Standard Error)
PlaceboNA Units on a scale (±NA Standard Error)
PlaceboNA Units on a scale (±NA Standard Error)
Placebo-0.0837 Units on a scale (±0.04549 Standard Error)
Placebo-0.1802 Units on a scale (±0.05031 Standard Error)
PlaceboNA Units on a scale (±NA Standard Error)
Placebo-0.1224 Units on a scale (±0.04755 Standard Error)
Placebo-0.1682 Units on a scale (±0.04998 Standard Error)
PlaceboNA Units on a scale (±NA Standard Error)
Placebo/Tofacitinib, 10 mg, Twice DailyNA Units on a scale (±NA Standard Error)
Placebo/Tofacitinib, 10 mg, Twice DailyNA Units on a scale (±NA Standard Error)
Placebo/Tofacitinib, 10 mg, Twice Daily-0.3302 Units on a scale (±0.07128 Standard Error)
Placebo/Tofacitinib, 10 mg, Twice Daily-0.4569 Units on a scale (±0.07704 Standard Error)
Placebo/Tofacitinib, 10 mg, Twice Daily-0.4839 Units on a scale (±0.07276 Standard Error)
Placebo/Tofacitinib, 10 mg, Twice Daily-0.3841 Units on a scale (±0.07369 Standard Error)
Placebo/Tofacitinib, 10 mg, Twice DailyNA Units on a scale (±NA Standard Error)
Placebo/Tofacitinib, 5 mg, Twice DailyNA Units on a scale (±NA Standard Error)
Placebo/Tofacitinib, 5 mg, Twice Daily-0.4104 Units on a scale (±0.07646 Standard Error)
Placebo/Tofacitinib, 5 mg, Twice Daily-0.3142 Units on a scale (±0.07315 Standard Error)
Placebo/Tofacitinib, 5 mg, Twice Daily-0.3843 Units on a scale (±0.07185 Standard Error)
Placebo/Tofacitinib, 5 mg, Twice DailyNA Units on a scale (±NA Standard Error)
Placebo/Tofacitinib, 5 mg, Twice Daily-0.2850 Units on a scale (±0.07075 Standard Error)
Placebo/Tofacitinib, 5 mg, Twice DailyNA Units on a scale (±NA Standard Error)
Tofacitinib, 10 mg, Twice Daily-0.4009 Units on a scale (±0.04678 Standard Error)
Tofacitinib, 10 mg, Twice Daily-0.4611 Units on a scale (±0.05179 Standard Error)
Tofacitinib, 10 mg, Twice Daily-0.2676 Units on a scale (±0.04426 Standard Error)
Tofacitinib, 10 mg, Twice Daily-0.3998 Units on a scale (±0.04716 Standard Error)
Tofacitinib, 10 mg, Twice Daily-0.2089 Units on a scale (±0.04208 Standard Error)
Tofacitinib, 10 mg, Twice Daily-0.4847 Units on a scale (±0.05096 Standard Error)
Tofacitinib, 10 mg, Twice Daily-0.5104 Units on a scale (±0.05365 Standard Error)
Tofacitinib, 10 mg, Twice Daily-0.4407 Units on a scale (±0.05039 Standard Error)
Tofacitinib, 5 mg, Twice Daily-0.5391 Units on a scale (±0.05324 Standard Error)
Tofacitinib, 5 mg, Twice Daily-0.3499 Units on a scale (±0.04665 Standard Error)
Tofacitinib, 5 mg, Twice Daily-0.4471 Units on a scale (±0.05136 Standard Error)
Tofacitinib, 5 mg, Twice Daily-0.4231 Units on a scale (±0.04982 Standard Error)
Tofacitinib, 5 mg, Twice Daily-0.2713 Units on a scale (±0.04626 Standard Error)
Tofacitinib, 5 mg, Twice Daily-0.2048 Units on a scale (±0.04363 Standard Error)
Tofacitinib, 5 mg, Twice Daily-0.1842 Units on a scale (±0.04131 Standard Error)
Tofacitinib, 5 mg, Twice Daily-0.5119 Units on a scale (±0.05038 Standard Error)
NCT01877668
OPAL BROADEN
Arthritis, PsoriaticPercentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20): Month 3
At end of Month 3
Adalimumab, 40 mg, Every 2 Weeks51.89 Percentage or participants
Placebo33.33 Percentage or participants
Tofacitinib, 10 mg, Twice Daily60.58 Percentage or participants
Tofacitinib, 5 mg, Twice Daily50.47 Percentage or participants
NCT01958827Crohn DiseasePercentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) at Week 8
Week 8
Adalimumab 80 mg75 percentage of participants
NCT01970475Arthritis, RheumatoidPercentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24
Baseline and Week 24
ABP 50174.6 percentage of participants
Adalimumab72.4 percentage of participants
NCT01970488PsoriasisPercent Improvement From Baseline in Psoriasis Area and Severity Index (PASI) at Week 16
Baseline and Week 16
Part 1: ABP 50180.91 percent change (±24.237 Standard Deviation)
Part 1: Adalimumab83.06 percent change (±25.195 Standard Deviation)
NCT02016105
ADACCESS
—PASI 75 Response Rate at Week 16 - GP2017 Adalimumab vs Humira ® Adalimumab
At Week 16 only
GP2017 Adalimumab66.8 percent of participants
Humira ® Adalimumab65.0 percent of participants
NCT02016482—For United States (US) Regulatory Purposes: Percentage of Participants With a Physician's Global Assessment of Fingernails (PGA-F) of "Clear" or "Minimal" at Week 26
Week 26
Adalimumab EOW48.9 percentage of participants
Placebo6.9 percentage of participants
NCT02016482—Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26
Week 26
Adalimumab EOW46.6 percentage of participants
Placebo3.4 percentage of participants
NCT02019472
SIRROUND-H
Arthritis, RheumatoidChange From Baseline in Disease Activity Index Score 28 (DAS28) Erythrocyte Sedimentation Rate (ESR) at Week 24
Baseline and Week 24
Adalimumab 40 mg-2.19 units on a scale (±1.437 Standard Deviation)
Adalimumab 40 mg6.89 units on a scale (±0.851 Standard Deviation)
Sirukumab 100 mg6.91 units on a scale (±0.863 Standard Deviation)
Sirukumab 100 mg-2.96 units on a scale (±1.58 Standard Deviation)
Sirukumab 50 mg-2.58 units on a scale (±1.524 Standard Deviation)
Sirukumab 50 mg6.90 units on a scale (±0.881 Standard Deviation)
NCT02019472
SIRROUND-H
Arthritis, RheumatoidPercentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 24
Week 24
Adalimumab 40 mg31.7 Percentage of participants
Sirukumab 100 mg35.3 Percentage of participants
Sirukumab 50 mg26.9 Percentage of participants
NCT02065557Colitis, UlcerativeCo-Primary Endpoint 1: Percentage of Participants Who Achieved Clinical Remission as Measured by Partial Mayo Score (PMS) at Week 8 - Induction Period
Week 8
Integrated Study (Main + Japan Sub-Study): I-HD58.8 percentage of participants
Integrated Study (Main + Japan Sub-Study): I-HD-OL66.7 percentage of participants
Integrated Study (Main + Japan Sub-Study): I-SD40.6 percentage of participants
Integrated Study (Main + Japan Sub-Study): I-SD + I-HD51.8 percentage of participants
Main Study: I-HD59.6 percentage of participants
Main Study: I-HD-OL68.8 percentage of participants
Main Study: I-SD43.3 percentage of participants
Main Study: I-SD + I-HD53.2 percentage of participants
NCT02065557Colitis, UlcerativeCo-Primary Endpoint 2: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 52 in Week 8 Responders Per PMS - Maintenance Period
Week 52
Integrated Study (Main + Japan Sub-Study): M-HD42.9 percentage of participants
Integrated Study (Main + Japan Sub-Study): M-PL33.3 percentage of participants
Integrated Study (Main + Japan Sub-Study): M-SD27.3 percentage of participants
Integrated Study (Main + Japan Sub-Study): M-SD + M-HD35.3 percentage of participants
Main Study: M-HD45.2 percentage of participants
Main Study: M-PL33.3 percentage of participants
Main Study: M-SD29.0 percentage of participants
Main Study: M-SD + M-HD37.1 percentage of participants
NCT02065570Crohn DiseaseNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)
From first dose of study drug until 70 days following last dose of study drug in the induction study (up to 12 weeks) or maintenance study (up to 56 weeks).
Induction: Higher Induction Dose17 Participants
Induction: Higher Induction Dose13 Participants
Induction: Higher Induction Dose0 Participants
Induction: Higher Induction Dose14 Participants
Induction: Higher Induction Dose0 Participants
Induction: Higher Induction Dose185 Participants
Induction: Higher Induction Dose75 Participants
Induction: Standard Induction Dose8 Participants
Induction: Standard Induction Dose10 Participants
Induction: Standard Induction Dose0 Participants
Induction: Standard Induction Dose13 Participants
Induction: Standard Induction Dose0 Participants
Induction: Standard Induction Dose133 Participants
Induction: Standard Induction Dose54 Participants
Maintenance: Clinically Adjusted (CA) Regimen5 Participants
Maintenance: Clinically Adjusted (CA) Regimen7 Participants
Maintenance: Clinically Adjusted (CA) Regimen0 Participants
Maintenance: Clinically Adjusted (CA) Regimen0 Participants
Maintenance: Clinically Adjusted (CA) Regimen29 Participants
Maintenance: Clinically Adjusted (CA) Regimen77 Participants
Maintenance: Clinically Adjusted (CA) Regimen8 Participants
Maintenance: Therapeutic Drug Monitoring (TDM) Regimen76 Participants
Maintenance: Therapeutic Drug Monitoring (TDM) Regimen0 Participants
Maintenance: Therapeutic Drug Monitoring (TDM) Regimen0 Participants
Maintenance: Therapeutic Drug Monitoring (TDM) Regimen9 Participants
Maintenance: Therapeutic Drug Monitoring (TDM) Regimen7 Participants
Maintenance: Therapeutic Drug Monitoring (TDM) Regimen6 Participants
Maintenance: Therapeutic Drug Monitoring (TDM) Regimen33 Participants
NCT02065570Crohn DiseasePercentage of Participants Who Achieved Clinical Remission at Week 4
Week 4
Induction: Higher Induction Dose43.5 percentage of participants
Induction: Standard Induction Dose43.7 percentage of participants
NCT02065570Crohn DiseasePercentage of Participants With Endoscopic Response at Week 12
Week 12
Induction: Higher Induction Dose42.9 percentage of participants
Induction: Standard Induction Dose39.3 percentage of participants
NCT02065622Colitis, UlcerativeInduction Period Primary Endpoint: Percentage of Participants With Clinical Remission Per Full Mayo Score (FMS) at Week 8
Week 8
Induction (Main Study + Japan Sub-study): I-HD13.8 percentage of participants
Induction (Main Study + Japan Sub-study): I-SD11.6 percentage of participants
Induction (Main Study): I-HD13.3 percentage of participants
Induction (Main Study): I-SD10.9 percentage of participants
NCT02065622Colitis, UlcerativeMaintenance Period Primary Endpoint: Percentage of Week 8 Responders (Per FMS) With Clinical Remission (Per FMS) at Week 52
Week 52
Maintenance (Main Study + Japan Sub-study): M-HD41.1 percentage of participants
Maintenance (Main Study + Japan Sub-study): M-SD30.1 percentage of participants
Maintenance (Main Study): M-HD39.5 percentage of participants
Maintenance (Main Study): M-SD29.0 percentage of participants
NCT02163759
HIBISCUS I
Colitis, UlcerativePercentage of Participants in Remission at Week 10 With Etrolizumab as Compared With Placebo, as Determined by the Mayo Clinic Score (MCS), GA28948 Population
Week 10
Etrolizumab19.4 Percentage of participants
Placebo6.9 Percentage of participants
NCT02167139Arthritis, RheumatoidAmerican College of Rheumatology 20% Response Criteria (ACR20)
Week 24
Humira (Adalimumab)72.2 percentage of participants
SB5 (Proposed Biosimilar to Adalimumab)72.4 percentage of participants
NCT02171429
HIBISCUS II
Colitis, UlcerativePercentage of Participants in Remission at Week 10 With Etrolizumab Compared With Placebo, as Determined by the Mayo Clinic Score (MCS), GA28949 Population
Week 10
Etrolizumab18.2 Percentage of participants
Placebo11.1 Percentage of participants
NCT02185014Crohn DiseasePercentage of Participants With Endoscopic Improvement at Week 40 in Participants With Endoscopic Improvement at Week 0
Week 40
Adalimumab31.6 percentage of participants
NCT02196701
CLEAR
PsoriasisPercentage of Participants Achieving a Satisfactory Response at Week 16 Based on Investigator Assessment
Week 16
Adalimumab + Methotrexate50.0 percentage of participants
Primary Sub-optimal Responders - ADA + MTX33.3 percentage of participants
Secondary Sub-optimal Responders - ADA + MTX52.5 percentage of participants
NCT02196701
CLEAR
PsoriasisPercentage of Participants Achieving a Satisfactory Response at Week 16 Based on Patient Self-assessment
Week 16
Adalimumab + Methotrexate47.8 percentage of participants
Primary Sub-optimal Responders - ADA + MTX16.7 percentage of participants
Secondary Sub-optimal Responders - ADA + MTX52.5 percentage of participants
NCT02207231
VOYAGE 1
PsoriasisPercentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) in the Guselkumab Group Compared to the Placebo Group at Week 16
Week 16
Guselkumab85.1 percentage of participants
Placebo6.9 percentage of participants
NCT02207231
VOYAGE 1
PsoriasisPercentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response in the Guselkumab Group Compared to the Placebo Group at Week 16
Week 16
Guselkumab73.3 percentage of participants
Placebo2.9 percentage of participants
NCT02207244
VOYAGE 2
PsoriasisPercentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) in the Guselkumab Group Compared to the Placebo Group at Week 16
Week 16
Guselkumab 100 mg84.1 percentage of participants
Placebo8.5 percentage of participants
NCT02207244
VOYAGE 2
PsoriasisPercentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response in the Guselkumab Group Compared to the Placebo Group at Week 16
Week 16
Guselkumab 100 mg70.0 percentage of participants
Placebo2.4 percentage of participants
NCT02332590Arthritis, RheumatoidDB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24
Baseline, Week 24
Adalimumab 40 mg/Sarilumab 200 mg-2.20 units on a scale (±0.106 Standard Error)
Sarilumab 200 mg/Sarilumab 200 mg-3.28 units on a scale (±0.105 Standard Error)
NCT02480153Arthritis, RheumatoidPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1
Week 12
Period 1: Adalimumab-EU71.33 percentage of participants
Period 1: PF-0641029368.35 percentage of participants
NCT02489227
PsOsim
—Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12
12 weeks
CHS-1420211 Participants
Humira (Adalimumab)203 Participants
NCT02497469Colitis, UlcerativePercentage of Participants Who Achieved Clinical Remission
Week 52
Adalimumab SC, 160/80/40 mg22.5 percentage of participants
Vedolizumab IV 300 mg31.3 percentage of participants
NCT02499783Crohn DiseasePercentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4
Week 4
Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg37.3 percentage of participants
Double-Blind Period, Weeks 0 to 4: Placebo6.8 percentage of participants
NCT02533375PsoriasisProportion of Participants Achieving Clinical Response at Week 16
Baseline and Week 16
Participants Receiving Adalimumab7 Participants
NCT02629159
SELECT-COMPARE
Arthritis, RheumatoidPercentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12
Week 12
Adalimumab18.0 percentage of participants
Placebo6.1 percentage of participants
Upadacitinib28.7 percentage of participants
NCT02629159
SELECT-COMPARE
Arthritis, RheumatoidPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Baseline and Week 12
Adalimumab63.0 percentage of participants
Placebo36.4 percentage of participants
Upadacitinib70.5 percentage of participants
NCT02632175Colitis, UlcerativeNumber of Participants With Adverse Events (AEs)
From first dose of study drug until 70 days following last dose of study drug (up to 298 weeks).
Adalimumab15 Participants
Adalimumab55 Participants
NCT02632175Colitis, UlcerativeProportion of Participants Who Achieve Clinical Remission as Measured by Partial Mayo Score (PMS)
Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288
Adalimumab32 Participants
Adalimumab25 Participants
Adalimumab27 Participants
Adalimumab28 Participants
Adalimumab29 Participants
Adalimumab30 Participants
Adalimumab31 Participants
Adalimumab33 Participants
Adalimumab37 Participants
Adalimumab36 Participants
Adalimumab40 Participants
Adalimumab42 Participants
Adalimumab42 Participants
Adalimumab40 Participants
Adalimumab45 Participants
Adalimumab43 Participants
Adalimumab51 Participants
Adalimumab47 Participants
Adalimumab50 Participants
NCT02632175Colitis, UlcerativeProportion of Participants Who Achieve Clinical Response as Measured by PMS (From Study M11-290 Baseline)
Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288
Adalimumab47 Participants
Adalimumab26 Participants
Adalimumab28 Participants
Adalimumab29 Participants
Adalimumab30 Participants
Adalimumab32 Participants
Adalimumab35 Participants
Adalimumab35 Participants
Adalimumab39 Participants
Adalimumab40 Participants
Adalimumab42 Participants
Adalimumab43 Participants
Adalimumab44 Participants
Adalimumab56 Participants
Adalimumab46 Participants
Adalimumab55 Participants
Adalimumab56 Participants
Adalimumab51 Participants
Adalimumab50 Participants
NCT02632175Colitis, UlcerativeProportion of Participants Who Achieve Pediatric Ulcerative Colitis Activity Index (PUCAI) Remission
Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288
Adalimumab46 Participants
Adalimumab50 Participants
Adalimumab50 Participants
Adalimumab42 Participants
Adalimumab44 Participants
Adalimumab39 Participants
Adalimumab38 Participants
Adalimumab42 Participants
Adalimumab40 Participants
Adalimumab37 Participants
Adalimumab37 Participants
Adalimumab34 Participants
Adalimumab33 Participants
Adalimumab30 Participants
Adalimumab28 Participants
Adalimumab28 Participants
Adalimumab27 Participants
Adalimumab26 Participants
Adalimumab24 Participants
NCT02632175Colitis, UlcerativeProportion of Participants Who Achieve PUCAI Response (From Study M11-290 Baseline)
Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96,108,120, 144, 168, 192, 216, 240, 264, and 288
Adalimumab23 Participants
Adalimumab38 Participants
Adalimumab43 Participants
Adalimumab42 Participants
Adalimumab30 Participants
Adalimumab27 Participants
Adalimumab25 Participants
Adalimumab26 Participants
Adalimumab49 Participants
Adalimumab21 Participants
Adalimumab47 Participants
Adalimumab32 Participants
Adalimumab34 Participants
Adalimumab36 Participants
Adalimumab37 Participants
Adalimumab37 Participants
Adalimumab47 Participants
Adalimumab40 Participants
Adalimumab39 Participants
NCT02694523PsoriasisPercentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)
Week 16
Adalimumab (Part A)47.4 percentage of participants
Risankizumab (Part A)72.4 percentage of participants
NCT02694523PsoriasisPercentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)
Week 16
Adalimumab (Part A)60.2 percentage of participants
Risankizumab (Part A)83.7 percentage of participants
NCT02694523PsoriasisPercentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI90 at Week 44 (Part B)
Week 44
Adalimumab/Rerandomized to Adalimumab (Part B)21.4 percentage of participants
Adalimumab/Rerandomized to Risankizumab (Part B)66.0 percentage of participants
NCT02696785
COAST-V
Spondylitis, AnkylosingPercentage of Participants Achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) Response
Week 16
Adalimumab35.6 percentage of participants
IXE80Q2W51.8 percentage of participants
IXE80Q4W48.1 percentage of participants
Placebo18.4 percentage of participants
NCT02744755
ADMYRA
Arthritis, RheumatoidStudy Period 1: Change in DAS28-CRP Score From Baseline at Week 12 in Patients Treated With GP2017 and Patients Treated With Humira
Study period 1: week 12
GP2017-2.16 scores on a scale (±0.114 Standard Error)
Humira / Switched GP2017-2.18 scores on a scale (±0.110 Standard Error)
NCT02745080
EXCEED 1
Arthritis, PsoriaticPercentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 52
Week 52
Adalimumab 40 mg s.c.61.5 Percentage of Participants
Secukinumab 300 mg s.c.67.4 Percentage of Participants
NCT02760407
CREDO 2
Arthritis, RheumatoidPercentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response
at Week 12
Arm 1: Olokizumab q4w + Methotrexate342 Participants
Arm 2: Olokizumab q2w + Methotrexate326 Participants
Arm 3: Adalimumab q2w + Methotrexate309 Participants
Arm 4: Placebo q2w + Methotrexate108 Participants
NCT02889796
FINCH 1
Arthritis, RheumatoidPercentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12
Week 12
Adalimumab70.5 percentage of participants
Filgotinib 100 mg69.8 percentage of participants
Filgotinib 200 mg76.6 percentage of participants
Placebo49.9 percentage of participants
NCT02904902Hidradenitis SuppurativaPercentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12
Week 12
Adalimumab86.7 percentage of participants
NCT03104400
SELECT - PsA 1
PsoriasisPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12
Baseline and Week 12
Adalimumab 40 mg65.0 percentage of participants
Placebo36.2 percentage of participants
Upadacitinib 15 mg70.6 percentage of participants
Upadacitinib 30 mg78.5 percentage of participants
NCT03172325—Percentage of Patients With DAS28-EULAR Good and Moderate Responses at Week 24
Week 24
AbbVie Adalimumab63 percentage of participants
CinnaGen Adalimumab63 percentage of participants
NCT03259074
SURPASS
Spondylitis, AnkylosingPercentage of Participants With no Radiographic Progression at Week 104 (Multiple Imputation) (Full Analysis Set)
Baseline and at Week 104
AIN457 150 mg/Placebo66.1 Percentage of participants
AIN457 300 mg66.9 Percentage of participants
GP2017 40mg65.6 Percentage of participants
NCT03412747
BE SURE
PsoriasisPercentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16
Week 16
Adalimumab (RS)47.2 percentage of participants
Bimekizumab 320 mg Q4W + Bimekizumab 320 mg Q4W/Q8W (RS)86.2 percentage of participants
NCT03412747
BE SURE
PsoriasisPercentage of Participants With an Investigator's Global Assessment (IGA) Response (Clear or Almost Clear With at Least 2-Category Improvement Relative to Baseline) at Week 16
Week 16
Adalimumab (RS)57.2 percentage of participants
Bimekizumab 320 mg Q4W + Bimekizumab 320 mg Q4W/Q8W (RS)85.3 percentage of participants
NCT03464136
SEAVUE
Crohn DiseasePercentage of Participants With Clinical Remission at Week 52
Week 52
Adalimumab61.0 percentage of participants
Ustekinumab64.9 percentage of participants
NCT03828019
ADVISE
UveitisCorticosteroid-sparing Treatment Success Within the First 6 Months After Randomization
6 months
Adalimumab (ADA)0.69 Cumulative proportion of participants
Conventional Immunosuppression (CON)0.54 Cumulative proportion of participants
NCT03895203
BE OPTIMAL
Arthritis, PsoriaticPercentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 16
Week 16
ADA 40 mg Q2W45.7 percentage of participants
BKZ 160 mg Q4W43.9 percentage of participants
Placebo10.0 percentage of participants
NCT03906136
AScalate
Axial SpondyloarthritisPercentage of Patients Achieving an ASAS40 Response at Week 24
Baseline, Week 24
Standard-of-care (SOC)49.2 Percentage of participants
Treat-to-Target (T2T)40.1 Percentage of participants
NCT04088409UveitisPart A: Percentage of Responders for Baricitinib at Week 24
Week 24
Baricitinib33.3 Percentage of participants
NCT04115748
PENGUIN 1
Arthritis, PsoriaticPercentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement Response at Week 12
Week 12
Adalimumab (Main Study)67.2 percentage of participants
Filgotinib 100 mg (Main Study)63.2 percentage of participants
Filgotinib 200 mg (Main Study)76.8 percentage of participants
Placebo (Main Study)44.8 percentage of participants
NCT04171414Arthritis, RheumatoidThe Usability as Assessed by Patients Rating Using PRE- and POST-Self-Injection Assessment Questionnaire (SIAQ) at Week 4
Week 4
"CT-P17 SC AI (Adalimumab)"8.23 scores on a scale (±1.191 Standard Deviation)
"CT-P17 SC AI (Adalimumab)"8.27 scores on a scale (±1.669 Standard Deviation)
"CT-P17 SC AI (Adalimumab)"8.16 scores on a scale (±2.036 Standard Deviation)
"CT-P17 SC AI (Adalimumab)"8.00 scores on a scale (±2.131 Standard Deviation)
"CT-P17 SC AI (Adalimumab)"6.55 scores on a scale (±1.859 Standard Deviation)
"CT-P17 SC AI (Adalimumab)"7.07 scores on a scale (±1.616 Standard Deviation)
"CT-P17 SC AI (Adalimumab)"9.59 scores on a scale (±0.968 Standard Deviation)
"CT-P17 SC AI (Adalimumab)"8.39 scores on a scale (±2.079 Standard Deviation)
"CT-P17 SC AI (Adalimumab)"8.70 scores on a scale (±1.457 Standard Deviation)
NCT04230213Arthritis, RheumatoidArea Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau) of Adalimumab
Pre-dose, 48, 72, 96, 144, 240 and 336 hours post dose on Day 211 (Week 30)
Non-switching Arm: Humira (Adalimumab)2365 Micrograms*hour per milliliter (±133 Geometric Coefficient of Variation)
Switching Arm: Humira and PF-06410293 (Adalimumab)2472 Micrograms*hour per milliliter (±129 Geometric Coefficient of Variation)
NCT04230213Arthritis, RheumatoidMaximum Observed Serum Concentration (Cmax) of Adalimumab
Pre-dose, 48, 72, 96, 144, 240 and 336 hours post dose on Day 211 (Week 30)
Non-switching Arm: Humira (Adalimumab)8.974 Micrograms per milliliter (±97 Geometric Coefficient of Variation)
Switching Arm: Humira and PF-06410293 (Adalimumab)9.156 Micrograms per milliliter (±97 Geometric Coefficient of Variation)
NCT04527380Arthritis, JuvenilePercentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 (Ixekizumab - OLT Period)
Week 16
Ixekizumab - OLT Period88.9 Percentage of participants
NCT04909801Arthritis, RheumatoidPercentage of SE+ Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 24
Baseline, week 24
Abatacept59.0 Percentage of participants
Adalimumab, Then Abatacept (OLE Period)60.3 Percentage of participants
NCT05073315—Area Under the Curve From Time 0 Over the Dosing Interval (AUCtau) of ABP 501 (Switching Group) and Adalimumab (Continued-use Group)
Week 28 pre-dose and 1hour, 1 day, 3 days, 4 days, 7 days, 11 days, and 14 days post Week 28 dose
Period 2 (Continued-use Group)1472.68 hr*μg/mL (±174.9 Geometric Coefficient of Variation)
Period 2 (Switching Group)1458.03 hr*μg/mL (±156.6 Geometric Coefficient of Variation)
NCT05073315—Maximum Serum Concentration (Cmax) of ABP 501 (Switching Group) and Adalimumab (Continued-use Group)
Week 28 pre-dose, 1h post Week 28 dose, 1 day post Week 28 dose, 3 days, 4 days, 7 days, 11 days, and 14 days post Week 28 dose
Period 2 (Continued-use Group)5.01 μg/mL (±160.4 Geometric Coefficient of Variation)
Period 2 (Switching Group)4.91 μg/mL (±153.6 Geometric Coefficient of Variation)
NCT05299242
Anti-FreazeF
BursitisNumber of Participants Consenting to be Included in the Trial
3 Months
Eligible Participants9 Participants
NCT05299242
Anti-FreazeF
BursitisNumber of Participants Eligible With Pain Predominant Frozen Shoulder
3 Months
All Screened Participants39 Participants
NCT05299242
Anti-FreazeF
BursitisShoulder Pain and Disability Index (SPADI) Score
Baseline and 3 months
Adalimumab40.1 score on a scale (±30.0 Standard Deviation)
Adalimumab70.8 score on a scale (±16.6 Standard Deviation)
Placebo45.8 score on a scale (±25.3 Standard Deviation)
Placebo55.4 score on a scale (±21.5 Standard Deviation)
NCT05299242
Anti-FreazeF
BursitisTime From First Injection to Second Injection
6 weeks
Adalimumab18.5 days (±3.3 Standard Deviation)
Placebo20.8 days (±5.9 Standard Deviation)
NCT05299242
Anti-FreazeF
BursitisTime From Randomisation to First Injection
2 weeks
Adalimumab12.3 days (±4.8 Standard Deviation)
Placebo7.2 days (±4.1 Standard Deviation)

Publications by year

1978–2026: 1,025 publications.

1978
1
1986
1
1989
2
1990
1
1994
1
1995
2
1996
4
1997
3
1998
8
1999
2
2000
4
2001
6
2002
10
2003
19
2004
20
2005
20
2006
22
2007
37
2008
42
2009
29
2010
30
2011
43
2012
27
2013
34
2014
45
2015
45
2016
48
2017
51
2018
33
2019
51
2020
62
2021
67
2022
79
2023
53
2024
60
2025
46
2026
17

Publications by indication

Arthritis, Rheumatoid (311)

  • Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN).
    Rheumatol Ther · 2026 · PMID 41963765 · NCT05913817
  • Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study.
    Ann Rheum Dis · 2026 · PMID 41991443 · NCT05814627
  • Sex Differences in Treatment Expectations, Satisfaction and Tolerance After Switching to CT-P17, an Adalimumab Biosimilar: A Post Hoc Analysis of the YU-MATTER Study.
    Rheumatol Ther · 2026 · PMID 41838366 · NCT05427942
  • Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease.
    Ann Rheum Dis · 2026 · PMID 40992967 · NCT02092467
  • Discontinuation versus continuation of maintenance treatment with tumor necrosis factor inhibitors in patients with rheumatoid arthritis with low disease activity or remission: A randomized double-blind placebo-controlled trial.
    Semin Arthritis Rheum · 2025 · PMID 41045868 · NCT01793519

Crohn Disease (199)

  • Serum protein profiles differ with adalimumab and ustekinumab treatment in moderately to severely active Crohn's disease.
    J Crohns Colitis · 2025 · PMID 41258994 · NCT03464136
  • Crohn's Disease Stricture Response to Treatment Assessed with Magnetic Resonance Imaging and Intestinal Ultrasound: STRIDENT Randomized Trial.
    Inflamm Bowel Dis · 2025 · PMID 40339148 · NCT03220841
  • Long-term Results of Drug Treatment for Crohn's Disease Strictures.
    Clin Gastroenterol Hepatol · 2025 · PMID 40972879 · NCT03220841
  • Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Cochrane Database Syst Rev · 2025 · PMID 40357993 · NCT04655807
  • Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
    Gut · 2025 · PMID 39794921 · NCT02994836

Psoriasis (122)

  • Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability.
    J Allergy Clin Immunol · 2026 · PMID 41580158 · NCT03412747
  • Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years.
    J Dermatolog Treat · 2026 · PMID 41800601 · NCT03412747
  • Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT.
    Dermatol Ther (Heidelb) · 2026 · PMID 41359217 · NCT03412747
  • Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials.
    Dermatol Ther (Heidelb) · 2025 · PMID 41060492 · NCT03412747
  • Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies.
    Am J Clin Dermatol · 2025 · PMID 40886218 · NCT03412747

Colitis, Ulcerative (83)

  • Psychological interventions for treatment of inflammatory bowel disease.
    Cochrane Database Syst Rev · 2025 · PMID 40243391 · NCT04183608
  • HLA-DQA1*05 Associates With Anti-Tumor Necrosis Factor Immunogenicity and Low Adalimumab Trough Concentrations in Inflammatory Bowel Disease Patients From the SERENE Ulcerative Colitis and Crohn's Disease Studies.
    J Crohns Colitis · 2025 · PMID 39162746 · NCT02065622
  • Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies.
    J Crohns Colitis · 2024 · PMID 37801628 · NCT02065622
  • Confocal laser endomicroscopy as predictive biomarker of clinical and endoscopic efficacy of vedolizumab in ulcerative colitis: The DETECT study.
    PLoS One · 2024 · PMID 38564601 · NCT02878083
  • Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis.
    Clin Gastroenterol Hepatol · 2023 · PMID 35934286 · NCT02497469

Arthritis, Psoriatic (78)

  • Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year.
    Dermatol Ther (Heidelb) · 2026 · PMID 41381988 · NCT03895203
  • Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
    Rheumatol Ther · 2026 · PMID 38446397 · NCT03895203
  • Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies.
    RMD Open · 2026 · PMID 41807031 · NCT03895203
  • Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.
    Rheumatology (Oxford) · 2026 · PMID 41838419 · NCT03895203
  • Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.
    Rheumatol Ther · 2025 · PMID 40347389 · NCT03895203

Spondylitis, Ankylosing (66)

  • Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials.
    Rheumatol Ther · 2026 · PMID 41417207 · NCT02696785
  • Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration.
    Adv Ther · 2025 · PMID 40694276 · NCT02696785
  • The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm.
    Lancet Rheumatol · 2025 · PMID 39983751 · NCT02696785
  • IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial.
    Lancet Rheumatol · 2024 · PMID 38229357 · NCT02893254
  • Improvement in spinal pain at night and its impact on long-term outcomes in radiographic axial spondyloarthritis: Results from Ixekizumab COAST-V randomised trial.
    Semin Arthritis Rheum · 2024 · PMID 39509838 · NCT02696785

Publications by journal

Trial-results highlights

In a study for juvenile arthritis (NCT00048542), the number of participants experiencing disease flare during the double-blind phase (Week 16 to Week 48) was 13 participants in the Double-Blind Adalimumab arm and 20 participants in the Double-Blind Placebo arm. For Crohn's disease, a study (NCT00055497) reported the number of participants achieving clinical remission at Week 56. Using the Last Observation Carried Forward (LOCF) method, 15 participants in the DB Adalimumab 40 mg Every Other Week arm and 15 participants in the DB Adalimumab 40 mg Every Week arm achieved remission, compared to 8 participants in the DB Placebo arm. Using the Non-Responder Imputation (NRI) method, 9 participants in the DB Adalimumab 40 mg Every Other Week arm and 12 participants in the DB Adalimumab 40 mg Every Week arm achieved remission, compared to 6 participants in the Placebo arm.

In a study for ankylosing spondylitis (NCT00085644), the mean change in the Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) at Week 104 was 0.9 score for the Any Adalimumab arm. For the ASAS 20 response at Week 12 in the same study, the Adalimumab arm reported numbers of responders as:

  • 83 participants
  • 121 participants
  • 4 participants

The Placebo arm reported numbers of responders as:

  • 22 participants
  • 3 participants
  • 82 participants

For rheumatoid arthritis, a study (NCT00195650) measured the change from baseline in the Disability Index of the Health Assessment Questionnaire (HAQ). The Adalimumab arm showed a change of -0.59 units at Week 260 and -0.52 units at Week 520. At Week 260, 243 participants in the Adalimumab arm were in clinical remission based on the Modified Disease Activity Score.

All values are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Adalimumab publications (1,025)

2026 (17 papers)

  1. Bimekizumab Efficacy and Safety in Patients with Psoriatic Arthritis with Substantial Skin and Nail Psoriasis to 1 Year.
    Thaçi D, Asahina A, Boehncke WH, et al. · Dermatol Ther (Heidelb) · 2026 · Trial result
    PubMed: PMID 41381988 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  2. Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.
    Mease PJ, Warren RB, Nash P, et al. · Rheumatol Ther · 2026 · Trial result
    PubMed: PMID 38446397 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  3. Bimekizumab long-term response in psoriasis: Mechanistic insights into efficacy level and durability.
    Krueger JG, Cutcutache I, Lebwohl M, et al. · J Allergy Clin Immunol · 2026 · Trial result
    PubMed: PMID 41580158 · NCT03412747 (BE SURE) · Psoriasis
  4. Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years.
    Gisondi P, Elewski B, Pinter A, et al. · J Dermatolog Treat · 2026 · Trial result
    PubMed: PMID 41800601 · NCT03412747 (BE SURE) · Psoriasis
  5. Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT.
    Armstrong A, Papp KA, Lebwohl M, et al. · Dermatol Ther (Heidelb) · 2026 · Trial result
    PubMed: PMID 41359217 · NCT03412747 (BE SURE) · Psoriasis
  6. Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis.
    Yamauchi PS, Chow V, Mytych DT, et al. · Adv Ther · 2026 · Derived
    PubMed: PMID 41954860 · NCT05073315
  7. Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis.
    Takeuchi T, Tanaka Y, Yamanaka H, et al. · Rheumatol Ther · 2026 · Derived
    PubMed: PMID 41565911 · NCT02187055 (ORAL STRATEGY)
  8. Evaluation of Injection Site Pain and Adherence in Patients Transitioning from a High to Low Volume Adalimumab Formulation (AVT02, Simlandi®) Across Multiple Indications (EASE PAIN).
    Shahrokh DK, Vender RB, Lynde CW, et al. · Rheumatol Ther · 2026 · Derived
    PubMed: PMID 41963765 · NCT05913817 (EASE PAIN) · Arthritis, Rheumatoid
  9. Adalimumab, Anakinra, and Tocilizumab in Patients With Noninfectious Uveitis: A Multicenter Randomized Controlled Trial.
    Saadoun D, Ghembaza A, Touhami S, et al. · Am J Ophthalmol · 2026 · Derived
    PubMed: PMID 41643758 · NCT02929251 (RUBI) · Uveitis
  10. Does HLA-B27 Status Influence Ixekizumab Efficacy in Axial Spondyloarthritis? Results From the COAST-V, COAST-W, and COAST-X Trials.
    Reveille JD, Rudwaleit M, Rahman P, et al. · Rheumatol Ther · 2026 · Derived
    PubMed: PMID 41417207 · NCT02696785 (COAST-V) · Spondylitis, Ankylosing
  11. Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab.
    Ramanan AV, Ruperto N, Foeldvari I, et al. · Lancet Rheumatol · 2026 · Derived
    PubMed: PMID 41785908 · NCT04527380 · Arthritis, Juvenile
  12. Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study.
    Mysler E, Sidiropoulos PI, Balanescu A, et al. · Ann Rheum Dis · 2026 · Derived
    PubMed: PMID 41991443 · NCT05814627 (SELECT- SWITCH) · Arthritis, Rheumatoid
  13. Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies.
    Mease PJ, Merola JF, Magrey M, et al. · RMD Open · 2026 · Derived
    PubMed: PMID 41807031 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  14. Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.
    Gossec L, Coates LC, Landewé RBM, et al. · Rheumatology (Oxford) · 2026 · Derived
    PubMed: PMID 41838419 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  15. Sex Differences in Treatment Expectations, Satisfaction and Tolerance After Switching to CT-P17, an Adalimumab Biosimilar: A Post Hoc Analysis of the YU-MATTER Study.
    Gossec L, Bouguen G, Dellal A, et al. · Rheumatol Ther · 2026 · Derived
    PubMed: PMID 41838366 · NCT05427942 (YU-MATTER) · Arthritis, Rheumatoid
  16. Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease.
    Giles JT, Charles-Schoeman C, Buch MH, et al. · Ann Rheum Dis · 2026 · Derived
    PubMed: PMID 40992967 · NCT02092467 · Arthritis, Rheumatoid
  17. Comparison of treatment with GP2017 (an adalimumab biosimilar) and reference adalimumab in people with plaque psoriasis: a plain language summary of the ADACCESS trial.
    Betteridge N, Blauvelt A, Edgerton C, et al. · Immunotherapy · 2026 · Derived
    PubMed: PMID 41709696 · NCT02016105 (ADACCESS)

2025 (46 papers)

  1. Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials.
    Strober B, Boehncke WH, Krueger JG, et al. · Dermatol Ther (Heidelb) · 2025 · Trial result
    PubMed: PMID 41060492 · NCT03412747 (BE SURE) · Psoriasis
  2. Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial.
    Nanchahal J, Ball C, Rombach I, et al. · Lancet Rheumatol · 2025 · Trial result
    PubMed: PMID 35949922 · NCT03180957 (RIDD) · Dupuytren Contracture
  3. Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.
    Mease PJ, Merola JF, Tanaka Y, et al. · Rheumatol Ther · 2025 · Trial result
    PubMed: PMID 40347389 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  4. Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.
    Acharya NR, Ramanan AV, Coyne AB, et al. · Lancet · 2025 · Trial result
    PubMed: PMID 39863370 · NCT03816397 (ADJUST) · Uveitis
  5. Adalimumab Dose Reduction and Withdrawal in Stable Non-Infectious Pediatric Uveitis: An Open-Label, Prospective, Pilot Study.
    Yuan PD, Hu YW, Chen XQ, et al. · Ocul Immunol Inflamm · 2025 · Derived
    PubMed: PMID 38652891 · NCT05155592 · Uveitis
  6. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials.
    Wright GC, Mysler E, Kwok K, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 38958913 · NCT02187055 (ORAL STRATEGY)
  7. Discontinuation versus continuation of maintenance treatment with tumor necrosis factor inhibitors in patients with rheumatoid arthritis with low disease activity or remission: A randomized double-blind placebo-controlled trial.
    Ward MM, Weinstein A, Alejandro-Silva P, et al. · Semin Arthritis Rheum · 2025 · Derived
    PubMed: PMID 41045868 · NCT01793519 (STARA) · Arthritis, Rheumatoid
  8. Serum protein profiles differ with adalimumab and ustekinumab treatment in moderately to severely active Crohn's disease.
    Venkat S, Zeeman M, Hart A, et al. · J Crohns Colitis · 2025 · Derived
    PubMed: PMID 41258994 · NCT03464136 (SEAVUE) · Crohn Disease
  9. Precision Medicine Proof-of-Concept Study of a TNF Inhibitor in FSGS and Treatment-Resistant Minimal Change Disease.
    Trachtman H, Modi ZJ, Ju W, et al. · Kidney360 · 2025 · Derived
    PubMed: PMID 39808779 · NCT04009668 · Glomerulosclerosis, Focal Segmental
  10. Filling the "GAP" in Real-World Assessment of Psoriatic Arthritis Disease Activity: Performance Characteristics of a Global/Pain Composite Endpoint.
    Tillett W, Birt J, Vadhariya A, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 38955921 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  11. Psychological interventions for treatment of inflammatory bowel disease.
    Tiles-Sar N, Neuser J, de Sordi D, et al. · Cochrane Database Syst Rev · 2025 · Derived
    PubMed: PMID 40243391 · NCT04183608 (CONTROL) · Colitis, Ulcerative
  12. Patients with High Baseline Neutrophil-to-Lymphocyte Ratio Exhibit Better Response to Filgotinib as Treatment for Rheumatoid Arthritis.
    Taylor PC, Downie B, Han L, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 38985247 · NCT02889796 (FINCH 1) · Arthritis, Rheumatoid
  13. The Uncoupling of Disease Activity from Joint Structural Progression in Patients with Rheumatoid Arthritis Treated with Filgotinib.
    Tanaka Y, Atsumi T, Aletaha D, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 39592547 · NCT02889796 (FINCH 1) · Arthritis, Rheumatoid
  14. Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial.
    Tamai H, Ikeda K, Miyamoto T, et al. · Ann Rheum Dis · 2025 · Derived
    PubMed: PMID 39874232 · NCT03505008 · Arthritis, Rheumatoid
  15. HLA-DQA1*05 Associates With Anti-Tumor Necrosis Factor Immunogenicity and Low Adalimumab Trough Concentrations in Inflammatory Bowel Disease Patients From the SERENE Ulcerative Colitis and Crohn's Disease Studies.
    Reppell M, Zheng X, Dreher I, et al. · J Crohns Colitis · 2025 · Derived
    PubMed: PMID 39162746 · NCT02065622 · Colitis, Ulcerative
  16. Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom Duration.
    Navarro-Compán V, Reveille JD, Rahman P, et al. · Adv Ther · 2025 · Derived
    PubMed: PMID 40694276 · NCT02696785 (COAST-V) · Spondylitis, Ankylosing
  17. Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies.
    Merola JF, Warren RB, Thaçi D, et al. · Am J Clin Dermatol · 2025 · Derived
    PubMed: PMID 40886218 · NCT03412747 (BE SURE) · Psoriasis
  18. Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials.
    Merola JF, Gottlieb AB, Pinter A, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
    PubMed: PMID 39578348 · NCT03412747 (BE SURE) · Psoriasis
  19. Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Mease PJ, Warren RB, Nash P, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 39120849 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  20. Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Mease PJ, Warren RB, Nash P, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 39120848 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  21. Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.
    Mease PJ, Merola JF, Tanaka Y, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 39215949 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  22. Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies.
    Mease PJ, Gensler LS, Orbai AM, et al. · RMD Open · 2025 · Derived
    PubMed: PMID 40194794 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  23. Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.
    McInnes IB, Coates LC, Mease PJ, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 41053449 · NCT05640245 · Psoriasis
  24. The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm.
    Maksymowych WP, Lambert RGW, Bolce RJ, et al. · Lancet Rheumatol · 2025 · Derived
    PubMed: PMID 39983751 · NCT02696785 (COAST-V) · Spondylitis, Ankylosing
  25. Crohn's Disease Stricture Response to Treatment Assessed with Magnetic Resonance Imaging and Intestinal Ultrasound: STRIDENT Randomized Trial.
    Lovett GC, Schulberg JD, Hamilton AL, et al. · Inflamm Bowel Dis · 2025 · Derived
    PubMed: PMID 40339148 · NCT03220841 (STRIDENT) · Crohn Disease
  26. Long-term Results of Drug Treatment for Crohn's Disease Strictures.
    Lovett GC, Schulberg JD, Hamilton AL, et al. · Clin Gastroenterol Hepatol · 2025 · Derived
    PubMed: PMID 40972879 · NCT03220841 (STRIDENT) · Crohn Disease
  27. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
    Liu ID, Willis NS, Craig JC, et al. · Cochrane Database Syst Rev · 2025 · Derived
    PubMed: PMID 40337980 · NCT00814255 (FONTII) · Glomerulosclerosis, Focal Segmental
  28. Synergistic Improvements in Synovitis, Enthesitis, and Patient-Reported Outcomes for Patients with Psoriatic Arthritis Treated with Ixekizumab in SPIRIT Trials.
    Kristensen LE, McGonagle D, Rudwaleit M, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 40014255 · NCT03151551 (SPIRIT-H2H) · Arthritis, Psoriatic
  29. Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone.
    Keystone EC, Breedveld FC, van der Heijde D, et al. · RMD Open · 2025 · Derived
    PubMed: PMID 29018564 · NCT00195663 (PREMIER) · Arthritis, Rheumatoid
  30. Treatment of hidradenitis suppurativa with adalimumab in the PIONEER I and II randomized controlled trials reduced indices of systemic inflammation, recognized risk factors for cardiovascular disease.
    Kearney N, Chen X, Bi Y, et al. · Clin Exp Dermatol · 2025 · Derived
    PubMed: PMID 39141589 · NCT01468207 (PIONEER I) · Psoriasis
  31. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Hasskamp J, Meinhardt C, Timmer A, et al. · Cochrane Database Syst Rev · 2025 · Derived
    PubMed: PMID 40357993 · NCT04655807 (DUET) · Crohn Disease
  32. Response to Tofacitinib in Patients with Psoriatic Arthritis and Probable Anxiety/Depressive Disorder: A Post Hoc Analysis of Phase 3 Trials.
    Gossec L, Sellas A, Gruben DC, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 41148555 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  33. Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies.
    Gladman DD, Mease PJ, Gossec L, et al. · J Rheumatol · 2025 · Derived
    PubMed: PMID 39892885 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  34. Long-term tofacitinib efficacy and safety in psoriatic arthritis with or without prior biologic DMARD exposure: a post hoc analysis.
    Gladman DD, Dougados M, Marzo-Ortega H, et al. · Rheumatol Adv Pract · 2025 · Derived
    PubMed: PMID 40241921 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  35. Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies.
    Gladman D, Tillett W, Gruben D, et al. · RMD Open · 2025 · Derived
    PubMed: PMID 40461265 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  36. Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
    Gisbert JP, Donday MG, Riestra S, et al. · Gut · 2025 · Derived
    PubMed: PMID 39794921 · NCT02994836 · Crohn Disease
  37. Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
    Fautrel B, Bouhnik Y, Salliot C, et al. · Drugs Real World Outcomes · 2025 · Derived
    PubMed: PMID 39384685 · NCT03662919 (PERFUSE) · Arthritis, Rheumatoid
  38. Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials.
    Egeberg A, Conrad C, Gorecki P, et al. · Dermatol Ther (Heidelb) · 2025 · Derived
    PubMed: PMID 38485863 · NCT02207231 (VOYAGE 1) · Psoriasis
  39. Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity.
    Coates LC, Orbai AM, Morita A, et al. · BMC Rheumatol · 2025 · Derived
    PubMed: PMID 30886974 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  40. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease.
    Burmester GR, Deodhar A, Irvine AD, et al. · Adv Ther · 2025 · Derived
    PubMed: PMID 40875187 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  41. Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate.
    Buch MH, Walker D, Edwards CJ, et al. · Rheumatology (Oxford) · 2025 · Derived
    PubMed: PMID 39331638 · NCT02889796 (FINCH 1) · Arthritis, Rheumatoid
  42. Association of bile acid diarrhea with symptoms and disease activity in Crohn's disease: post-hoc clinical trial analysis of serum 7a-hydroxy-4cholestern-3-one, C4, in patients with active Crohn's disease.
    Battat R, Kandi S, Lacerda AP, et al. · J Crohns Colitis · 2025 · Derived
    PubMed: PMID 40202488 · NCT02065570 · Crohn Disease
  43. Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance.
    Batko B, Jeka S, Wiland P, et al. · Rheumatol Ther · 2025 · Derived
    PubMed: PMID 39060905 · NCT02092467 · Arthritis, Rheumatoid
  44. The Role of Cytokines in Degenerative Retinal Diseases: A Comprehensive Review.
    Siqueira RC, Brandão CC · Biomedicines · 2025 · Background
    PubMed: PMID 40722794 · NCT07348588 (ADARET) · Retinal Degeneration
  45. New Interleukin-23 Antagonists' Use in Crohn's Disease.
    Biskup L, Semeradt J, Rogowska J, et al. · Pharmaceuticals (Basel) · 2025 · Background
    PubMed: PMID 40283885 · NCT07495644 · Crohn Disease
  46. Standardization of Nomenclature for Ocular Tuberculosis - Results of Collaborative Ocular Tuberculosis Study (COTS) Workshop.
    Agrawal R, Agarwal A, Jabs DA, et al. · Ocul Immunol Inflamm · 2025 · Background
    PubMed: PMID 31821096 · NCT05015335 · Uveitis, Anterior

2024 (60 papers)

  1. Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis.
    Moulin D, Millard M, Taïeb M, et al. · Ann Rheum Dis · 2024 · Trial result
    PubMed: PMID 38049981 · NCT01382160 (AFORA) · Arthritis, Rheumatoid
  2. Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies.
    Kristensen LE, Tillett W, Nash P, et al. · Ther Adv Musculoskelet Dis · 2024 · Trial result
    PubMed: PMID 39534481 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  3. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
    Gordon KB, Langley RG, Warren RB, et al. · Br J Dermatol · 2024 · Trial result
    PubMed: PMID 37950894 · NCT03412747 (BE SURE) · Psoriasis
  4. IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial.
    Xu H, Li Z, Wu J, et al. · Lancet Rheumatol · 2024 · Derived
    PubMed: PMID 38229357 · NCT02893254 · Spondylitis, Ankylosing
  5. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment.
    Winthrop KL, Curtis JR, Yamaoka K, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 34870800 · NCT02187055 (ORAL STRATEGY)
  6. The protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomized controlled trial.
    Watson M, Tillett W, Jadon D, et al. · Ther Adv Musculoskelet Dis · 2024 · Derived
    PubMed: PMID 38826570 · NCT03739853 (SPEED) · Arthritis, Psoriatic
  7. Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.
    Warren RB, McInnes IB, Nash P, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 38488975 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  8. Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study.
    Wang J, Kong X, Ma L, et al. · Rheumatology (Oxford) · 2024 · Derived
    PubMed: PMID 37540159 · NCT04300686 · Takayasu Arteritis
  9. Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies.
    Verstockt B, Pivorunas V, Al Mahi N, et al. · J Crohns Colitis · 2024 · Derived
    PubMed: PMID 37801628 · NCT02065622 · Colitis, Ulcerative
  10. A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire.
    Tillett W, Lin CY, Zbrozek A, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 31154634 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  11. Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial.
    Tamai H, Ikeda K, Miyamoto T, et al. · Lancet Rheumatol · 2024 · Derived
    PubMed: PMID 38251524 · NCT03505008 · Arthritis, Rheumatoid
  12. Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
    Strober B, Coates LC, Lebwohl MG, et al. · Drug Saf · 2024 · Derived
    PubMed: PMID 37906417 · NCT02207244 (VOYAGE 2) · Psoriasis
  13. Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure.
    Spreafico A, Couselo EM, Irmisch A, et al. · Front Oncol · 2024 · Derived
    PubMed: PMID 38577337 · NCT04551352 · Melanoma
  14. Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis.
    Smolen JS, Taylor PC, Tanaka Y, et al. · Rheumatology (Oxford) · 2024 · Derived
    PubMed: PMID 39222436 · NCT01500278 · Arthritis, Rheumatoid
  15. Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain.
    Schlueter M, Finn E, Díaz S, et al. · Clinicoecon Outcomes Res · 2024 · Derived
    PubMed: PMID 31239736 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  16. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.
    Rubbert-Roth A, Kakehasi AM, Takeuchi T, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 37982966 · NCT03104400 (SELECT - PsA 1) · Psoriasis
  17. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies.
    Ritchlin CT, Giles JT, Ogdie A, et al. · ACR Open Rheumatol · 2024 · Derived
    PubMed: PMID 32910531 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  18. Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data.
    Rehberg M, Giegerich C, Praestgaard A, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 34519964 · NCT02332590 · Arthritis, Rheumatoid
  19. Improvement in spinal pain at night and its impact on long-term outcomes in radiographic axial spondyloarthritis: Results from Ixekizumab COAST-V randomised trial.
    Ramiro S, Lukas C, Nissen MJ, et al. · Semin Arthritis Rheum · 2024 · Derived
    PubMed: PMID 39509838 · NCT02696785 (COAST-V) · Spondylitis, Ankylosing
  20. Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis.
    Ramiro S, Lukas C, Bessette L, et al. · RMD Open · 2024 · Derived
    PubMed: PMID 39004432 · NCT02696785 (COAST-V) · Spondylitis, Ankylosing
  21. Confocal laser endomicroscopy as predictive biomarker of clinical and endoscopic efficacy of vedolizumab in ulcerative colitis: The DETECT study.
    Quénéhervé L, Trang-Poisson C, Fantou A, et al. · PLoS One · 2024 · Derived
    PubMed: PMID 38564601 · NCT02878083 (DETECT) · Colitis, Ulcerative
  22. Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial.
    Puig L, Costanzo A, de Jong EMGJ, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 39153060 · NCT02207231 (VOYAGE 1) · Psoriasis
  23. Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.
    Puig L, Costanzo A, de Jong EMGJ, et al. · Am J Clin Dermatol · 2024 · Derived
    PubMed: PMID 37804472 · NCT02207231 (VOYAGE 1) · Psoriasis
  24. Tofacitinib Monotherapy in Rheumatoid Arthritis: Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention.
    Pope J, Finckh A, Silva-Fernández L, et al. · Open Access Rheumatol · 2024 · Derived
    PubMed: PMID 38883150 · NCT02187055 (ORAL STRATEGY)
  25. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies.
    Orbai AM, Mease PJ, Helliwell PS, et al. · BMC Rheumatol · 2024 · Derived
    PubMed: PMID 36045453 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  26. Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis.
    Mease P, Walsh JA, Baraliakos X, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 31254223 · NCT02696785 (COAST-V) · Spondylitis, Ankylosing
  27. Comparative Effectiveness of Bimekizumab in Psoriatic Arthritis: A Model-Based Meta-Analysis of American College of Rheumatology Response Criteria.
    Maloney A, Dua P, Ahmed GF, et al. · Clin Pharmacol Ther · 2024 · Derived
    PubMed: PMID 38073049 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  28. Impact of RA treatment strategies on lipids and vascular inflammation in rheumatoid arthritis: a secondary analysis of the TARGET randomized active comparator trial.
    Liao KP, Rist P, Giles J, et al. · Arthritis Res Ther · 2024 · Derived
    PubMed: PMID 38915065 · NCT02374021 (TARGET) · Arthritis, Rheumatoid
  29. Comparing anti-drug antibody signal-to-noise ratios to assess immunogenicity and interchangeability in adalimumab biosimilar studies.
    Lemke L, Blauvelt A, Brückmann I, et al. · Expert Opin Biol Ther · 2024 · Derived
    PubMed: PMID 39545451 · NCT02016105 (ADACCESS)
  30. Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1).
    Kameda H, Hagimori K, Morisaki Y, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 37858007 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  31. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients.
    Kamal ME, Werida RH, Radwan MA, et al. · Inflammopharmacology · 2024 · Derived
    PubMed: PMID 38985232 · NCT05291039 · Inflammatory Bowel Diseases
  32. Enthesitis in patients with psoriatic arthritis treated with secukinumab or adalimumab: a post hoc analysis of the EXCEED study.
    Kaeley GS, Schett G, Conaghan PG, et al. · Rheumatology (Oxford) · 2024 · Derived
    PubMed: PMID 37097894 · NCT02745080 (EXCEED 1) · Arthritis, Psoriatic
  33. Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis.
    Jabado O, Maldonado MA, Schiff M, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 34878629 · NCT00929864 · Arthritis, Rheumatoid
  34. Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies.
    Husni ME, Mease PJ, Merola JF, et al. · RMD Open · 2024 · Derived
    PubMed: PMID 39313302 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  35. Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis.
    Hsieh CY, Hsu FL, Tsai TF, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 39073712 · NCT02694523 · Psoriasis
  36. Anti-TNF (adalimumab) injection for the treatment of pain-predominant early-stage frozen shoulder: the Anti-Freaze-Feasibility randomised controlled trial.
    Hopewell S, Srikesavan C, Evans A, et al. · BMJ Open · 2024 · Derived
    PubMed: PMID 38692727 · NCT05299242 (Anti-FreazeF) · Bursitis
  37. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib.
    Hetland ML, Strangfeld A, Bonfanti G, et al. · Arthritis Res Ther · 2024 · Derived
    PubMed: PMID 39192350 · NCT00550446 · Arthritis, Rheumatoid
  38. Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies.
    Gossec L, Orbai AM, de Wit M, et al. · Rheumatology (Oxford) · 2024 · Derived
    PubMed: PMID 38754125 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  39. Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis.
    Gladman DD, Nash P, Mease PJ, et al. · Arthritis Res Ther · 2024 · Derived
    PubMed: PMID 39702318 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  40. Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study.
    Fleischmann RM, Saikali W, Lakhanpal S, et al. · Lancet Rheumatol · 2024 · Derived
    PubMed: PMID 38251497 · NCT04230213 · Arthritis, Rheumatoid
  41. Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE).
    Fleischmann R, Weinblatt M, Ahmad H, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 31642045 · NCT00929864 · Arthritis, Rheumatoid
  42. Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study.
    Fleischmann R, Swierkot J, Penn SK, et al. · RMD Open · 2024 · Derived
    PubMed: PMID 38806190 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  43. Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE.
    Fleischmann R, Blanco R, Van den Bosch F, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 38498140 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  44. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib.
    Dikranian A, Gold D, Bessette L, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 34921355 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  45. Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis.
    de Vlam K, Mease PJ, Bushmakin AG, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 36076054 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  46. Exploring the Effects of Ixekizumab on Pain in Patients with Ankylosing Spondylitis Based on Objective Measures of Inflammation: Post Hoc Analysis from a Large Randomized Clinical Trial.
    de Vlam K, Maksymowych WP, Gallo G, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 38637464 · NCT02696785 (COAST-V) · Spondylitis, Ankylosing
  47. Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis.
    Curtis JR, Emery P, Downie B, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 38057656 · NCT02889796 (FINCH 1) · Arthritis, Rheumatoid
  48. Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER).
    Colombel JF, Ungaro RC, Sands BE, et al. · Clin Gastroenterol Hepatol · 2024 · Derived
    PubMed: PMID 37743037 · NCT02764762 · Crohn Disease
  49. Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study.
    Coates LC, Tillett W, D'Agostino MA, et al. · Lancet Rheumatol · 2024 · Derived
    PubMed: PMID 38288922 · NCT02814175 (CONTROL) · Arthritis, Psoriatic
  50. Cardiovascular Events, Malignancies, and Efficacy Outcomes in Latin American Patients With Rheumatoid Arthritis Receiving Tofacitinib or Tumor Necrosis Factor Inhibitors: A Post Hoc Analysis of the ORAL Surveillance Study.
    Citera G, Mysler E, Kakehasi AM, et al. · J Clin Rheumatol · 2024 · Derived
    PubMed: PMID 38880956 · NCT02092467 · Arthritis, Rheumatoid
  51. Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials.
    Citera G, Jain R, Irazoque F, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 37925660 · NCT02187055 (ORAL STRATEGY)
  52. Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials.
    Cantini F, Marchesoni A, Novelli L, et al. · Rheumatology (Oxford) · 2024 · Derived
    PubMed: PMID 38331400 · NCT03104400 (SELECT - PsA 1) · Psoriasis
  53. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
    Burmester GR, Stigler J, Rubbert-Roth A, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 38683479 · NCT03104400 (SELECT - PsA 1) · Psoriasis
  54. Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.
    Buch MH, Bhatt DL, Charles-Schoeman C, et al. · RMD Open · 2024 · Derived
    PubMed: PMID 38609322 · NCT02092467 · Arthritis, Rheumatoid
  55. Patient Satisfaction and Experience with CT-P17 Following Transition from Reference Adalimumab or Another Adalimumab Biosimilar: Results from the Real-World YU-MATTER Study.
    Bouguen G, Gossec L, Abitbol V, et al. · BioDrugs · 2024 · Derived
    PubMed: PMID 39322802 · NCT05427942 (YU-MATTER) · Arthritis, Rheumatoid
  56. Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy.
    Blauvelt A, Langley RG, Branigan PJ, et al. · JID Innov · 2024 · Derived
    PubMed: PMID 39114670 · NCT02207231 (VOYAGE 1) · Psoriasis
  57. Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis.
    Balsa A, Wassenberg S, Tanaka Y, et al. · Rheumatol Ther · 2024 · Derived
    PubMed: PMID 37747626 · NCT02889796 (FINCH 1) · Arthritis, Rheumatoid
  58. Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity.
    Armstrong AW, Jaleel T, Merola JF, et al. · Dermatol Ther (Heidelb) · 2024 · Derived
    PubMed: PMID 38814433 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  59. Assessing the effects of distinct biologic therapies on rheumatoid arthritis pain by nociceptive, neuropathic and nociplastic pain components: a randomised feasibility study.
    Ahmed L, Biddle K, Blundell A, et al. · Pilot Feasibility Stud · 2024 · Derived
    PubMed: PMID 38755699 · NCT04255134 (BIORA-PAIN) · Arthritis, Rheumatoid
  60. Immunogenicity of biologics in inflammatory bowel disease.
    Vermeire S, Gils A, Accossato P, et al. · Ther Adv Gastroenterol · 2024 · Background
    PubMed: PMID 29383030 · NCT07495644 · Crohn Disease

2023 (53 papers)

  1. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
    Thaçi D, Vender R, de Rie MA, et al. · Br J Dermatol · 2023 · Trial result
    PubMed: PMID 36689515 · NCT03412747 (BE SURE) · Psoriasis
  2. Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
    Ritchlin CT, Coates LC, McInnes IB, et al. · Ann Rheum Dis · 2023 · Trial result
    PubMed: PMID 37696588 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  3. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs.
    Winthrop KL, Yndestad A, Henrohn D, et al. · Rheumatol Ther · 2023 · Derived
    PubMed: PMID 36526796 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  4. Microbiota-derived butyrate dampens linaclotide stimulation of the guanylate cyclase C pathway in patient-derived colonoids.
    Velez Lopez A, Waddell A, Antonacci S, et al. · Neurogastroenterol Motil · 2023 · Derived
    PubMed: PMID 37736865 · NCT04131504 (ENvISION) · Crohn Disease
  5. Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
    Tillett W, Egeberg A, Sonkoly E, et al. · Arthritis Res Ther · 2023 · Derived
    PubMed: PMID 37715294 · NCT02207244 (VOYAGE 2) · Psoriasis
  6. Ocular immunosuppressive microenvironment and novel drug delivery for control of uveitis.
    Teabagy S, Wood E, Bilsbury E, et al. · Adv Drug Deliv Rev · 2023 · Derived
    PubMed: PMID 37172782 · NCT03828019 (ADVISE) · Uveitis
  7. Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate.
    Tanaka Y, Taylor PC, Elboudwarej E, et al. · Rheumatol Ther · 2023 · Derived
    PubMed: PMID 37490202 · NCT02889796 (FINCH 1) · Arthritis, Rheumatoid
  8. Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials.
    Tanaka Y, Atsumi T, Aletaha D, et al. · Rheumatol Ther · 2023 · Derived
    PubMed: PMID 36327094 · NCT02889796 (FINCH 1) · Arthritis, Rheumatoid
  9. Efficacy and safety of adalimumab for inflammatory flare prevention in paediatric non-infectious anterior uveitis with peripheral retinal vascular leakage: a study protocol for a single-centre, randomised controlled trial.
    Song H, Zhao C, Zhang Y, et al. · BMJ Open · 2023 · Derived
    PubMed: PMID 36600374 · NCT05015335 · Uveitis, Anterior
  10. Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis.
    Solomon DH, Giles JT, Liao KP, et al. · Ann Rheum Dis · 2023 · Derived
    PubMed: PMID 36450449 · NCT02374021 (TARGET) · Arthritis, Rheumatoid
  11. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
    Schneeberger EE, Citera G, Nash P, et al. · Semin Arthritis Rheum · 2023 · Derived
    PubMed: PMID 36476498 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  12. Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis.
    Ponce-Bobadilla AV, Stodtmann S, Chen MJ, et al. · Clin Pharmacokinet · 2023 · Derived
    PubMed: PMID 36905528 · NCT02065570 · Crohn Disease
  13. External validation of the alternative Ankylosing Spondylitis Disease Activity Score in three randomized clinical trials of ixekizumab.
    Ortolan A, Ramiro S, Ramonda R, et al. · Rheumatology (Oxford) · 2023 · Derived
    PubMed: PMID 36282526 · NCT02696785 (COAST-V) · Spondylitis, Ankylosing
  14. Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis.
    Orbai AM, Chakravarty SD, You Y, et al. · Dermatol Ther (Heidelb) · 2023 · Derived
    PubMed: PMID 37713133 · NCT02207244 (VOYAGE 2) · Psoriasis
  15. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.
    Mysler E, Tanaka Y, Kavanaugh A, et al. · Rheumatology (Oxford) · 2023 · Derived
    PubMed: PMID 36018230 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  16. The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease.
    Müller-Ladner U, Dignass A, Gaffney K, et al. · BioDrugs · 2023 · Derived
    PubMed: PMID 37632666 · NCT04089514 (PROPER) · Arthritis, Rheumatoid
  17. Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies.
    Mease PJ, Orbai AM, FitzGerald O, et al. · Arthritis Res Ther · 2023 · Derived
    PubMed: PMID 37608391 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  18. Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study.
    McInnes IB, Kato K, Magrey M, et al. · Rheumatol Ther · 2023 · Derived
    PubMed: PMID 36243812 · NCT03104400 (SELECT - PsA 1) · Psoriasis
  19. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
    McInnes IB, Asahina A, Coates LC, et al. · Lancet · 2023 · Derived
    PubMed: PMID 36493791 · NCT03895203 (BE OPTIMAL) · Arthritis, Psoriatic
  20. PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients.
    Martinez-Vinson C, Lemoine A, Bouhnik Y, et al. · J Pediatr Gastroenterol Nutr · 2023 · Derived
    PubMed: PMID 36729422 · NCT03662919 (PERFUSE) · Arthritis, Rheumatoid
  21. Robust analyses for radiographic progression in rheumatoid arthritis.
    Landewé R, Sun L, Chen YF, et al. · RMD Open · 2023 · Derived
    PubMed: PMID 37015757 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  22. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
    Kristensen LE, Danese S, Yndestad A, et al. · Ann Rheum Dis · 2023 · Derived
    PubMed: PMID 36931693 · NCT02092467 · Arthritis, Rheumatoid
  23. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
    Kokolakis G, Warren RB, Strober B, et al. · Br J Dermatol · 2023 · Derived
    PubMed: PMID 36751950 · NCT03412747 (BE SURE) · Psoriasis
  24. A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
    Kirkham BW, Egeberg A, Behrens F, et al. · Rheumatol Ther · 2023 · Derived
    PubMed: PMID 37400681 · NCT03151551 (SPIRIT-H2H) · Arthritis, Psoriatic
  25. Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.
    Kim BS, Jo SJ, Youn S, et al. · Dermatol Ther (Heidelb) · 2023 · Derived
    PubMed: PMID 37750995 · NCT02207231 (VOYAGE 1) · Psoriasis
  26. Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance.
    Karpouzas GA, Szekanecz Z, Baecklund E, et al. · Ther Adv Musculoskelet Dis · 2023 · Derived
    PubMed: PMID 37942277 · NCT02092467 · Arthritis, Rheumatoid
  27. Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program.
    Kakehasi AM, Radominski SC, Baravalle MD, et al. · Clin Rheumatol · 2023 · Derived
    PubMed: PMID 36715850 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  28. Early Initiation of Adalimumab Significantly Diminishes Postoperative Crohn's Disease Endoscopic Recurrence and Is Superior to 6-Mercaptopurine Therapy: An Open-Label, Randomized Controlled Study.
    Hirsch A, Scapa E, Fliss-Isakov N, et al. · J Clin Med · 2023 · Derived
    PubMed: PMID 38137669 · NCT01629628 (POPART) · Crohn Disease
  29. Fracture in clinical studies of tofacitinib in rheumatoid arthritis.
    Hansen KE, Mortezavi M, Nagy E, et al. · Ther Adv Musculoskelet Dis · 2023 · Derived
    PubMed: PMID 36601090 · NCT02092467 · Arthritis, Rheumatoid
  30. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
    Fleischmann R, Curtis JR, Charles-Schoeman C, et al. · Ann Rheum Dis · 2023 · Derived
    PubMed: PMID 37308218 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  31. Assessing the Interchangeability of AVT02 and Humira® in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study.
    Feldman SR, Kay R, Reznichenko N, et al. · BioDrugs · 2023 · Derived
    PubMed: PMID 37204631 · NCT04453137
  32. Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study.
    Fautrel B, Bouhnik Y, Dieude P, et al. · Rheumatol Adv Pract · 2023 · Derived
    PubMed: PMID 37122809 · NCT03662919 (PERFUSE) · Arthritis, Rheumatoid
  33. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension.
    Eder L, Gladman DD, Mease P, et al. · RMD Open · 2023 · Derived
    PubMed: PMID 36958766 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  34. Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis.
    Dulai PS, Feagan BG, Sands BE, et al. · Clin Gastroenterol Hepatol · 2023 · Derived
    PubMed: PMID 35934286 · NCT02497469 · Colitis, Ulcerative
  35. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis.
    Dougados M, Taylor PC, Bingham CO, et al. · RMD Open · 2023 · Derived
    PubMed: PMID 36814062 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  36. Long-Term Safety and Efficacy of Ixekizumab in Patients With Axial Spondyloarthritis: 3-year Data From the COAST Program.
    Deodhar A, Poddubnyy D, Rahman P, et al. · J Rheumatol · 2023 · Derived
    PubMed: PMID 36792107 · NCT02696785 (COAST-V) · Spondylitis, Ankylosing
  37. Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringe.
    Damjanov N, Kirvalidze N, Kurashvili N, et al. · Expert Opin Biol Ther · 2023 · Derived
    PubMed: PMID 36205514 · NCT04224194
  38. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
    Curtis JR, Yamaoka K, Chen YH, et al. · Ann Rheum Dis · 2023 · Derived
    PubMed: PMID 36600185 · NCT00550446 · Arthritis, Rheumatoid
  39. Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials.
    Conaghan PG, Pavelka K, Hsieh SC, et al. · Rheumatol Adv Pract · 2023 · Derived
    PubMed: PMID 36794283 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  40. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis.
    Combe B, Besuyen R, Gómez-Centeno A, et al. · Rheumatol Ther · 2023 · Derived
    PubMed: PMID 36205910 · NCT02889796 (FINCH 1) · Arthritis, Rheumatoid
  41. Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab.
    Choy E, Bykerk V, Lee YC, et al. · Rheumatology (Oxford) · 2023 · Derived
    PubMed: PMID 36413080 · NCT02332590 · Arthritis, Rheumatoid
  42. Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib.
    Charles-Schoeman C, Hyde C, Guan S, et al. · J Rheumatol · 2023 · Derived
    PubMed: PMID 37453736 · NCT00550446 · Arthritis, Rheumatoid
  43. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Charles-Schoeman C, Choy E, McInnes IB, et al. · RMD Open · 2023 · Derived
    PubMed: PMID 37945286 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  44. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.
    Charles-Schoeman C, Buch MH, Dougados M, et al. · Ann Rheum Dis · 2023 · Derived
    PubMed: PMID 36137735 · NCT02092467 · Arthritis, Rheumatoid
  45. Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa Trial.
    Buttgereit F, Aelion J, Rojkovich B, et al. · Arthritis Rheumatol · 2023 · Derived
    PubMed: PMID 36512671 · NCT03823391 · Arthritis, Rheumatoid
  46. Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis.
    Burmester GR, Strand V, Kivitz AJ, et al. · Rheumatology (Oxford) · 2023 · Derived
    PubMed: PMID 36727470 · NCT02332590 · Arthritis, Rheumatoid
  47. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.
    Burmester GR, Cohen SB, Winthrop KL, et al. · RMD Open · 2023 · Derived
    PubMed: PMID 36754548 · NCT03104400 (SELECT - PsA 1) · Psoriasis
  48. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.
    Baraliakos X, Ranza R, Östör A, et al. · Arthritis Res Ther · 2023 · Derived
    PubMed: PMID 37038159 · NCT03104400 (SELECT - PsA 1) · Psoriasis
  49. Biological drug and drug delivery-mediated immunotherapy.
    Xiao Q, Li X, Li Y, et al. · Acta Pharm Sin B · 2023 · Background
    PubMed: PMID 33996408 · NCT05379049 (TNF-alpha) · Arthritis, Rheumatoid
  50. Feasibility of Conducting Comparative Effectiveness Research and Validation of a Clinical Disease Activity Score for Chronic Nonbacterial Osteomyelitis.
    Wu EY, Oliver M, Scheck J, et al. · J Rheumatol · 2023 · Background
    PubMed: PMID 37399459 · NCT04725422 (CHOIR) · Chronic recurrent multifocal osteomyelitis
  51. First-in-Human Intrathoracic Implantation of Multidrug-Eluting Microdevices for In Situ Chemotherapeutic Sensitivity Testing as Proof of Concept in Nonsmall Cell Lung Cancer.
    Tsai LL, Phillips WW, Hung YP, et al. · Ann Surg · 2023 · Background
    PubMed: PMID 35129472 · NCT07352566 · Psoriasis
  52. Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas.
    Peruzzi P, Dominas C, Fell G, et al. · Sci Transl Med · 2023 · Background
    PubMed: PMID 37672566 · NCT07352566 · Psoriasis
  53. Anti-TNF (adalimumab) injection for the treatment of adults with frozen shoulder during the pain predominant stage protocol for a multi-centre, randomised, double blind, parallel group, feasibility trial.
    Hopewell S, Kenealy N, Knight R, et al. · NIHR Open Res · 2023 · Background
    PubMed: PMID 37881307 · NCT05299242 (Anti-FreazeF) · Bursitis

2022 (79 papers)

  1. Activated Peripheral Blood B Cells in Rheumatoid Arthritis and Their Relationship to Anti-Tumor Necrosis Factor Treatment and Response: A Randomized Clinical Trial of the Effects of Anti-Tumor Necrosis Factor on B Cells.
    Meednu N, Barnard J, Callahan K, et al. · Arthritis Rheumatol · 2022 · Trial result
    PubMed: PMID 34347945 · NCT00837434 · Arthritis, Rheumatoid
  2. Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial.
    Gottenberg JE, Brocq O, Perdriger A, et al. · JAMA · 2022 · Trial result
    PubMed: PMID 27654603 · NCT01000441 (ROC) · Arthritis, Rheumatoid
  3. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
    Gordon KB, Langley RG, Warren RB, et al. · JAMA Dermatol · 2022 · Trial result
    PubMed: PMID 35544084 · NCT03412747 (BE SURE) · Psoriasis
  4. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
    Glatt S, Jemec GBE, Forman S, et al. · JAMA Dermatol · 2022 · Trial result
    PubMed: PMID 34406364 · NCT03248531 · Hidradenitis Suppurativa
  5. Cost-effectiveness of adalimumab for early-stage Dupuytren's disease : an economic evaluation based on a randomized controlled trial and individual-patient simulation model.
    Dakin H, Rombach I, Dritsaki M, et al. · Bone Jt Open · 2022 · Trial result
    PubMed: PMID 36378072 · NCT03180957 (RIDD) · Dupuytren Contracture
  6. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study.
    Cai L, Li L, Cheng H, et al. · Adv Ther · 2022 · Trial result
    PubMed: PMID 34816373 · NCT03316781
  7. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
    Ytterberg SR, Bhatt DL, Mikuls TR, et al. · N Engl J Med · 2022 · Derived
    PubMed: PMID 35081280 · NCT02092467 · Arthritis, Rheumatoid
  8. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan.
    Yamaoka K, Tanaka Y, Kameda H, et al. · Drug Saf · 2022 · Derived
    PubMed: PMID 34041702 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  9. A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST).
    Wynne C, Schwabe C, Lemech C, et al. · Expert Opin Investig Drugs · 2022 · Derived
    PubMed: PMID 35107050 · NCT03849313
  10. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
    Weitz JI, Szekanecz Z, Charles-Schoeman C, et al. · RMD Open · 2022 · Derived
    PubMed: PMID 36323490 · NCT02092467 · Arthritis, Rheumatoid
  11. Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination.
    Vittecoq O, Guillou C, Hardouin J, et al. · Arthritis Res Ther · 2022 · Derived
    PubMed: PMID 35313956 · NCT00234234 · Arthritis, Rheumatoid
  12. Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.
    van der Horst-Bruinsma IE, de Vlam K, Walsh JA, et al. · Adv Ther · 2022 · Derived
    PubMed: PMID 35429281 · NCT02696785 (COAST-V) · Spondylitis, Ankylosing
  13. Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years.
    van der Heijde D, Østergaard M, Reveille JD, et al. · J Rheumatol · 2022 · Derived
    PubMed: PMID 34853086 · NCT02696785 (COAST-V) · Spondylitis, Ankylosing
  14. Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND.
    van der Heijde D, Kartman CE, Xie L, et al. · J Rheumatol · 2022 · Derived
    PubMed: PMID 34526397 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  15. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Taylor PC, Takeuchi T, Burmester GR, et al. · Ann Rheum Dis · 2022 · Derived
    PubMed: PMID 34706874 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  16. Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies.
    Taylor PC, Bushmakin AG, Cappelleri JC, et al. · J Dermatolog Treat · 2022 · Derived
    PubMed: PMID 35385361 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  17. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.
    Strand V, Tundia N, Bergman M, et al. · Rheumatology (Oxford) · 2022 · Derived
    PubMed: PMID 33590829 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  18. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials.
    Strand V, Michalska M, Birchwood C, et al. · RMD Open · 2022 · Derived
    PubMed: PMID 28955499 · NCT01119859 · Arthritis, Rheumatoid
  19. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1.
    Strand V, Mease PJ, Soriano ER, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 34636026 · NCT03104400 (SELECT - PsA 1) · Psoriasis
  20. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.
    Smolen JS, Feist E, Fatenejad S, et al. · N Engl J Med · 2022 · Derived
    PubMed: PMID 36001712 · NCT02760407 (CREDO 2) · Arthritis, Rheumatoid
  21. T-cell immunoglobulin and mucin domain 3 is upregulated in rheumatoid arthritis, but insufficient in controlling inflammation.
    Skejoe C, Hansen AS, Stengaard-Pedersen K, et al. · Am J Clin Exp Immunol · 2022 · Derived
    PubMed: PMID 35874466 · NCT00660647 (OPERA) · Arthritis, Rheumatoid
  22. Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial.
    Schulberg JD, Wright EK, Holt BA, et al. · Lancet Gastroenterol Hepatol · 2022 · Derived
    PubMed: PMID 34890567 · NCT03220841 (STRIDENT) · Crohn Disease
  23. Distinct aberrations in cerebral pain processing differentiating patients with fibromyalgia from patients with rheumatoid arthritis.
    Sandström A, Ellerbrock I, Löfgren M, et al. · Pain · 2022 · Derived
    PubMed: PMID 34224497 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  24. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
    Sands BE, Irving PM, Hoops T, et al. · Lancet · 2022 · Derived
    PubMed: PMID 35691323 · NCT03464136 (SEAVUE) · Crohn Disease
  25. Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease.
    Sandborn WJ, Lewis JD, Panes J, et al. · J Crohns Colitis · 2022 · Derived
    PubMed: PMID 34546360 · NCT00077779 (CHARM) · Crohn Disease
  26. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Rubin DT, Dotan I, DuVall A, et al. · Lancet Gastroenterol Hepatol · 2022 · Derived
    PubMed: PMID 34798036 · NCT02163759 (HIBISCUS I) · Colitis, Ulcerative
  27. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.
    Rubbert-Roth A, Furst DE, Fiore S, et al. · Arthritis Res Ther · 2022 · Derived
    PubMed: PMID 36008838 · NCT02332590 · Arthritis, Rheumatoid
  28. Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study.
    Rivas AB, Lopez-Picado A, Calamia V, et al. · BMJ Open · 2022 · Derived
    PubMed: PMID 35318229 · NCT04798755 (Co-THEIA) · Uveitis
  29. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
    Reich K, Gordon KB, Strober BE, et al. · Br J Dermatol · 2022 · Derived
    PubMed: PMID 34105767 · NCT02207244 (VOYAGE 2) · Psoriasis
  30. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).
    Peyrin-Biroulet L, Loftus EV, Colombel JF, et al. · Gastroenterology · 2022 · Derived
    PubMed: PMID 34144047 · NCT02497469 · Colitis, Ulcerative
  31. Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program.
    Peterfy CG, Strand V, Friedman A, et al. · Rheumatology (Oxford) · 2022 · Derived
    PubMed: PMID 34897366 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  32. Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis.
    Nash P, Richette P, Gossec L, et al. · Rheumatology (Oxford) · 2022 · Derived
    PubMed: PMID 34864911 · NCT03104400 (SELECT - PsA 1) · Psoriasis
  33. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials.
    Muensterman E, Engelhardt B, Gopalakrishnan S, et al. · Clin Transl Sci · 2022 · Derived
    PubMed: PMID 34464029 · NCT03104400 (SELECT - PsA 1) · Psoriasis
  34. Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy.
    Motoya S, Watanabe M, Wallace K, et al. · Inflamm Intest Dis · 2022 · Derived
    PubMed: PMID 30221150 · NCT01958827 · Crohn Disease
  35. Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials.
    Mease P, Kavanaugh A, Gladman D, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 35606663 · NCT03104400 (SELECT - PsA 1) · Psoriasis
  36. Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging.
    Maksymowych WP, Bolce R, Gallo G, et al. · Rheumatology (Oxford) · 2022 · Derived
    PubMed: PMID 35188180 · NCT02696785 (COAST-V) · Spondylitis, Ankylosing
  37. Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials.
    Lebwohl MG, Soliman AM, Yang H, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
    PubMed: PMID 34921669 · NCT02694523 · Psoriasis
  38. Cost-Effectiveness of Tight Control for Crohn's Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective.
    Lakatos PL, Kaplan GG, Bressler B, et al. · J Can Assoc Gastroenterol · 2022 · Derived
    PubMed: PMID 35919766 · NCT01235689 (CALM) · Crohn Disease
  39. Inflammatory and structural changes in vertebral bodies and posterior elements of the spine in axial spondyloarthritis: construct validity, responsiveness and discriminatory ability of the anatomy-based CANDEN scoring system in a randomised placebo-controlled trial.
    Krabbe S, Sørensen IJ, Jensen B, et al. · RMD Open · 2022 · Derived
    PubMed: PMID 29556419 · NCT01029847 (ASIM) · Spondylarthritis
  40. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
    Kivitz AJ, FitzGerald O, Nash P, et al. · Clin Rheumatol · 2022 · Derived
    PubMed: PMID 34510295 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  41. Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis.
    Keystone EC, Breedveld FC, Kupper H, et al. · RMD Open · 2022 · Derived
    PubMed: PMID 29955381 · NCT00195663 (PREMIER) · Arthritis, Rheumatoid
  42. Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis.
    Kay J, Bock AE, Rehman M, et al. · RMD Open · 2022 · Derived
    PubMed: PMID 36180101 · NCT02480153 · Arthritis, Rheumatoid
  43. Interventions for focal segmental glomerulosclerosis in adults.
    Hodson EM, Sinha A, Cooper TE, et al. · Cochrane Database Syst Rev · 2022 · Derived
    PubMed: PMID 35224732 · NCT00193648 · Glomerulosclerosis, Focal Segmental
  44. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.
    Gladman DD, Coates LC, Wu J, et al. · Arthritis Res Ther · 2022 · Derived
    PubMed: PMID 35139908 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  45. Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.
    Fleischmann RM, Bock AE, Zhang W, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 35304684 · NCT02480153 · Arthritis, Rheumatoid
  46. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
    Fleischmann RM, Blanco R, Hall S, et al. · Ann Rheum Dis · 2022 · Derived
    PubMed: PMID 33148701 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  47. The relationship between the nail and systemic enthesitis in psoriatic arthritis.
    Elliott A, Pendleton A, Wright G, et al. · Rheumatol Adv Pract · 2022 · Derived
    PubMed: PMID 34888436 · NCT03955861 · Psoriasis
  48. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
    Elewski BE, Blauvelt A, Gallo G, et al. · Dermatol Ther (Heidelb) · 2022 · Derived
    PubMed: PMID 35279805 · NCT03151551 (SPIRIT-H2H) · Arthritis, Psoriatic
  49. Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials.
    Eder L, Tony HP, Odhav S, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 35397092 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  50. Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure.
    Deodhar AA, Combe B, Accioly AP, et al. · Ann Rheum Dis · 2022 · Derived
    PubMed: PMID 35393269 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  51. Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results.
    D'Haens GR, Sandborn WJ, Loftus EV, et al. · Gastroenterology · 2022 · Derived
    PubMed: PMID 35122766 · NCT02065570 · Crohn Disease
  52. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
    Cohen SB, van Vollenhoven RF, Winthrop KL, et al. · Ann Rheum Dis · 2022 · Derived
    PubMed: PMID 33115760 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  53. Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis.
    Coates LC, Smolen JS, Mease PJ, et al. · RMD Open · 2022 · Derived
    PubMed: PMID 36171019 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  54. Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.
    Coates LC, Kishimoto M, Gottlieb A, et al. · RMD Open · 2022 · Derived
    PubMed: PMID 29299340 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  55. Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab.
    Coates LC, Abraham S, Tillett W, et al. · Arthritis Care Res (Hoboken) · 2022 · Derived
    PubMed: PMID 32937016 · NCT01064856
  56. Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial.
    Chen B, Gao X, Zhong J, et al. · Ther Adv Gastroenterol · 2022 · Derived
    PubMed: PMID 32733600 · NCT02499783 · Crohn Disease
  57. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
    Burmester GR, Winthrop K, Blanco R, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 34970731 · NCT03104400 (SELECT - PsA 1) · Psoriasis
  58. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
    Bingham CO, Walker D, Nash P, et al. · Arthritis Res Ther · 2022 · Derived
    PubMed: PMID 34980223 · NCT02889796 (FINCH 1) · Arthritis, Rheumatoid
  59. Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials.
    Bessette L, Mysler E, Kinch CD, et al. · J Rheumatol · 2022 · Derived
    PubMed: PMID 35232809 · NCT02187055 (ORAL STRATEGY)
  60. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.
    Bergman M, Buch MH, Tanaka Y, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 36125701 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  61. Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial.
    Bechara FG, Podda M, Prens EP, et al. · JAMA Surg · 2022 · Derived
    PubMed: PMID 34406349 · NCT02808975 (SHARPS) · Hidradenitis Suppurativa
  62. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.
    Balanescu AR, Citera G, Pascual-Ramos V, et al. · Ann Rheum Dis · 2022 · Derived
    PubMed: PMID 35922124 · NCT02092467 · Arthritis, Rheumatoid
  63. A Randomized Pharmacokinetic Study in Healthy Male Subjects Comparing a High-concentration, Citrate-free SB5 Formulation (40 mg/0.4 ml) and Prior SB5 (Adalimumab Biosimilar).
    Ahn SS, Lee M, Baek Y, et al. · Rheumatol Ther · 2022 · Derived
    PubMed: PMID 35776269 · NCT04514796
  64. TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease.
    Vickman RE, Aaron-Brooks L, Zhang R, et al. · Nat Commun · 2022 · Background
    PubMed: PMID 35440548 · NCT06062875 · Prostatic Hyperplasia
  65. Adalimumab with Methotrexate vs. Adalimumab Monotherapy in Psoriasis: First-Year Results of a Single-Blind Randomized Controlled Trial.
    van der Kraaij G, Busard C, van den Reek J, et al. · J Invest Dermatol · 2022 · Background
    PubMed: PMID 35276223 · NCT05889338 · Psoriasis
  66. A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.
    Tatarova Z, Blumberg DC, Korkola JE, et al. · Nat Biotechnol · 2022 · Background
    PubMed: PMID 35788566 · NCT07352566 · Psoriasis
  67. Outcomes of freehand transperineal prostate biopsy with omission of antibiotic prophylaxis.
    Setia SA, Smith J, Cendo D, et al. · BJU Int · 2022 · Background
    PubMed: PMID 34491606 · NCT06062875 · Prostatic Hyperplasia
  68. Questionnaire Modifications and Alternative Scoring Methods of the Dermatology Life Quality Index: A Systematic Review.
    Rencz F, Szabó Á, Brodszky V, et al. · Value Health · 2022 · Background
    PubMed: PMID 34372982 · NCT05889338 · Psoriasis
  69. Deucravacitinib for the Treatment of Psoriatic Disease.
    Lé AM, Puig L, Torres T, et al. · Am J Clin Dermatol · 2022 · Background
    PubMed: PMID 35960487 · NCT07013838 · Takayasu Arteritis
  70. Adjunct Thrombolysis Enhances Brain Reperfusion following Successful Thrombectomy.
    Laredo C, Rodríguez A, Oleaga L, et al. · Ann Neurol · 2022 · Background
    PubMed: PMID 36054449 · NCT07495644 · Crohn Disease
  71. PUCCINI: Safety of Anti-TNF in the Perioperative Setting.
    Hyman NH, Cheifetz AS · Gastroenterology · 2022 · Background
    PubMed: PMID 35525321 · NCT06062875 · Prostatic Hyperplasia
  72. How I do it: Aquablation in very large prostates (> 150 mL).
    Helfand BT, Kasraeian A, Sterious S, et al. · Can J Urol · 2022 · Background
    PubMed: PMID 35429430 · NCT06062875 · Prostatic Hyperplasia
  73. Men with lower urinary tract symptoms secondary to BPH undergoing Aquablation with very large prostates (> 150 mL).
    Helfand BT, Glaser AP, Kasraeian A, et al. · Can J Urol · 2022 · Background
    PubMed: PMID 34895392 · NCT06062875 · Prostatic Hyperplasia
  74. Comparisons of efficacy and complications between transrectal and transperineal prostate biopsy with or without antibiotic prophylaxis.
    He J, Guo Z, Huang Y, et al. · Urol Oncol · 2022 · Background
    PubMed: PMID 35168882 · NCT06062875 · Prostatic Hyperplasia
  75. Impact of Sleep Disturbance, Physical Function, Depression and Anxiety on Male Lower Urinary Tract Symptoms: Results from the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN).
    Glaser AP, Mansfield S, Smith AR, et al. · J Urol · 2022 · Background
    PubMed: PMID 35212573 · NCT06062875 · Prostatic Hyperplasia
  76. The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry.
    Girschick H, Finetti M, Orlando F, et al. · Rheumatology (Oxford) · 2022 · Background
    PubMed: PMID 29596638 · NCT04725422 (CHOIR) · Chronic recurrent multifocal osteomyelitis
  77. Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles.
    Fuchs F, Schillinger D, Atreya R, et al. · Front Immunol · 2022 · Background
    PubMed: PMID 28717358 · NCT03885713 (BioIBD) · Crohn Disease
  78. Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery.
    Cohen BL, Fleshner P, Kane SV, et al. · Gastroenterology · 2022 · Background
    PubMed: PMID 35413359 · NCT06062875 · Prostatic Hyperplasia
  79. EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain.
    Chaparro M, Barreiro-de Acosta M, Benítez JM, et al. · Ther Adv Gastroenterol · 2022 · Background
    PubMed: PMID 31205485 · NCT05313620 · Colitis, Ulcerative

2021 (67 papers)

  1. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study.
    Zhang H, Wu M, Sun J, et al. · Pharmacol Res Perspect · 2021 · Trial result
    PubMed: PMID 33682358 · NCT03357939 · Immune System Diseases
  2. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Suhler EB, Jaffe GJ, Fortin E, et al. · Ophthalmology · 2021 · Trial result
    PubMed: PMID 33157077 · NCT01148225 (VISUAL III) · Uveitis
  3. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial.
    Ducourau E, Rispens T, Samain M, et al. · RMD Open · 2021 · Trial result
    PubMed: PMID 31958280 · NCT01895764 (COMARIS) · Spondylitis, Ankylosing
  4. Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study.
    Wiland P, Jeka S, Dokoupilová E, et al. · BioDrugs · 2021 · Derived
    PubMed: PMID 33119861 · NCT02744755 (ADMYRA) · Arthritis, Rheumatoid
  5. Bimekizumab versus Adalimumab in Plaque Psoriasis.
    Warren RB, Blauvelt A, Bagel J, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 33891379 · NCT03412747 (BE SURE) · Psoriasis
  6. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.
    Ungaro RC, Yzet C, Bossuyt P, et al. · Gastroenterology · 2021 · Derived
    PubMed: PMID 32224129 · NCT01235689 (CALM) · Crohn Disease
  7. Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
    Takeuchi T, Fleischmann R, Iikuni N, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 34429160 · NCT02187055 (ORAL STRATEGY)
  8. Model-Based Comparison of Dose-Response Profiles of Tofacitinib in Japanese Versus Western Rheumatoid Arthritis Patients.
    Suzuki M, Shoji S, Miyoshi S, et al. · J Clin Pharmacol · 2021 · Derived
    PubMed: PMID 31512746 · NCT00550446 · Arthritis, Rheumatoid
  9. Exposure-Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis.
    Suleiman AA, Khatri A, Oberoi RK, et al. · Clin Pharmacokinet · 2021 · Derived
    PubMed: PMID 31667790 · NCT02694523 · Psoriasis
  10. High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab.
    Strand V, Boklage SH, Kimura T, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 33081825 · NCT02332590 · Arthritis, Rheumatoid
  11. Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study.
    Smolen JS, Sebba A, Ruderman EM, et al. · Rheumatol Ther · 2021 · Derived
    PubMed: PMID 33200394 · NCT03151551 (SPIRIT-H2H) · Arthritis, Psoriatic
  12. Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis.
    Smolen JS, Choe JY, Weinblatt ME, et al. · RMD Open · 2021 · Derived
    PubMed: PMID 31958281 · NCT02167139 · Arthritis, Rheumatoid
  13. Twenty years of clinical trials in axial spondyloarthritis: what can we learn for the future?
    Sieper J, Poddubnyy D · Curr Opin Rheumatol · 2021 · Derived
    PubMed: PMID 33978600 · NCT03259074 (SURPASS) · Spondylitis, Ankylosing
  14. Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain.
    Schweikert B, Malmberg C, Núñez M, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 32792421 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  15. Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.
    Sandborn WJ, Vermeire S, Tyrrell H, et al. · Adv Ther · 2021 · Derived
    PubMed: PMID 32445184 · NCT02163759 (HIBISCUS I) · Colitis, Ulcerative
  16. HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA.
    Rigby W, Buckner JH, Louis Bridges S, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 34537057 · NCT02557100 · Arthritis, Rheumatoid
  17. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
    Reich K, Armstrong AW, Foley P, et al. · Am J Clin Dermatol · 2021 · Derived
    PubMed: PMID 32910434 · NCT02207244 (VOYAGE 2) · Psoriasis
  18. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT).
    Ramanan AV, Guly CM, Keller SY, et al. · Trials · 2021 · Derived
    PubMed: PMID 34627340 · NCT04088409 · Uveitis
  19. Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate.
    Poddubnyy D, Hammel L, Heyne M, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 32998926 · NCT03906136 (AScalate) · Axial Spondyloarthritis
  20. Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis.
    Paul S, Marotte H, Kavanaugh A, et al. · Clin Transl Sci · 2021 · Derived
    PubMed: PMID 32100960 · NCT01500278 · Arthritis, Rheumatoid
  21. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
    Panaccione R, Isaacs JD, Chen LA, et al. · Dig Dis Sci · 2021 · Derived
    PubMed: PMID 32816215 · NCT00550446 · Arthritis, Rheumatoid
  22. Fetuin-A and thyroxin binding globulin predict rituximab response in rheumatoid arthritis patients with insufficient response to anti-TNFα.
    Nguyen MVC, Courtier A, Adrait A, et al. · Clin Rheumatol · 2021 · Derived
    PubMed: PMID 32212002 · NCT01000441 (ROC) · Arthritis, Rheumatoid
  23. Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment.
    Neyt M, Christiaens A, Aloi M, et al. · JMIR Form Res · 2021 · Derived
    PubMed: PMID 33492239 · NCT02852694 (RCT) · Crohn Disease
  24. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
    McInnes IB, Anderson JK, Magrey M, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 33789011 · NCT03104400 (SELECT - PsA 1) · Psoriasis
  25. Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial.
    Matar M, Shamir R, Turner D, et al. · Inflamm Bowel Dis · 2021 · Derived
    PubMed: PMID 31793630 · NCT02256462 · Crohn Disease
  26. The Effect of Adalimumab Treatment on Linear Growth in Children With Crohn Disease: A Post-hoc Analysis of the PAILOT Randomized Control Trial.
    Matar M, Shamir R, Lev-Zion R, et al. · J Pediatr Gastroenterol Nutr · 2021 · Derived
    PubMed: PMID 32324651 · NCT02256462 · Crohn Disease
  27. Similar lipid level changes in early rheumatoid arthritis patients following 1-year treat-to-target strategy with adalimumab plus methotrexate versus placebo plus methotrexate: secondary analyses from the randomised controlled OPERA trial.
    Mašić D, Stengaard-Pedersen K, Løgstrup BB, et al. · Rheumatol Int · 2021 · Derived
    PubMed: PMID 33386898 · NCT00660647 (OPERA) · Arthritis, Rheumatoid
  28. Whole-body Magnetic Resonance Imaging Inflammation in Peripheral Joints and Entheses in Axial Spondyloarthritis: Distribution and Changes during Adalimumab Treatment.
    Krabbe S, Eshed I, Sørensen IJ, et al. · J Rheumatol · 2021 · Derived
    PubMed: PMID 30936290 · NCT01029847 (ASIM) · Spondylarthritis
  29. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.
    Keystone EC, Ahmad HA, Yazici Y, et al. · Rheumatology (Oxford) · 2021 · Derived
    PubMed: PMID 31819995 · NCT00929864 · Arthritis, Rheumatoid
  30. Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity.
    Kang J, Eudy-Byrne RJ, Mondick J, et al. · Br J Clin Pharmacol · 2021 · Derived
    PubMed: PMID 32363771 · NCT02045979
  31. Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial.
    Janssen L, Romberg-Camps M, van Bodegraven A, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 33947729 · NCT03917303 (CoCroS) · Crohn Disease
  32. Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity.
    Huizinga TWJ, Torii Y, Muniz R, et al. · Rheumatol Ther · 2021 · Derived
    PubMed: PMID 33263165 · NCT02480153 · Arthritis, Rheumatoid
  33. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course.
    Harris RE, Aloi M, de Ridder L, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 32611737 · NCT02852694 (RCT) · Crohn Disease
  34. Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn's disease patients.
    Greener T, Boland K, Milgrom R, et al. · Eur J Gastroenterol Hepatol · 2021 · Derived
    PubMed: PMID 34402466 · NCT02065622 · Colitis, Ulcerative
  35. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
    Genovese MC, Fleischmann R, Kivitz A, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 32522251 · NCT02332590 · Arthritis, Rheumatoid
  36. Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials.
    Genovese MC, Burmester GR, Hagino O, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 32907617 · NCT02332590 · Arthritis, Rheumatoid
  37. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
    Gabay C, Burmester GR, Strand V, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 32264972 · NCT02332590 · Arthritis, Rheumatoid
  38. Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293.
    Fleischmann RM, Alvarez DF, Bock AE, et al. · RMD Open · 2021 · Derived
    PubMed: PMID 33883254 · NCT02480153 · Arthritis, Rheumatoid
  39. Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
    Fleischmann RM, Alvarez DF, Bock AE, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 34563243 · NCT02480153 · Arthritis, Rheumatoid
  40. Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study.
    Feldman SR, Reznichenko N, Pulka G, et al. · BioDrugs · 2021 · Derived
    PubMed: PMID 34657274 · NCT03849404
  41. Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis.
    Emery P, Tanaka Y, Cardillo T, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 32414425 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  42. Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.
    Emery P, Suh CH, Weinblatt ME, et al. · Scand J Rheumatol · 2021 · Derived
    PubMed: PMID 32468892 · NCT02167139 · Arthritis, Rheumatoid
  43. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results.
    Deodhar AA, Mease PJ, Rahman P, et al. · BMC Rheumatol · 2021 · Derived
    PubMed: PMID 34538257 · NCT02696785 (COAST-V) · Spondylitis, Ankylosing
  44. Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib.
    de Vlam K, Ogdie A, Bushmakin AG, et al. · RMD Open · 2021 · Derived
    PubMed: PMID 34226183 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  45. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Croft NM, Faubion WA, Kugathasan S, et al. · Lancet Gastroenterol Hepatol · 2021 · Derived
    PubMed: PMID 34153231 · NCT02065557 · Colitis, Ulcerative
  46. Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies.
    Combe B, Tsai TF, Huffstutter JE, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 33499913 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  47. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
    Combe B, Kivitz A, Tanaka Y, et al. · Ann Rheum Dis · 2021 · Derived
    PubMed: PMID 33504485 · NCT02889796 (FINCH 1) · Arthritis, Rheumatoid
  48. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
    Cohen SB, Tanaka Y, Mariette X, et al. · RMD Open · 2021 · Derived
    PubMed: PMID 33127856 · NCT00550446 · Arthritis, Rheumatoid
  49. Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib.
    Coates LC, Bushmakin AG, FitzGerald O, et al. · Arthritis Res Ther · 2021 · Derived
    PubMed: PMID 33766074 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  50. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
    Chandran V, van der Heijde D, Fleischmann RM, et al. · Rheumatology (Oxford) · 2021 · Derived
    PubMed: PMID 32031665 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  51. An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.
    Burmester GR, Curtis JR, Yun H, et al. · Drug Saf · 2021 · Derived
    PubMed: PMID 32006348 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  52. Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis.
    Boyapati A, Schwartzman S, Msihid J, et al. · Arthritis Rheumatol · 2021 · Derived
    PubMed: PMID 32343882 · NCT02332590 · Arthritis, Rheumatoid
  53. Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial.
    Bouhuys M, Lexmond WS, Dijkstra G, et al. · BMJ Open · 2021 · Derived
    PubMed: PMID 34732500 · NCT04646187 (FREE) · Crohn Disease
  54. Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).
    Blauvelt A, Leonardi CL, Gaylis N, et al. · BioDrugs · 2021 · Derived
    PubMed: PMID 33651341 · NCT02016105 (ADACCESS)
  55. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis.
    Singh S, Murad MH, Fumery M, et al. · Clin Gastroenterol Hepatol · 2021 · Background
    PubMed: PMID 31945470 · NCT06269185 · Colitis, Ulcerative
  56. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
    Reynolds KA, Pithadia DJ, Lee EB, et al. · Am J Clin Dermatol · 2021 · Background
    PubMed: PMID 32048187 · NCT04808739 · Psoriasis
  57. Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis.
    Lee YI, Park Y, Park SJ, et al. · Gut Liver · 2021 · Background
    PubMed: PMID 32616683 · NCT06269185 · Colitis, Ulcerative
  58. Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis.
    Kristyanto H, Blomberg NJ, Slot LM, et al. · Sci Transl Med · 2021 · Background
    PubMed: PMID 33208502 · NCT05502731 (JAKAR) · Arthritis, Rheumatoid
  59. Evaluation of adalimumab biosimilar in treatment of psoriatic arthritis with concomitant moderate to severe chronic plaque psoriasis: An open-labeled, prospective, pilot case series.
    Khandpur S, Sondhi P, Taneja N, et al. · J Am Acad Dermatol · 2021 · Background
    PubMed: PMID 32087993 · NCT04808739 · Psoriasis
  60. Serum Tumor Necrosis Factor-Alpha as a Competent Biomarker for Evaluation of Disease Activity in Early Rheumatoid Arthritis.
    Inam Illahi M, Amjad S, Alam SM, et al. · Cureus · 2021 · Background
    PubMed: PMID 34221763 · NCT05379049 (TNF-alpha) · Arthritis, Rheumatoid
  61. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
    Hercogová J, Papp KA, Chyrok V, et al. · Br J Dermatol · 2021 · Background
    PubMed: PMID 31206593 · NCT04808739 · Psoriasis
  62. An Ex Vivo Study to Evaluate the Effect of Tegaserod on Platelet Activation and Aggregation.
    Gurbel PA, Bliden K, Barnett SD, et al. · J Cardiovasc Pharmacol Ther · 2021 · Background
    PubMed: PMID 32672062 · NCT05313620 · Colitis, Ulcerative
  63. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP, Chaparro M · J Crohns Colitis · 2021 · Background
    PubMed: PMID 31777929 · NCT05313620 · Colitis, Ulcerative
  64. Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel.
    Cirillo P, Taglialatela V, Pellegrino G, et al. · J Thromb Thrombolysis · 2021 · Background
    PubMed: PMID 32335777 · NCT05313620 · Colitis, Ulcerative
  65. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
    Chaparro M, Garre A, Mesonero F, et al. · J Crohns Colitis · 2021 · Background
    PubMed: PMID 32969471 · NCT05313620 · Colitis, Ulcerative
  66. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Alulis S, Vadstrup K, Borsi A, et al. · Scand J Gastroenterol · 2021 · Background
    PubMed: PMID 32116064 · NCT07495644 · Crohn Disease
  67. Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST-Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial.
    Acharya NR, Ebert CD, Kelly NK, et al. · Trials · 2021 · Background
    PubMed: PMID 33109240 · NCT03816397 (ADJUST) · Uveitis

2020 (62 papers)

  1. Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis.
    Wells AF, Greenwald M, Bradley JD, et al. · Rheumatol Ther · 2020 · Derived
    PubMed: PMID 29680881 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  2. Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial.
    Wei JC, Tsou HK, Leong PY, et al. · Front Med (Lausanne) · 2020 · Derived
    PubMed: PMID 33195311 · NCT02489760 · Spondylitis, Ankylosing
  3. Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis.
    Virone A, Bastard JP, Fellahi S, et al. · RMD Open · 2020 · Derived
    PubMed: PMID 31413865 · NCT01000441 (ROC) · Arthritis, Rheumatoid
  4. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.
    Vande Casteele N, Baert F, Bian S, et al. · J Crohns Colitis · 2020 · Derived
    PubMed: PMID 30820530 · NCT02450513 · Crohn Disease
  5. Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab.
    van der Heijde D, Gladman DD, FitzGerald O, et al. · J Rheumatol · 2020 · Derived
    PubMed: PMID 30824647 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  6. Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan.
    Tanaka Y, Mimori T, Yamanaka H, et al. · Mod Rheumatol · 2020 · Derived
    PubMed: PMID 31267801 · NCT01736189 · Arthritis, Rheumatoid
  7. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
    Tanaka Y, Fautrel B, Keystone EC, et al. · Ann Rheum Dis · 2020 · Derived
    PubMed: PMID 31040122 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  8. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
    Suleiman AA, Minocha M, Khatri A, et al. · Clin Pharmacokinet · 2020 · Derived
    PubMed: PMID 31054118 · NCT02694523 · Psoriasis
  9. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
    Strand V, Mysler E, Moots RJ, et al. · RMD Open · 2020 · Derived
    PubMed: PMID 31673419 · NCT02187055 (ORAL STRATEGY)
  10. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
    Strand V, de Vlam K, Covarrubias-Cobos JA, et al. · RMD Open · 2020 · Derived
    PubMed: PMID 30713721 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  11. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
    Smolen JS, Mease P, Tahir H, et al. · Ann Rheum Dis · 2020 · Derived
    PubMed: PMID 32660977 · NCT03151551 (SPIRIT-H2H) · Arthritis, Psoriatic
  12. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
    Smolen JS, Genovese MC, Takeuchi T, et al. · J Rheumatol · 2020 · Derived
    PubMed: PMID 30219772 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  13. Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials.
    Smolen J, Fleischmann R, Aletaha D, et al. · Arthritis Res Ther · 2020 · Derived
    PubMed: PMID 31707982 · NCT00195702 · Arthritis, Rheumatoid
  14. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
    Reich K, Papp KA, Armstrong AW, et al. · Br J Dermatol · 2020 · Derived
    PubMed: PMID 30485400 · NCT02207244 (VOYAGE 2) · Psoriasis
  15. Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis.
    Plein S, Erhayiem B, Fent G, et al. · Ann Rheum Dis · 2020 · Derived
    PubMed: PMID 32859608 · NCT01295151 (SWITCH) · Arthritis, Rheumatoid
  16. Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial.
    Panaccione R, Colombel JF, Travis SPL, et al. · Gut · 2020 · Derived
    PubMed: PMID 31285357 · NCT01235689 (CALM) · Crohn Disease
  17. Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study.
    Noe MH, Wan MT, Shin DB, et al. · J Am Acad Dermatol · 2020 · Derived
    PubMed: PMID 31163241 · NCT01553058 (VIP) · Psoriasis
  18. Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis.
    Nash P, Vanhoof J, Hall S, et al. · Rheumatol Ther · 2020 · Derived
    PubMed: PMID 27747583 · NCT01561313 · Arthritis, Rheumatoid
  19. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.
    Nash P, Coates LC, Fleischmann R, et al. · Rheumatol Ther · 2020 · Derived
    PubMed: PMID 30414064 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  20. Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis.
    Nader A, Mohamed MF, Winzenborg I, et al. · Clin Pharmacol Ther · 2020 · Derived
    PubMed: PMID 31610021 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  21. Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial.
    Michaud K, Pope JE, Emery P, et al. · Rheumatol Ther · 2020 · Derived
    PubMed: PMID 31228100 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  22. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
    McInnes IB, Behrens F, Mease PJ, et al. · Lancet · 2020 · Derived
    PubMed: PMID 32386593 · NCT02745080 (EXCEED 1) · Arthritis, Psoriatic
  23. Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.
    Landewé R, Ritchlin CT, Aletaha D, et al. · Rheumatology (Oxford) · 2020 · Derived
    PubMed: PMID 30608620 · NCT00646386 · Arthritis
  24. Similar Improvements in Patient-Reported Outcomes Among Rheumatoid Arthritis Patients Treated with Two Different Doses of Methotrexate in Combination with Adalimumab: Results From the MUSICA Trial.
    Kaeley GS, MacCarter DK, Goyal JR, et al. · Rheumatol Ther · 2020 · Derived
    PubMed: PMID 29574622 · NCT01185288 (MUSICA) · Arthritis, Rheumatoid
  25. A randomized phase I pharmacokinetic trial comparing the potential biosimilar adalimumab (CinnoRA®) with the reference product (Humira®) in healthy volunteers.
    Jamshidi A, Sabzvari A, Anjidani N, et al. · Expert Opin Investig Drugs · 2020 · Derived
    PubMed: PMID 31985294 · NCT03273192
  26. Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial.
    Inoue N, Kobayashi K, Naganuma M, et al. · Intest Res · 2020 · Derived
    PubMed: PMID 28670237 · NCT01243671
  27. Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis.
    Imamura M, Scott NW, Wallace SA, et al. · Cochrane Database Syst Rev · 2020 · Derived
    PubMed: PMID 32734597 · NCT01295814 · Cystitis, Interstitial
  28. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
    Gossec L, Strand V, Proudfoot C, et al. · J Rheumatol · 2020 · Derived
    PubMed: PMID 30877216 · NCT02332590 · Arthritis, Rheumatoid
  29. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.
    Gordon KB, Armstrong AW, Foley P, et al. · J Invest Dermatol · 2020 · Derived
    PubMed: PMID 31207232 · NCT02207244 (VOYAGE 2) · Psoriasis
  30. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.
    Gladman DD, Orbai AM, Klitz U, et al. · Arthritis Res Ther · 2020 · Derived
    PubMed: PMID 30696483 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  31. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.
    Gladman DD, Charles-Schoeman C, McInnes IB, et al. · Arthritis Care Res (Hoboken) · 2020 · Derived
    PubMed: PMID 31112005 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  32. Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis.
    Ghil J, Zielińska A, Lee Y, et al. · Curr Med Res Opin · 2020 · Derived
    PubMed: PMID 30561229 · NCT02565810 · Arthritis, Rheumatoid
  33. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.
    Fleischmann RM, Genovese MC, Enejosa JV, et al. · Ann Rheum Dis · 2020 · Derived
    PubMed: PMID 31362993 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  34. Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study.
    Emery P, Burmester GR, Naredo E, et al. · Ann Rheum Dis · 2020 · Derived
    PubMed: PMID 32404343 · NCT02198651 (PREDICTRA) · Arthritis, Rheumatoid
  35. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
    Dougados M, Wei JC, Landewé R, et al. · Ann Rheum Dis · 2020 · Derived
    PubMed: PMID 31685553 · NCT02696785 (COAST-V) · Spondylitis, Ankylosing
  36. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis.
    Combe B, Rahman P, Kameda H, et al. · Arthritis Res Ther · 2020 · Derived
    PubMed: PMID 31964419 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  37. Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib.
    Combe B, Balsa A, Sarzi-Puttini P, et al. · Ann Rheum Dis · 2020 · Derived
    PubMed: PMID 30842122 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  38. Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.
    Cella D, Wilson H, Shalhoub H, et al. · J Patient Rep Outcomes · 2020 · Derived
    PubMed: PMID 31111255 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  39. Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.
    Cella D, Wilson H, Shalhoub H, et al. · J Patient Rep Outcomes · 2020 · Derived
    PubMed: PMID 30680661 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  40. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
    Calabrese LH, Abud-Mendoza C, Lindsey SM, et al. · Arthritis Care Res (Hoboken) · 2020 · Derived
    PubMed: PMID 31207152 · NCT02187055 (ORAL STRATEGY)
  41. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
    Burmester GR, Strand V, Rubbert-Roth A, et al. · RMD Open · 2020 · Derived
    PubMed: PMID 31673415 · NCT02332590 · Arthritis, Rheumatoid
  42. Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).
    Baraliakos X, Østergaard M, Gensler LS, et al. · Clin Drug Investig · 2020 · Derived
    PubMed: PMID 31983056 · NCT03259074 (SURPASS) · Spondylitis, Ankylosing
  43. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
    Yada K, Nogami K, Ogiwara K, et al. · Int J Hematol · 2020 · Background
    PubMed: PMID 31254165 · NCT05313620 · Colitis, Ulcerative
  44. Effects of fibrinogen supplementation on clot formation in blood samples from cardiac surgery patients before and after tranexamic acid administration.
    Waldén K, Shams Hakimi C, Jeppsson A, et al. · Transfus Med · 2020 · Background
    PubMed: PMID 31115109 · NCT05313620 · Colitis, Ulcerative
  45. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS, Landewé RBM, Bijlsma JWJ, et al. · Ann Rheum Dis · 2020 · Background
    PubMed: PMID 31969328 · NCT05379049 (TNF-alpha) · Arthritis, Rheumatoid
  46. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.
    Shivaji UN, Sharratt CL, Thomas T, et al. · Aliment Pharmacol Ther · 2020 · Background
    PubMed: PMID 30735257 · NCT05291039 · Inflammatory Bowel Diseases
  47. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme.
    Sandborn WJ, Panés J, Sands BE, et al. · Aliment Pharmacol Ther · 2020 · Background
    PubMed: PMID 31599001 · NCT05313620 · Colitis, Ulcerative
  48. Biologics and surgical outcomes in Crohn's disease: is there a direct relationship?
    Quaresma AB, Yamamoto T, Kotze PG, et al. · Ther Adv Gastroenterol · 2020 · Background
    PubMed: PMID 32728389 · NCT06062875 · Prostatic Hyperplasia
  49. Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience.
    Pouillon L, Baumann C, Rousseau H, et al. · Inflamm Bowel Dis · 2020 · Background
    PubMed: PMID 30329067 · NCT06269185 · Colitis, Ulcerative
  50. Management of venous thromboembolism: an update.
    Piran S, Schulman S · Thromb J · 2020 · Background
    PubMed: PMID 27766049 · NCT05313620 · Colitis, Ulcerative
  51. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A, Desai RJ, Solomon DH, et al. · Ann Rheum Dis · 2020 · Background
    PubMed: PMID 30679153 · NCT04115423 · Arthritis, Rheumatoid
  52. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas.
    Patel-Hett S, Martin EJ, Mohammed BM, et al. · Haemophilia · 2020 · Background
    PubMed: PMID 31336410 · NCT05313620 · Colitis, Ulcerative
  53. Hypercoagulability After Resection of Thoracic Malignancy: A Prospective Evaluation.
    Mulder MB, Proctor KG, Valle EJ, et al. · World J Surg · 2020 · Background
    PubMed: PMID 31407092 · NCT05313620 · Colitis, Ulcerative
  54. Efficacy and safety of adalimumab in ankylosing spondylitis.
    Mounach A, El Maghraoui A · Open Access Rheumatol · 2020 · Background
    PubMed: PMID 27790037 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  55. Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition.
    Meah MN, Raftis J, Wilson SJ, et al. · Arterioscler Thromb Vasc Biol · 2020 · Background
    PubMed: PMID 32907366 · NCT05313620 · Colitis, Ulcerative
  56. Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis.
    Lightner DJ, Wymer K, Sanchez J, et al. · J Urol · 2020 · Background
    PubMed: PMID 31441676 · NCT06062875 · Prostatic Hyperplasia
  57. New insights and long-term safety of tocilizumab in rheumatoid arthritis.
    Jones G, Panova E · Ther Adv Musculoskelet Dis · 2020 · Background
    PubMed: PMID 30327685 · NCT04115423 · Arthritis, Rheumatoid
  58. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    GBD 2017 Inflammatory Bowel Disease Collaborators · Lancet Gastroenterol Hepatol · 2020 · Background
    PubMed: PMID 31648971 · NCT07495644 · Crohn Disease
  59. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R, Pangan AL, Song IH, et al. · Arthritis Rheumatol · 2020 · Background
    PubMed: PMID 31287230 · NCT02629159 (SELECT-COMPARE) · Arthritis, Rheumatoid
  60. Reassessment of Crohn's disease treated with at least 12 months of anti-TNF therapy: how likely is treatment withdrawal?
    Dart RJ, Griffin N, Taylor K, et al. · Frontline Gastroenterol · 2020 · Background
    PubMed: PMID 28839767 · NCT02994836 · Crohn Disease
  61. The Effect of Immunosuppression on Coagulation After Liver Transplantation.
    Bedreli S, Straub K, Achterfeld A, et al. · Liver Transpl · 2020 · Background
    PubMed: PMID 31021493 · NCT05313620 · Colitis, Ulcerative
  62. Strategies toward rheumatoid arthritis therapy; the old and the new.
    Abbasi M, Mousavi MJ, Jamalzehi S, et al. · J Cell Physiol · 2020 · Background
    PubMed: PMID 30536757 · NCT05379049 (TNF-alpha) · Arthritis, Rheumatoid

2019 (51 papers)

  1. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
    Weinblatt ME, Baranauskaite A, Niebrzydowski J, et al. · Arthritis Rheumatol · 2019 · Derived
    PubMed: PMID 28950421 · NCT02167139 · Arthritis, Rheumatoid
  2. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
    Weinblatt ME, Baranauskaite A, Dokoupilova E, et al. · Arthritis Rheumatol · 2019 · Derived
    PubMed: PMID 29439289 · NCT02167139 · Arthritis, Rheumatoid
  3. Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial.
    van der Heijde D, Sieper J, Maksymowych WP, et al. · Arthritis Res Ther · 2019 · Derived
    PubMed: PMID 29587851 · NCT00939003 · Axial Spondyloarthritis
  4. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
    van der Heijde D, Gladman DD, Kishimoto M, et al. · J Rheumatol · 2019 · Derived
    PubMed: PMID 29247148 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  5. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.
    Taylor PC, Schiff MH, Wang Q, et al. · Ann Rheum Dis · 2019 · Derived
    PubMed: PMID 29483080 · NCT02019472 (SIRROUND-H) · Arthritis, Rheumatoid
  6. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.
    Taylor PC, Kremer JM, Emery P, et al. · Ann Rheum Dis · 2019 · Derived
    PubMed: PMID 29463520 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  7. Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis.
    Tanaka Y, McInnes IB, Taylor PC, et al. · Arthritis Rheumatol · 2019 · Derived
    PubMed: PMID 30058112 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  8. Plasma MicroRNA Profiles in Patients with Early Rheumatoid Arthritis Responding to Adalimumab plus Methotrexate vs Methotrexate Alone: A Placebo-controlled Clinical Trial.
    Sode J, Krintel SB, Carlsen AL, et al. · J Rheumatol · 2019 · Derived
    PubMed: PMID 29142030 · NCT00660647 (OPERA) · Arthritis, Rheumatoid
  9. Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate.
    Smolen JS, van Vollenhoven RF, Florentinus S, et al. · Ann Rheum Dis · 2019 · Derived
    PubMed: PMID 30076156 · NCT00420927 (OPTIMA) · Arthritis, Rheumatoid
  10. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
    Sands BE, Peyrin-Biroulet L, Loftus EV, et al. · N Engl J Med · 2019 · Derived
    PubMed: PMID 31553834 · NCT02497469 · Colitis, Ulcerative
  11. Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2.
    Ruemmele FM, Rosh J, Faubion WA, et al. · J Crohns Colitis · 2019 · Derived
    PubMed: PMID 29939254 · NCT00686374 · Crohn Disease
  12. Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis.
    Rivière E, Sellam J, Pascaud J, et al. · Arthritis Res Ther · 2019 · Derived
    PubMed: PMID 29884223 · NCT01000441 (ROC) · Arthritis, Rheumatoid
  13. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.
    Papp K, Bachelez H, Costanzo A, et al. · Br J Dermatol · 2019 · Derived
    PubMed: PMID 28755394 · NCT01970488 · Psoriasis
  14. Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial.
    Möller B, Everts-Graber J, Florentinus S, et al. · Arthritis Care Res (Hoboken) · 2019 · Derived
    PubMed: PMID 28950430 · NCT00195663 (PREMIER) · Arthritis, Rheumatoid
  15. Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial.
    Mehta NN, Shin DB, Joshi AA, et al. · Circ Cardiovasc Imaging · 2019 · Derived
    PubMed: PMID 29776990 · NCT01553058 (VIP) · Psoriasis
  16. Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate.
    Mease PJ, Genovese MC, Weinblatt ME, et al. · Arthritis Rheumatol · 2019 · Derived
    PubMed: PMID 29855175 · NCT02349451 · Arthritis, Psoriatic
  17. Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program.
    Mariette X, Chen C, Biswas P, et al. · Arthritis Care Res (Hoboken) · 2019 · Derived
    PubMed: PMID 28941219 · NCT00550446 · Arthritis, Rheumatoid
  18. Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis.
    Khatri A, Klünder B, Peloso PM, et al. · Rheumatology (Oxford) · 2019 · Derived
    PubMed: PMID 30376130 · NCT02349451 · Arthritis, Psoriatic
  19. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis.
    Kavanaugh A, van Vollenhoven RF, Fleischmann R, et al. · Ann Rheum Dis · 2019 · Derived
    PubMed: PMID 29146743 · NCT00420927 (OPTIMA) · Arthritis, Rheumatoid
  20. Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate.
    Kaeley GS, MacCarter DK, Pangan AL, et al. · J Rheumatol · 2019 · Derived
    PubMed: PMID 30173153 · NCT01185288 (MUSICA) · Arthritis, Rheumatoid
  21. Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease.
    Horneff G, Seyger MMB, Arikan D, et al. · J Pediatr · 2019 · Derived
    PubMed: PMID 30054164 · NCT01251614
  22. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
    Helliwell P, Coates LC, FitzGerald O, et al. · Arthritis Res Ther · 2019 · Derived
    PubMed: PMID 30373651 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  23. Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.
    Goss SL, Klein CE, Jin Z, et al. · Clin Ther · 2019 · Derived
    PubMed: PMID 29402521 · NCT01185301 (CONCERTO) · Arthritis, Rheumatoid
  24. ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study.
    Genovese MC, Weinblatt ME, Aelion JA, et al. · Arthritis Rheumatol · 2019 · Derived
    PubMed: PMID 29855172 · NCT02141997 · Arthritis, Rheumatoid
  25. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
    Foley P, Gordon K, Griffiths CEM, et al. · JAMA Dermatol · 2019 · Derived
    PubMed: PMID 29799960 · NCT02207244 (VOYAGE 2) · Psoriasis
  26. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis.
    Fleischmann RM, Alten R, Pileckyte M, et al. · Arthritis Res Ther · 2019 · Derived
    PubMed: PMID 30111357 · NCT02480153 · Arthritis, Rheumatoid
  27. Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab.
    Burmester GR, Kaeley GS, Kavanaugh AF, et al. · RMD Open · 2019 · Derived
    PubMed: PMID 28955494 · NCT01185301 (CONCERTO) · Arthritis, Rheumatoid
  28. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S, Everett CC, Naraghi K, et al. · Health Technol Assess · 2019 · Derived
    PubMed: PMID 29900829 · NCT01295151 (SWITCH) · Arthritis, Rheumatoid
  29. Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.
    Bingham CO, Gaich CL, DeLozier AM, et al. · Trials · 2019 · Derived
    PubMed: PMID 30902094 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  30. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
    Assa A, Matar M, Turner D, et al. · Gastroenterology · 2019 · Derived
    PubMed: PMID 31194979 · NCT02256462 · Crohn Disease
  31. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
    Armstrong AW, Reich K, Foley P, et al. · Am J Clin Dermatol · 2019 · Derived
    PubMed: PMID 30417277 · NCT02207244 (VOYAGE 2) · Psoriasis
  32. Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions.
    Zhao Y, Wu EY, Oliver MS, et al. · Arthritis Care Res (Hoboken) · 2019 · Background
    PubMed: PMID 29112802 · NCT04725422 (CHOIR) · Chronic recurrent multifocal osteomyelitis
  33. Platelet and coagulation disorders in newly diagnosed patients with pulmonary arterial hypertension.
    Vrigkou E, Tsangaris I, Bonovas S, et al. · Platelets · 2019 · Background
    PubMed: PMID 30047809 · NCT05313620 · Colitis, Ulcerative
  34. Cardiac Toxicity of Immune Checkpoint Inhibitors: Cardio-Oncology Meets Immunology.
    Varricchi G, Galdiero MR, Tocchetti CG, et al. · Circulation · 2019 · Background
    PubMed: PMID 29158212 · NCT03619876 (AMiRA) · Arthritis, Rheumatoid
  35. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
    van der Heijde D, Baraliakos X, Gensler LS, et al. · Lancet · 2019 · Background
    PubMed: PMID 30360970 · NCT05313620 · Colitis, Ulcerative
  36. Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease.
    Stikvoort A, Chen Y, Rådestad E, et al. · Front Immunol · 2019 · Background
    PubMed: PMID 28674539 · NCT03885713 (BioIBD) · Crohn Disease
  37. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease.
    Seyedian SS, Nokhostin F, Malamir MD, et al. · J Med Life · 2019 · Background
    PubMed: PMID 31406511 · NCT05291039 · Inflammatory Bowel Diseases
  38. The B cell response to citrullinated antigens in the development of rheumatoid arthritis.
    Scherer HU, Huizinga TWJ, Krönke G, et al. · Nat Rev Rheumatol · 2019 · Background
    PubMed: PMID 29416134 · NCT05502731 (JAKAR) · Arthritis, Rheumatoid
  39. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sands BE, Sandborn WJ, Panaccione R, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 31553833 · NCT05313620 · Colitis, Ulcerative
  40. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
    Sands BE, Sandborn WJ, Feagan BG, et al. · J Crohns Colitis · 2019 · Background
    PubMed: PMID 29917064 · NCT05313620 · Colitis, Ulcerative
  41. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Rutherford AI, Subesinghe S, Hyrich KL, et al. · Ann Rheum Dis · 2019 · Background
    PubMed: PMID 29592917 · NCT04115423 · Arthritis, Rheumatoid
  42. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.
    Reich K, Gooderham M, Thaçi D, et al. · Lancet · 2019 · Background
    PubMed: PMID 31280967 · NCT02694523 · Psoriasis
  43. Disease burden and social impact of pediatric chronic nonbacterial osteomyelitis from the patient and family perspective.
    Oliver M, Lee TC, Halpern-Felsher B, et al. · Pediatr Rheumatol Online J · 2019 · Background
    PubMed: PMID 30547806 · NCT04725422 (CHOIR) · Chronic recurrent multifocal osteomyelitis
  44. The potential impact of monitoring disease activity biomarkers on rheumatoid arthritis outcomes and costs.
    Oderda GM, Lawless GD, Wright GC, et al. · Per Med · 2019 · Background
    PubMed: PMID 29693487 · NCT05379049 (TNF-alpha) · Arthritis, Rheumatoid
  45. Symptom Based Clustering of Men in the LURN Observational Cohort Study.
    Liu G, Andreev VP, Helmuth ME, et al. · J Urol · 2019 · Background
    PubMed: PMID 31120372 · NCT06062875 · Prostatic Hyperplasia
  46. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.
    l'Ami MJ, Krieckaert CL, Nurmohamed MT, et al. · Ann Rheum Dis · 2019 · Background
    PubMed: PMID 28939629 · NCT04222920 (ADDORA-low) · Arthritis, Rheumatoid
  47. Prevalence and Characteristics of Urinary Incontinence in a Treatment Seeking Male Prospective Cohort: Results from the LURN Study.
    Helfand BT, Smith AR, Lai HH, et al. · J Urol · 2019 · Background
    PubMed: PMID 29477718 · NCT06062875 · Prostatic Hyperplasia
  48. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
    Grøn KL, Arkema EV, Glintborg B, et al. · Ann Rheum Dis · 2019 · Background
    PubMed: PMID 30612115 · NCT04115423 · Arthritis, Rheumatoid
  49. Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus.
    Danese S, Allez M, van Bodegraven AA, et al. · Dig Dis · 2019 · Background
    PubMed: PMID 30726845 · NCT05313620 · Colitis, Ulcerative
  50. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
    Chaparro M, Garre A, Ricart E, et al. · Aliment Pharmacol Ther · 2019 · Background
    PubMed: PMID 30281832 · NCT05313620 · Colitis, Ulcerative
  51. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
    Bonovas S, Lytras T, Nikolopoulos G, et al. · Aliment Pharmacol Ther · 2019 · Background
    PubMed: PMID 29205421 · NCT06269185 · Colitis, Ulcerative

2018 (33 papers)

  1. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA.
    Travis S, Feagan BG, Peyrin-Biroulet L, et al. · J Crohns Colitis · 2018 · Trial result
    PubMed: PMID 28981846 · NCT01550965 (InspirAda) · Colitis, Ulcerative
  2. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Papp K, Thaçi D, Marcoux D, et al. · Lancet · 2018 · Trial result
    PubMed: PMID 28478975 · NCT01251614
  3. Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial.
    Nanchahal J, Ball C, Davidson D, et al. · EBioMedicine · 2018 · Trial result
    PubMed: PMID 29983350 · NCT03180957 (RIDD) · Dupuytren Contracture
  4. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis.
    Jamshidi A, Gharibdoost F, Vojdanian M, et al. · Arthritis Res Ther · 2018 · Trial result
    PubMed: PMID 28728599 · NCT03172325
  5. Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease.
    Faubion WA, Dubinsky M, Ruemmele FM, et al. · Inflamm Bowel Dis · 2018 · Trial result
    PubMed: PMID 28129288 · NCT00686374 · Crohn Disease
  6. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
    Ryan C, Sobell JM, Leonardi CL, et al. · Am J Clin Dermatol · 2018 · Derived
    PubMed: PMID 29380251 · NCT00385736 · Colitis, Ulcerative
  7. Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab.
    Mease PJ, Van den Bosch F, Sieper J, et al. · J Rheumatol · 2018 · Derived
    PubMed: PMID 28298558 · NCT01064856
  8. Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial.
    López-Sanromán A, Vera-Mendoza I, Domènech E, et al. · J Crohns Colitis · 2018 · Derived
    PubMed: PMID 28402454 · NCT01564823 (APPRECIA) · Crohn Disease
  9. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study.
    Landewé R, Sieper J, Mease P, et al. · Lancet · 2018 · Derived
    PubMed: PMID 29961640 · NCT01808118 · Spondylitis, Ankylosing
  10. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).
    Gottlieb AB, Strand V, Kishimoto M, et al. · Rheumatology (Oxford) · 2018 · Derived
    PubMed: PMID 29945203 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  11. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
    Fleischmann R, Mysler E, Hall S, et al. · Lancet · 2018 · Derived
    PubMed: PMID 28629665 · NCT02187055 (ORAL STRATEGY)
  12. Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) patients (PREDICTRA).
    Emery P, Burmester GR, Naredo E, et al. · BMJ Open · 2018 · Derived
    PubMed: PMID 29490959 · NCT02198651 (PREDICTRA) · Arthritis, Rheumatoid
  13. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF, Panaccione R, Bossuyt P, et al. · Lancet · 2018 · Derived
    PubMed: PMID 29096949 · NCT01235689 (CALM) · Crohn Disease
  14. Chronic Nonbacterial Osteomyelitis and Chronic Recurrent Multifocal Osteomyelitis in Children.
    Zhao Y, Ferguson PJ · Pediatr Clin North Am · 2018 · Background
    PubMed: PMID 30031498 · NCT04725422 (CHOIR) · Chronic recurrent multifocal osteomyelitis
  15. Ulcerative colitis.
    Ungaro R, Mehandru S, Allen PB, et al. · Lancet · 2018 · Background
    PubMed: PMID 27914657 · NCT05313620 · Colitis, Ulcerative
  16. Endoscopy in inflammatory bowel disease: advances in disease management.
    Scoville EA, Schwartz DA · Gastrointest Endosc · 2018 · Background
    PubMed: PMID 28886962 · NCT03885713 (BioIBD) · Crohn Disease
  17. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
    Scott IC, Hider SL, Scott DL, et al. · Drug Saf · 2018 · Background
    PubMed: PMID 29500799 · NCT05313620 · Colitis, Ulcerative
  18. Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis.
    Planell N, Masamunt MC, Leal RF, et al. · J Crohns Colitis · 2018 · Background
    PubMed: PMID 28981629 · NCT03885713 (BioIBD) · Crohn Disease
  19. Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease.
    Park SH, Aniwan S, Loftus EV, et al. · Curr Opin Pharmacol · 2018 · Background
    PubMed: PMID 28992449 · NCT03885713 (BioIBD) · Crohn Disease
  20. Evaluation of hypercoagulability with rotational thromboelastometry in children with iron deficiency anemia.
    Özdemir ZC, Düzenli Kar Y, Gündüz E, et al. · Hematology · 2018 · Background
    PubMed: PMID 29544395 · NCT05313620 · Colitis, Ulcerative
  21. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
    Ng SC, Shi HY, Hamidi N, et al. · Lancet · 2018 · Background
    PubMed: PMID 29050646 · NCT05313620 · Colitis, Ulcerative
  22. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
    Mesa RA, Vannucchi AM, Mead A, et al. · Lancet Haematol · 2018 · Background
    PubMed: PMID 28336242 · NCT05313620 · Colitis, Ulcerative
  23. Can We Predict the Efficacy of Anti-TNF-α Agents?
    Lopetuso LR, Gerardi V, Papa V, et al. · Int J Mol Sci · 2018 · Background
    PubMed: PMID 28906475 · NCT03885713 (BioIBD) · Crohn Disease
  24. Effect of Albumin in Combination With Mannitol on Whole-blood Coagulation In Vitro Assessed by Thromboelastometry.
    Lillemäe K, Laine AT, Schramko A, et al. · J Neurosurg Anesthesiol · 2018 · Background
    PubMed: PMID 28498140 · NCT05313620 · Colitis, Ulcerative
  25. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
    Hyland E, Mant T, Vlachos P, et al. · Br J Clin Pharmacol · 2018 · Background
    PubMed: PMID 27285856 · NCT03273192
  26. The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
    Hindryckx P, Vande Casteele N, Novak G, et al. · J Crohns Colitis · 2018 · Background
    PubMed: PMID 28961959 · NCT03885713 (BioIBD) · Crohn Disease
  27. The revised Bristol Rheumatoid Arthritis Fatigue measures and the Rheumatoid Arthritis Impact of Disease scale: validation in six countries.
    Hewlett S, Kirwan J, Bode C, et al. · Rheumatology (Oxford) · 2018 · Background
    PubMed: PMID 29087507 · NCT05502731 (JAKAR) · Arthritis, Rheumatoid
  28. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
    Hassan EA, Ramadan HK, Ismael AA, et al. · Saudi J Gastroenterol · 2018 · Background
    PubMed: PMID 28721978 · NCT03885713 (BioIBD) · Crohn Disease
  29. Tranexamic acid is associated with selective increase in inflammatory markers following total knee arthroplasty (TKA): a pilot study.
    Grant AL, Letson HL, Morris JL, et al. · J Orthop Surg Res · 2018 · Background
    PubMed: PMID 29914535 · NCT05313620 · Colitis, Ulcerative
  30. Ustekinumab to treat Crohn's disease.
    Gisbert JP, Chaparro M · Gastroenterol Hepatol · 2018 · Background
    PubMed: PMID 29042094 · NCT03885713 (BioIBD) · Crohn Disease
  31. Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease.
    Feng T, Chen B, Li L, et al. · Inflamm Bowel Dis · 2018 · Background
    PubMed: PMID 28644181 · NCT03885713 (BioIBD) · Crohn Disease
  32. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
    Domènech E, Gisbert JP · Gastroenterol Hepatol · 2018 · Background
    PubMed: PMID 26948838 · NCT03885713 (BioIBD) · Crohn Disease
  33. Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission.
    Brooks AJ, Sebastian S, Cross SS, et al. · J Crohns Colitis · 2018 · Background
    PubMed: PMID 25311864 · NCT02994836 · Crohn Disease

2017 (51 papers)

  1. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS, Burmester GR, Combe B, et al. · Lancet · 2017 · Trial result
    PubMed: PMID 27863807 · NCT01500278 · Arthritis, Rheumatoid
  2. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis.
    Ramanan AV, Dick AD, Jones AP, et al. · N Engl J Med · 2017 · Trial result
    PubMed: PMID 28445659 · NCT05015335 · Uveitis, Anterior
  3. Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis.
    Hull DN, Cooksley H, Chokshi S, et al. · Arthritis Res Ther · 2017 · Trial result
    PubMed: PMID 28010726 · NCT01060098 · Arthritis, Rheumatoid
  4. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.
    Wynne C, Altendorfer M, Sonderegger I, et al. · Expert Opin Investig Drugs · 2017 · Derived
    PubMed: PMID 27813422 · NCT02045979
  5. A psychometric analysis of outcome measures in peripheral spondyloarthritis.
    Turina MC, Ramiro S, Baeten DL, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 26245756 · NCT01064856
  6. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
    Taylor PC, Keystone EC, van der Heijde D, et al. · N Engl J Med · 2017 · Derived
    PubMed: PMID 28199814 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  7. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
    Sheppard J, Joshi A, Betts KA, et al. · JAMA Ophthalmol · 2017 · Derived
    PubMed: PMID 28426849 · NCT01138657 (VISUAL l) · Uveitis
  8. Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial.
    Scheinfeld N, Sundaram M, Teixeira H, et al. · Dermatol Online J · 2017 · Derived
    PubMed: PMID 27136622 · NCT00918255 · Hidradenitis Suppurativa
  9. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
    Mease PJ, van der Heijde D, Ritchlin CT, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 27553214 · NCT01695239 (SPIRIT-P1) · Arthritis, Psoriatic
  10. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
    Mease P, Hall S, FitzGerald O, et al. · N Engl J Med · 2017 · Derived
    PubMed: PMID 29045212 · NCT01877668 (OPAL BROADEN) · Arthritis, Psoriatic
  11. Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage.
    Krabbe S, Bolce R, Brahe CH, et al. · Scand J Rheumatol · 2017 · Derived
    PubMed: PMID 27682742 · NCT00696059 (HURRAH) · Arthritis, Rheumatoid
  12. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC, Taylor PC, Tanaka Y, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 28798049 · NCT01710358 (RA-BEAM) · Arthritis, Rheumatoid
  13. Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate.
    Kaeley GS, Nishio MJ, Goyal JR, et al. · Arthritis Rheumatol · 2017 · Derived
    PubMed: PMID 27214046 · NCT01185288 (MUSICA) · Arthritis, Rheumatoid
  14. Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial.
    Kaeley GS, Evangelisto AM, Nishio MJ, et al. · J Rheumatol · 2017 · Derived
    PubMed: PMID 27307526 · NCT01185288 (MUSICA) · Arthritis, Rheumatoid
  15. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
    Hørslev-Petersen K, Hetland ML, Ørnbjerg LM, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 26489704 · NCT00660647 (OPERA) · Arthritis, Rheumatoid
  16. Association of Disorganization of Retinal Inner Layers With Visual Acuity In Eyes With Uveitic Cystoid Macular Edema.
    Grewal DS, O'Sullivan ML, Kron M, et al. · Am J Ophthalmol · 2017 · Derived
    PubMed: PMID 28237411 · NCT01138657 (VISUAL l) · Uveitis
  17. Magnetic resonance imaging assessed inflammation in the wrist is associated with patient-reported physical impairment, global assessment of disease activity and pain in early rheumatoid arthritis: longitudinal results from two randomised controlled trials.
    Glinatsi D, Baker JF, Hetland ML, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 28611080 · NCT00660647 (OPERA) · Arthritis, Rheumatoid
  18. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
    Gabay C, McInnes IB, Kavanaugh A, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 26613768 · NCT01119859 · Arthritis, Rheumatoid
  19. Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis.
    Fleischmann R, Weinblatt ME, Schiff M, et al. · Arthritis Care Res (Hoboken) · 2017 · Derived
    PubMed: PMID 26473625 · NCT00929864 · Arthritis, Rheumatoid
  20. Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab.
    Fleischmann R, Connolly SE, Maldonado MA, et al. · Arthritis Rheumatol · 2017 · Derived
    PubMed: PMID 27111089 · NCT00929864 · Arthritis, Rheumatoid
  21. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
    Cohen SB, Tanaka Y, Mariette X, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 28143815 · NCT00550446 · Arthritis, Rheumatoid
  22. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
    Cohen S, Genovese MC, Choy E, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 28584187 · NCT01970475 · Arthritis, Rheumatoid
  23. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.
    Charles-Schoeman C, Burmester G, Nash P, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 26275429 · NCT00550446 · Arthritis, Rheumatoid
  24. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
    Burmester GR, Lin Y, Patel R, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 27856432 · NCT02332590 · Arthritis, Rheumatoid
  25. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis.
    Burmester GR, Landewé R, Genovese MC, et al. · Ann Rheum Dis · 2017 · Derived
    PubMed: PMID 27338778 · NCT00647491 · Arthritis, Rheumatoid
  26. TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study.
    Bissonnette R, Harel F, Krueger JG, et al. · J Invest Dermatol · 2017 · Derived
    PubMed: PMID 28286061 · NCT01722214 · Psoriasis
  27. Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab.
    Armstrong AW, Villanueva Quintero DG, Echeverría CM, et al. · Am J Clin Dermatol · 2017 · Derived
    PubMed: PMID 27815915 · NCT00237887 · Psoriasis
  28. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
    Westhovens R, Taylor PC, Alten R, et al. · Ann Rheum Dis · 2017 · Background
    PubMed: PMID 27993829 · NCT05502731 (JAKAR) · Arthritis, Rheumatoid
  29. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials.
    Vuitton L, Marteau P, Sandborn WJ, et al. · Gut · 2017 · Background
    PubMed: PMID 26353983 · NCT03885713 (BioIBD) · Crohn Disease
  30. Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF.
    Viazis N, Giakoumis M, Bamias G, et al. · Dig Liver Dis · 2017 · Background
    PubMed: PMID 27866814 · NCT03885713 (BioIBD) · Crohn Disease
  31. Mass Cytometry of the Human Mucosal Immune System Identifies Tissue- and Disease-Associated Immune Subsets.
    van Unen V, Li N, Molendijk I, et al. · Immunity · 2017 · Background
    PubMed: PMID 27178470 · NCT03885713 (BioIBD) · Crohn Disease
  32. Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases.
    Torres J, Caprioli F, Katsanos KH, et al. · J Crohns Colitis · 2017 · Background
    PubMed: PMID 27282402 · NCT02852694 (RCT) · Crohn Disease
  33. Mass Cytometry: Single Cells, Many Features.
    Spitzer MH, Nolan GP · Cell · 2017 · Background
    PubMed: PMID 27153492 · NCT03885713 (BioIBD) · Crohn Disease
  34. Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies.
    Singh JA · Curr Rheumatol Rep · 2017 · Background
    PubMed: PMID 27613285 · NCT04115423 · Arthritis, Rheumatoid
  35. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA, Hossain A, Tanjong Ghogomu E, et al. · Cochrane Database Syst Rev · 2017 · Background
    PubMed: PMID 28282491 · NCT04115423 · Arthritis, Rheumatoid
  36. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
    Sandborn WJ, Sakuraba A, Wang A, et al. · Curr Med Res Opin · 2017 · Background
    PubMed: PMID 26986449 · NCT06269185 · Colitis, Ulcerative
  37. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.
    Ramiro S, Sepriano A, Chatzidionysiou K, et al. · Ann Rheum Dis · 2017 · Background
    PubMed: PMID 28298374 · NCT04115423 · Arthritis, Rheumatoid
  38. Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease.
    Pineton de Chambrun G, Blanc P, Peyrin-Biroulet L, et al. · Expert Rev Gastroenterol Hepatol · 2017 · Background
    PubMed: PMID 27043489 · NCT03885713 (BioIBD) · Crohn Disease
  39. Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015.
    Matsui T, Umetsu R, Kato Y, et al. · Int J Med Sci · 2017 · Background
    PubMed: PMID 28260984 · NCT05889338 · Psoriasis
  40. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study.
    Maksymowych WP, Dougados M, van der Heijde D, et al. · Ann Rheum Dis · 2017 · Background
    PubMed: PMID 26269397 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  41. Effects of preoperative aspirin on perioperative platelet activation and dysfunction in patients undergoing off-pump coronary artery bypass graft surgery: A prospective randomized study.
    Lee J, Jung CW, Jeon Y, et al. · PLoS One · 2017 · Background
    PubMed: PMID 28715503 · NCT05313620 · Colitis, Ulcerative
  42. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study.
    Kievit W, van Herwaarden N, van den Hoogen FH, et al. · Ann Rheum Dis · 2017 · Background
    PubMed: PMID 26764260 · NCT04194827 (ADDORA) · Arthritis, Rheumatoid
  43. Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis.
    Kerkman PF, Fabre E, van der Voort EI, et al. · Ann Rheum Dis · 2017 · Background
    PubMed: PMID 26034045 · NCT05502731 (JAKAR) · Arthritis, Rheumatoid
  44. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab.
    Kaur P, Chow V, Zhang N, et al. · Ann Rheum Dis · 2017 · Background
    PubMed: PMID 27466231 · NCT03273192
  45. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.
    Jani RH, Gupta R, Bhatia G, et al. · Int J Rheum Dis · 2017 · Background
    PubMed: PMID 26176644 · NCT05172817 (ACT) · Arthritis, Rheumatoid
  46. Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study.
    Hamam RN, Barikian AW, Antonios RS, et al. · Ocul Immunol Inflamm · 2017 · Background
    PubMed: PMID 25549063 · NCT02706704 (IVAS) · Uveitis
  47. The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    Gisbert JP, Marín AC, Chaparro M, et al. · Am J Gastroenterol · 2017 · Background
    PubMed: PMID 27002797 · NCT02994836 · Crohn Disease
  48. Phage display-derived human antibodies in clinical development and therapy.
    Frenzel A, Schirrmann T, Hust M, et al. · MAbs · 2017 · Background
    PubMed: PMID 27416017 · NCT05889338 · Psoriasis
  49. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ, Chaparro M, García-Sánchez V, et al. · Am J Gastroenterol · 2017 · Background
    PubMed: PMID 27958281 · NCT02994836 · Crohn Disease
  50. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.
    Arbelaiz A, Azkargorta M, Krawczyk M, et al. · Hepatology · 2017 · Background
    PubMed: PMID 28555885 · NCT03885713 (BioIBD) · Crohn Disease
  51. Procoagulant profile in patients with immune thrombocytopenia.
    Álvarez-Román MT, Fernández-Bello I, Jiménez-Yuste V, et al. · Br J Haematol · 2017 · Background
    PubMed: PMID 27766635 · NCT05313620 · Colitis, Ulcerative

2016 (48 papers)

  1. Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease.
    Wu KC, Ran ZH, Gao X, et al. · Intest Res · 2016 · Trial result
    PubMed: PMID 27175116 · NCT02015793 · Crohn Disease
  2. Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group.
    Trachtman H, Vento S, Herreshoff E, et al. · BMC Nephrol · 2016 · Trial result
    PubMed: PMID 26198842 · NCT00814255 (FONTII) · Glomerulosclerosis, Focal Segmental
  3. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
    Kimball AB, Okun MM, Williams DA, et al. · N Engl J Med · 2016 · Trial result
    PubMed: PMID 27518661 · NCT01468233 (PIONEER II) · Psoriasis
  4. Adalimumab in Patients with Active Noninfectious Uveitis.
    Jaffe GJ, Dick AD, Brézin AP, et al. · N Engl J Med · 2016 · Trial result
    PubMed: PMID 27602665 · NCT01138657 (VISUAL l) · Uveitis
  5. A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis.
    Burgos-Vargas R, Tse SM, Horneff G, et al. · Arthritis Care Res (Hoboken) · 2016 · Trial result
    PubMed: PMID 26223543 · NCT01166282 · Spondylitis, Ankylosing
  6. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
    Weinblatt ME, Mease P, Mysler E, et al. · Arthritis Rheumatol · 2016 · Derived
    PubMed: PMID 26138593 · NCT01373151 · Arthritis, Rheumatoid
  7. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.
    Wallenstein GV, Kanik KS, Wilkinson B, et al. · Clin Exp Rheumatol · 2016 · Derived
    PubMed: PMID 27156561 · NCT00550446 · Arthritis, Rheumatoid
  8. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations.
    Van den Bosch F, Kavanaugh A, Kron M, et al. · J Rheumatol · 2016 · Derived
    PubMed: PMID 25834212 · NCT00235885 (STEREO) · Arthritis, Psoriatic
  9. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy.
    Taylor PC, Genovese MC, Greenwood M, et al. · Ann Rheum Dis · 2016 · Derived
    PubMed: PMID 25074688 · NCT01264770 (OSKIRA -4) · Arthritis, Rheumatoid
  10. Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease.
    Tanida S, Inoue N, Kobayashi K, et al. · Clin Gastroenterol Hepatol · 2016 · Derived
    PubMed: PMID 25245624 · NCT01243671
  11. Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.
    Sweiss NJ, Noth I, Mirsaeidi M, et al. · Sarcoidosis Vasc Diffuse Lung Dis · 2016 · Derived
    PubMed: PMID 24751453 · NCT00311246 · Sarcoidosis
  12. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial.
    Sokolove J, Schiff M, Fleischmann R, et al. · Ann Rheum Dis · 2016 · Derived
    PubMed: PMID 26359449 · NCT00929864 · Arthritis, Rheumatoid
  13. Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration.
    Schiff M, Weinblatt ME, Valente R, et al. · RMD Open · 2016 · Derived
    PubMed: PMID 27110385 · NCT00929864 · Arthritis, Rheumatoid
  14. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial.
    Rutgeerts P, Reinisch W, Colombel JF, et al. · Gastrointest Endosc · 2016 · Derived
    PubMed: PMID 26234693 · NCT00348283 · Crohn Disease
  15. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.
    Porter D, van Melckebeke J, Dale J, et al. · Lancet · 2016 · Derived
    PubMed: PMID 27197690 · NCT01021735 (ORBIT) · Arthritis, Rheumatoid
  16. Course of Magnetic Resonance Imaging-Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Double-Blind, Placebo-Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berlin and Spondyloarthritis Research Consortium of Canada Methods.
    Pedersen SJ, Poddubnyy D, Sørensen IJ, et al. · Arthritis Rheumatol · 2016 · Derived
    PubMed: PMID 26414004 · NCT00477893 (DANISH) · Spondylarthritis
  17. Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.
    Papp KA, Armstrong AW, Reich K, et al. · Am J Clin Dermatol · 2016 · Derived
    PubMed: PMID 26547918 · NCT00645814 · Psoriasis
  18. Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis.
    Landewé R, Smolen JS, Florentinus S, et al. · Arthritis Res Ther · 2016 · Derived
    PubMed: PMID 25994819 · NCT00195663 (PREMIER) · Arthritis, Rheumatoid
  19. Dysregulation of RasGRP1 in rheumatoid arthritis and modulation of RasGRP3 as a biomarker of TNFα inhibitors.
    Golinski ML, Vandhuick T, Derambure C, et al. · Arthritis Res Ther · 2016 · Derived
    PubMed: PMID 26714738 · NCT00234234 · Arthritis, Rheumatoid
  20. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.
    Furst DE, Kavanaugh A, Florentinus S, et al. · Rheumatology (Oxford) · 2016 · Derived
    PubMed: PMID 26199453 · NCT00195650 · Arthritis, Rheumatoid
  21. Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?
    Emery P, Kavanaugh A, Bao Y, et al. · Ann Rheum Dis · 2016 · Derived
    PubMed: PMID 25139667 · NCT00195702 · Arthritis, Rheumatoid
  22. A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.
    Chatzidionysiou K, Turesson C, Teleman A, et al. · RMD Open · 2016 · Derived
    PubMed: PMID 26819752 · NCT00808509 (ADMIRE) · Arthritis, Rheumatoid
  23. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H, Xie F, Delzell E, et al. · Arthritis Rheumatol · 2016 · Background
    PubMed: PMID 26315675 · NCT04115423 · Arthritis, Rheumatoid
  24. The epidemiology and risk factors of inflammatory bowel disease.
    Ye Y, Pang Z, Chen W, et al. · Int J Clin Exp Med · 2016 · Background
    PubMed: PMID 26885239 · NCT05313620 · Colitis, Ulcerative
  25. Whole-body Magnetic Resonance Imaging in Chronic Recurrent Multifocal Osteomyelitis: Clinical Longterm Assessment May Underestimate Activity.
    Voit AM, Arnoldi AP, Douis H, et al. · J Rheumatol · 2016 · Background
    PubMed: PMID 25979713 · NCT04725422 (CHOIR) · Chronic recurrent multifocal osteomyelitis
  26. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients.
    Vallet H, Riviere S, Sanna A, et al. · J Autoimmun · 2016 · Background
    PubMed: PMID 26162757 · NCT05105347 · Uveitis
  27. Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study.
    Tsantes AE, Kyriakou E, Ikonomidis I, et al. · Medicine (Baltimore) · 2016 · Background
    PubMed: PMID 27057830 · NCT05313620 · Colitis, Ulcerative
  28. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.
    Tew GW, Hackney JA, Gibbons D, et al. · Gastroenterology · 2016 · Background
    PubMed: PMID 26522261 · NCT03885713 (BioIBD) · Crohn Disease
  29. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease.
    Shah SC, Colombel JF, Sands BE, et al. · Aliment Pharmacol Ther · 2016 · Background
    PubMed: PMID 26607562 · NCT03885713 (BioIBD) · Crohn Disease
  30. Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
    Sakai R, Cho SK, Nanki T, et al. · Arthritis Res Ther · 2016 · Background
    PubMed: PMID 25880658 · NCT04115423 · Arthritis, Rheumatoid
  31. Health Care Cost Analysis in a Population-based Inception Cohort of Inflammatory Bowel Disease Patients in the First Year of Diagnosis.
    Niewiadomski O, Studd C, Hair C, et al. · J Crohns Colitis · 2016 · Background
    PubMed: PMID 26129692 · NCT03885713 (BioIBD) · Crohn Disease
  32. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
    Nguyen QD, Merrill PT, Jaffe GJ, et al. · Lancet · 2016 · Background
    PubMed: PMID 27542302 · NCT03816397 (ADJUST) · Uveitis
  33. Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy.
    Nair N, Mei HE, Chen SY, et al. · Arthritis Res Ther · 2016 · Background
    PubMed: PMID 25981462 · NCT03885713 (BioIBD) · Crohn Disease
  34. The Role of Platelets in Venous Thromboembolism.
    Montoro-García S, Schindewolf M, Stanford S, et al. · Semin Thromb Hemost · 2016 · Background
    PubMed: PMID 26926584 · NCT05313620 · Colitis, Ulcerative
  35. Biomarkers in axial spondyloarthritis.
    Maksymowych WP · Curr Opin Rheumatol · 2016 · Background
    PubMed: PMID 26002025 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  36. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C, Huang V, Fedorak DK, et al. · J Clin Gastroenterol · 2016 · Background
    PubMed: PMID 25389599 · NCT06269185 · Colitis, Ulcerative
  37. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.
    Kopylov U, Seidman E · Ther Adv Gastroenterol · 2016 · Background
    PubMed: PMID 27366220 · NCT03885713 (BioIBD) · Crohn Disease
  38. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
    Khanna R, Bressler B, Levesque BG, et al. · Lancet · 2016 · Background
    PubMed: PMID 26342731 · NCT02852694 (RCT) · Crohn Disease
  39. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.
    Jonas O, Landry HM, Fuller JE, et al. · Sci Transl Med · 2016 · Background
    PubMed: PMID 25904741 · NCT07352566 · Psoriasis
  40. Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
    Johnson DB, Balko JM, Compton ML, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27806233 · NCT03619876 (AMiRA) · Arthritis, Rheumatoid
  41. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis.
    Jin Y, Lin Y, Lin LJ, et al. · World J Gastroenterol · 2016 · Background
    PubMed: PMID 26034371 · NCT07495644 · Crohn Disease
  42. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys.
    Gordon JP, McEwan PC, Maguire A, et al. · Eur J Gastroenterol Hepatol · 2016 · Background
    PubMed: PMID 25933126 · NCT03885713 (BioIBD) · Crohn Disease
  43. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy.
    Gisbert JP, Marín AC, Chaparro M, et al. · Aliment Pharmacol Ther · 2016 · Background
    PubMed: PMID 26075832 · NCT02994836 · Crohn Disease
  44. [Vedolizumab in the treatment of Crohn's disease].
    Gisbert JP, Domènech E · Gastroenterol Hepatol · 2016 · Background
    PubMed: PMID 25619903 · NCT03885713 (BioIBD) · Crohn Disease
  45. Clinical recovery from surgery correlates with single-cell immune signatures.
    Gaudillière B, Fragiadakis GK, Bruggner RV, et al. · Sci Transl Med · 2016 · Background
    PubMed: PMID 25253674 · NCT03885713 (BioIBD) · Crohn Disease
  46. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.
    Ding NS, Hart A, De Cruz P, et al. · Aliment Pharmacol Ther · 2016 · Background
    PubMed: PMID 26515897 · NCT03885713 (BioIBD) · Crohn Disease
  47. Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy.
    Dahlén R, Magnusson MK, Bajor A, et al. · Scand J Gastroenterol · 2016 · Background
    PubMed: PMID 25877762 · NCT03885713 (BioIBD) · Crohn Disease
  48. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.
    Chen DY, Chen YM, Hsieh TY, et al. · Rheumatology (Oxford) · 2016 · Background
    PubMed: PMID 26324949 · NCT04222920 (ADDORA-low) · Arthritis, Rheumatoid

2015 (45 papers)

  1. Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis.
    Hull DN, Williams RO, Pathan E, et al. · Clin Exp Immunol · 2015 · Trial result
    PubMed: PMID 25766640 · NCT01060098 · Arthritis, Rheumatoid
  2. Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers.
    Weiß A, Song IH, Haibel H, et al. · Arthritis Res Ther · 2015 · Derived
    PubMed: PMID 24476416 · NCT00235105 · Spondylitis, Ankylosing
  3. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
    Watanabe M, Hibi T, Mostafa NM, et al. · J Crohns Colitis · 2015 · Derived
    PubMed: PMID 24874893 · NCT00445432 · Crohn Disease
  4. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
    van der Heijde D, Breban M, Halter D, et al. · Rheumatology (Oxford) · 2015 · Derived
    PubMed: PMID 25541333 · NCT00085644 (ATLAS) · Spondylitis, Ankylosing
  5. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.
    Ternant D, Ducourau E, Fuzibet P, et al. · Br J Clin Pharmacol · 2015 · Derived
    PubMed: PMID 25223394 · NCT00234234 · Arthritis, Rheumatoid
  6. The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.
    Navarro Coy NC, Brown S, Bosworth A, et al. · BMC Musculoskelet Disord · 2015 · Derived
    PubMed: PMID 25539805 · NCT01295151 (SWITCH) · Arthritis, Rheumatoid
  7. Anti-TNF inhibits the airways neutrophilic inflammation induced by inhaled endotoxin in human.
    Michel O, Dinh PH, Doyen V, et al. · BMC Pharmacol Toxicol · 2015 · Derived
    PubMed: PMID 25371053 · NCT02252809
  8. Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee.
    Maksymowych WP, Russell AS, Chiu P, et al. · Arthritis Res Ther · 2015 · Derived
    PubMed: PMID 23036475 · NCT00686439 · Osteoarthritis
  9. Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis.
    Laustsen JK, Rasmussen TK, Stengaard-Pedersen K, et al. · Arthritis Res Ther · 2015 · Derived
    PubMed: PMID 25359291 · NCT00660647 (OPERA) · Arthritis, Rheumatoid
  10. Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis.
    Landewé R, Østergaard M, Keystone EC, et al. · Arthritis Care Res (Hoboken) · 2015 · Derived
    PubMed: PMID 25073879 · NCT00195702 · Arthritis, Rheumatoid
  11. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years.
    Kingsbury DJ, Bader-Meunier B, Patel G, et al. · Clin Rheumatol · 2015 · Derived
    PubMed: PMID 24487484 · NCT00775437 · Arthritis, Juvenile
  12. Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study).
    Kennedy WP, Simon JA, Offutt C, et al. · Arthritis Res Ther · 2015 · Derived
    PubMed: PMID 25359150 · NCT01225393 · Arthritis, Rheumatoid
  13. CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic 'window of opportunity'.
    Greisen SR, Schelde KK, Rasmussen TK, et al. · Arthritis Res Ther · 2015 · Derived
    PubMed: PMID 25249397 · NCT00660647 (OPERA) · Arthritis, Rheumatoid
  14. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
    Gordon KB, Duffin KC, Bissonnette R, et al. · N Engl J Med · 2015 · Derived
    PubMed: PMID 26154787 · NCT01483599 (X-PLORE) · Psoriasis
  15. CCL20 and IL22 Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis: A Randomized Clinical Trial.
    Goldminz AM, Suárez-Fariñas M, Wang AC, et al. · JAMA Dermatol · 2015 · Derived
    PubMed: PMID 25946554 · NCT00932113 (MOA) · Psoriasis
  16. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.
    Dennis G, Holweg CT, Kummerfeld SK, et al. · Arthritis Res Ther · 2015 · Derived
    PubMed: PMID 25167216 · NCT01119859 · Arthritis, Rheumatoid
  17. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
    Cohen S, Radominski SC, Gomez-Reino JJ, et al. · Arthritis Rheumatol · 2015 · Derived
    PubMed: PMID 25047021 · NCT00550446 · Arthritis, Rheumatoid
  18. Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study.
    Burmester GR, Matucci-Cerinic M, Mariette X, et al. · Arthritis Res Ther · 2015 · Derived
    PubMed: PMID 24460746 · NCT00234884 (ReAlise) · Arthritis, Rheumatoid
  19. Effectiveness of anti-tumour necrosis factor-α therapy in Danish patients with inflammatory bowel diseases.
    Bank S, Andersen PS, Burisch J, et al. · Dan Med J · 2015 · Derived
    PubMed: PMID 25748864 · NCT02322008 · Crohn Disease
  20. CRP genotype and haplotype associations with serum C-reactive protein level and DAS28 in untreated early rheumatoid arthritis patients.
    Ammitzbøll CG, Steffensen R, Bøgsted M, et al. · Arthritis Res Ther · 2015 · Derived
    PubMed: PMID 25359432 · NCT00660647 (OPERA) · Arthritis, Rheumatoid
  21. Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy.
    Wright HL, Thomas HB, Moots RJ, et al. · Rheumatology (Oxford) · 2015 · Background
    PubMed: PMID 25125592 · NCT02878161 · Arthritis, Rheumatoid
  22. Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy?
    Sorrentino D, Nash P, Viladomiu M, et al. · Inflamm Bowel Dis · 2015 · Background
    PubMed: PMID 24572206 · NCT02994836 · Crohn Disease
  23. Prevention and reversal of type 1 diabetes--past challenges and future opportunities.
    Skyler JS · Diabetes Care · 2015 · Background
    PubMed: PMID 25998292 · NCT02586831 (DIPIT) · Autoimmune Diseases
  24. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study.
    Sharma S, Eckert D, Hyams JS, et al. · Inflamm Bowel Dis · 2015 · Background
    PubMed: PMID 25723614 · NCT02852694 (RCT) · Crohn Disease
  25. IgA rheumatoid factor as a serological predictor of poor response to tumour necrosis factor α inhibitors in rheumatoid arthritis.
    Sakthiswary R, Shaharir SS, Mohd Said MS, et al. · Int J Rheum Dis · 2015 · Background
    PubMed: PMID 25292482 · NCT02878161 · Arthritis, Rheumatoid
  26. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
    Ruemmele FM, Veres G, Kolho KL, et al. · J Crohns Colitis · 2015 · Background
    PubMed: PMID 24909831 · NCT02852694 (RCT) · Crohn Disease
  27. Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence.
    Regueiro M, Kip KE, Baidoo L, et al. · Clin Gastroenterol Hepatol · 2015 · Background
    PubMed: PMID 24440221 · NCT02994836 · Crohn Disease
  28. Key findings towards optimising adalimumab treatment: the concentration-effect curve.
    Pouw MF, Krieckaert CL, Nurmohamed MT, et al. · Ann Rheum Dis · 2015 · Background
    PubMed: PMID 24326008 · NCT04194827 (ADDORA) · Arthritis, Rheumatoid
  29. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
    Peyrin-Biroulet L, Sandborn W, Sands BE, et al. · Am J Gastroenterol · 2015 · Background
    PubMed: PMID 26303131 · NCT03885713 (BioIBD) · Crohn Disease
  30. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis.
    Paul S, Moreau AC, Del Tedesco E, et al. · Inflamm Bowel Dis · 2015 · Background
    PubMed: PMID 24831559 · NCT02256462 · Crohn Disease
  31. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis.
    Mease P, Sieper J, Van den Bosch F, et al. · Arthritis Rheumatol · 2015 · Background
    PubMed: PMID 25545240 · NCT01064856
  32. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis.
    Márquez A, Ferreiro-Iglesias A, Dávila-Fajardo CL, et al. · Arthritis Res Ther · 2015 · Background
    PubMed: PMID 24612463 · NCT02878161 · Arthritis, Rheumatoid
  33. Treatment of rheumatoid arthritis with traditional chinese medicine.
    Lee WY, Chen HY, Chen KC, et al. · Biomed Res Int · 2015 · Background
    PubMed: PMID 24991562 · NCT03172325
  34. A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design.
    Khanna R, Bouguen G, Feagan BG, et al. · Inflamm Bowel Dis · 2015 · Background
    PubMed: PMID 25029615 · NCT03885713 (BioIBD) · Crohn Disease
  35. Thrombosis in inflammatory bowel diseases: what's the link?
    Giannotta M, Tapete G, Emmi G, et al. · Thromb J · 2015 · Background
    PubMed: PMID 25866483 · NCT05313620 · Colitis, Ulcerative
  36. Towards personalized care in IBD.
    Gerich ME, McGovern DP · Nat Rev Gastroenterol Hepatol · 2015 · Background
    PubMed: PMID 24345887 · NCT03885713 (BioIBD) · Crohn Disease
  37. CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages.
    Fergusson JR, Smith KE, Fleming VM, et al. · Cell Rep · 2015 · Background
    PubMed: PMID 25437561 · NCT03885713 (BioIBD) · Crohn Disease
  38. Physiological intermolecular modification spectroscopy for the prediction of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel diseases.
    Eftekhari P, Glaubitz L, Breidert M, et al. · Dig Dis · 2015 · Background
    PubMed: PMID 24969293 · NCT03885713 (BioIBD) · Crohn Disease
  39. Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy.
    Dai C, Liu WX, Jiang M, et al. · PLoS One · 2015 · Background
    PubMed: PMID 25330148 · NCT02994836 · Crohn Disease
  40. Rotation thromboelastometry and the hypercoagulable state in Cushing's syndrome.
    Coelho MC, Vieira Neto L, Kasuki L, et al. · Clin Endocrinol (Oxf) · 2015 · Background
    PubMed: PMID 24815846 · NCT05313620 · Colitis, Ulcerative
  41. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.
    Choi IY, Gerlag DM, Herenius MJ, et al. · Ann Rheum Dis · 2015 · Background
    PubMed: PMID 24297376 · NCT02878161 · Arthritis, Rheumatoid
  42. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.
    Chauvin A, Le Thuaut A, Belhassan M, et al. · Dig Liver Dis · 2015 · Background
    PubMed: PMID 24893686 · NCT02994836 · Crohn Disease
  43. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
    Chang CY, Meyer RM, Reiff AO, et al. · Arthritis Care Res (Hoboken) · 2015 · Background
    PubMed: PMID 25220674 · NCT03816397 (ADJUST) · Uveitis
  44. Hypercoagulability detected by whole blood thromboelastometry (ROTEM®) and impedance aggregometry (MULTIPLATE®) in obese patients.
    Campello E, Spiezia L, Zabeo E, et al. · Thromb Res · 2015 · Background
    PubMed: PMID 25592651 · NCT05313620 · Colitis, Ulcerative
  45. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
    Alvarez Román MT, Fernández Bello I, Arias-Salgado EG, et al. · Thromb Haemost · 2015 · Background
    PubMed: PMID 24500066 · NCT05313620 · Colitis, Ulcerative

2014 (45 papers)

  1. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.
    Huang F, Gu J, Zhu P, et al. · Ann Rheum Dis · 2014 · Trial result
    PubMed: PMID 23475983 · NCT02893254 · Spondylitis, Ankylosing
  2. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome.
    Bosch PC · J Urol · 2014 · Trial result
    PubMed: PMID 23792149 · NCT01295814 · Cystitis, Interstitial
  3. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.
    Yamanaka H, Ishiguro N, Takeuchi T, et al. · Rheumatology (Oxford) · 2014 · Derived
    PubMed: PMID 24441150 · NCT00870467 · Arthritis, Rheumatoid
  4. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis.
    Wolf D, D'Haens G, Sandborn WJ, et al. · Aliment Pharmacol Ther · 2014 · Derived
    PubMed: PMID 25041859 · NCT00408629 · Colitis, Ulcerative
  5. Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis.
    van der Heijde D, Sieper J, Maksymowych WP, et al. · Arthritis Rheumatol · 2014 · Derived
    PubMed: PMID 24574227 · NCT00939003 · Axial Spondyloarthritis
  6. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.
    Smolen JS, Emery P, Fleischmann R, et al. · Lancet · 2014 · Derived
    PubMed: PMID 24168956 · NCT00420927 (OPTIMA) · Arthritis, Rheumatoid
  7. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial.
    Seror R, Baron G, Hachulla E, et al. · Ann Rheum Dis · 2014 · Derived
    PubMed: PMID 23897775 · NCT00305539 · Giant Cell Arteritis
  8. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.
    Schiff M, Weinblatt ME, Valente R, et al. · Ann Rheum Dis · 2014 · Derived
    PubMed: PMID 23962455 · NCT00929864 · Arthritis, Rheumatoid
  9. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants.
    Reinisch W, Sandborn WJ, Panaccione R, et al. · Inflamm Bowel Dis · 2014 · Derived
    PubMed: PMID 23665965 · NCT00385736 · Colitis, Ulcerative
  10. No overall damage progression despite persistent inflammation in adalimumab-treated psoriatic arthritis patients: results from an investigator-initiated 48-week comparative magnetic resonance imaging, computed tomography and radiography trial.
    Poggenborg RP, Wiell C, Bøyesen P, et al. · Rheumatology (Oxford) · 2014 · Derived
    PubMed: PMID 24369412 · NCT01465438 (HUPSA) · Arthritis, Psoriatic
  11. Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.
    Panaccione R, Colombel JF, Sandborn WJ, et al. · Aliment Pharmacol Ther · 2014 · Derived
    PubMed: PMID 24134498 · NCT00077779 (CHARM) · Crohn Disease
  12. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.
    Keystone EC, van der Heijde D, Kavanaugh A, et al. · J Rheumatol · 2014 · Derived
    PubMed: PMID 23818718 · NCT00195702 · Arthritis, Rheumatoid
  13. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
    Keystone EC, Haraoui B, Guérette B, et al. · J Rheumatol · 2014 · Derived
    PubMed: PMID 24293583 · NCT00195663 (PREMIER) · Arthritis, Rheumatoid
  14. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
    Keystone EC, Breedveld FC, van der Heijde D, et al. · J Rheumatol · 2014 · Derived
    PubMed: PMID 24241487 · NCT00195663 (PREMIER) · Arthritis, Rheumatoid
  15. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
    Feagan BG, Sandborn WJ, Lazar A, et al. · Gastroenterology · 2014 · Derived
    PubMed: PMID 24067881 · NCT00408629 · Colitis, Ulcerative
  16. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
    Dewint P, Hansen BE, Verhey E, et al. · Gut · 2014 · Derived
    PubMed: PMID 23525574 · NCT00736983 (Adafi) · Crohn Disease
  17. Adalimumab induces deep remission in patients with Crohn's disease.
    Colombel JF, Rutgeerts PJ, Sandborn WJ, et al. · Clin Gastroenterol Hepatol · 2014 · Derived
    PubMed: PMID 23856361 · NCT00348283 · Crohn Disease
  18. M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis.
    Ammitzbøll CG, Thiel S, Jensenius JC, et al. · Arthritis Rheum · 2014 · Derived
    PubMed: PMID 24022747 · NCT00660647 (OPERA) · Arthritis, Rheumatoid
  19. Pharmacogenomics of biological treatment in rheumatoid arthritis.
    Xie X, Zhang D, Chen JW, et al. · Expert Opin Biol Ther · 2014 · Background
    PubMed: PMID 24295560 · NCT02878161 · Arthritis, Rheumatoid
  20. Comparison of magnetic resonance and balloon enteroscopic examination of the small intestine in patients with Crohn's disease.
    Takenaka K, Ohtsuka K, Kitazume Y, et al. · Gastroenterology · 2014 · Background
    PubMed: PMID 24732015 · NCT02332356 · Crohn Disease
  21. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease.
    Stidham RW, Lee TC, Higgins PD, et al. · Aliment Pharmacol Ther · 2014 · Background
    PubMed: PMID 24749763 · NCT03885713 (BioIBD) · Crohn Disease
  22. Recurrence of uveitis after discontinuation of infliximab.
    Shakoor A, Esterberg E, Acharya NR, et al. · Ocul Immunol Inflamm · 2014 · Background
    PubMed: PMID 23876234 · NCT03816397 (ADJUST) · Uveitis
  23. Proteomic patterns of colonic mucosal tissues delineate Crohn's colitis and ulcerative colitis.
    Seeley EH, Washington MK, Caprioli RM, et al. · Proteomics Clin Appl · 2014 · Background
    PubMed: PMID 23382084 · NCT03885713 (BioIBD) · Crohn Disease
  24. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).
    Ramanan AV, Dick AD, Benton D, et al. · Trials · 2014 · Background
    PubMed: PMID 24405833 · NCT03816397 (ADJUST) · Uveitis
  25. Phenotypic characterization of very early-onset IBD due to mutations in the IL10, IL10 receptor alpha or beta gene: a survey of the Genius Working Group.
    Pigneur B, Escher J, Elawad M, et al. · Inflamm Bowel Dis · 2014 · Background
    PubMed: PMID 24216686 · NCT02852694 (RCT) · Crohn Disease
  26. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.
    Pariente B, Laharie D · Aliment Pharmacol Ther · 2014 · Background
    PubMed: PMID 24957164 · NCT02994836 · Crohn Disease
  27. A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment in Japanese patients with rheumatoid arthritis.
    Nishimoto T, Seta N, Anan R, et al. · Clin Exp Rheumatol · 2014 · Background
    PubMed: PMID 24321457 · NCT02878161 · Arthritis, Rheumatoid
  28. Cytokines in inflammatory bowel disease.
    Neurath MF · Nat Rev Immunol · 2014 · Background
    PubMed: PMID 24751956 · NCT07495644 · Crohn Disease
  29. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.
    Molander P, Färkkilä M, Salminen K, et al. · Inflamm Bowel Dis · 2014 · Background
    PubMed: PMID 24798636 · NCT02994836 · Crohn Disease
  30. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain.
    Ma VY, Chan L, Carruthers KJ, et al. · Arch Phys Med Rehabil · 2014 · Background
    PubMed: PMID 24462839 · NCT03273192
  31. Inflammatory bowel disease: an expanding global health problem.
    M'Koma AE · Clin Med Insights Gastroenterol · 2014 · Background
    PubMed: PMID 24833941 · NCT03885713 (BioIBD) · Crohn Disease
  32. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G, Jabs DA, Read RW, et al. · Ophthalmology · 2014 · Background
    PubMed: PMID 24359625 · NCT05105347 · Uveitis
  33. Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort.
    Kristensen LE, Bliddal H, Christensen R, et al. · Arthritis Care Res (Hoboken) · 2014 · Background
    PubMed: PMID 23982986 · NCT02878161 · Arthritis, Rheumatoid
  34. Behçet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab.
    Kaburaki T, Namba K, Sonoda KH, et al. · Jpn J Ophthalmol · 2014 · Background
    PubMed: PMID 24482146 · NCT05105347 · Uveitis
  35. Behçet's disease: new insight into the relationship between procoagulant state, endothelial activation/damage and disease activity.
    Fernández-Bello I, López-Longo FJ, Arias-Salgado EG, et al. · Orphanet J Rare Dis · 2014 · Background
    PubMed: PMID 23711081 · NCT05313620 · Colitis, Ulcerative
  36. Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy.
    Farkas K, Lakatos PL, Nagy F, et al. · Scand J Gastroenterol · 2014 · Background
    PubMed: PMID 24131338 · NCT02994836 · Crohn Disease
  37. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
    Dávila-Fajardo CL, Márquez A, Pascual-Salcedo D, et al. · Pharmacogenet Genomics · 2014 · Background
    PubMed: PMID 24253594 · NCT02878161 · Arthritis, Rheumatoid
  38. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.
    Daïen CI, Morel J · Mediators Inflamm · 2014 · Background
    PubMed: PMID 24523570 · NCT02878161 · Arthritis, Rheumatoid
  39. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
    Coskun M, Salem M, Pedersen J, et al. · Pharmacol Res · 2014 · Background
    PubMed: PMID 23827161 · NCT05313620 · Colitis, Ulcerative
  40. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
    Colombel JF, Sandborn WJ, Ghosh S, et al. · Am J Gastroenterol · 2014 · Background
    PubMed: PMID 25155227 · NCT00573794 · Colitis, Ulcerative
  41. The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis.
    Chatu S, Subramanian V, Saxena S, et al. · Am J Gastroenterol · 2014 · Background
    PubMed: PMID 24322839 · NCT02852694 (RCT) · Crohn Disease
  42. [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease].
    Cabriada JL, Vera I, Domènech E, et al. · Gastroenterol Hepatol · 2014 · Background
    PubMed: PMID 23433780 · NCT02994836 · Crohn Disease
  43. East-West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort.
    Burisch J, Pedersen N, Čuković-Čavka S, et al. · Gut · 2014 · Background
    PubMed: PMID 23604131 · NCT05313620 · Colitis, Ulcerative
  44. Primary haemostasis: newer insights.
    Berndt MC, Metharom P, Andrews RK, et al. · Haemophilia · 2014 · Background
    PubMed: PMID 24762270 · NCT05313620 · Colitis, Ulcerative
  45. Impact of preoperative immunosuppressive agents on postoperative outcomes in Crohn's disease.
    Ahmed Ali U, Martin ST, Rao AD, et al. · Dis Colon Rectum · 2014 · Background
    PubMed: PMID 24819109 · NCT06062875 · Prostatic Hyperplasia

2013 (34 papers)

  1. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW, Shergy WJ, Kaine JL, et al. · Arthritis Rheum · 2013 · Trial result
    PubMed: PMID 21360491 · NCT00298272 · Arthritis, Rheumatoid
  2. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
    Weinblatt ME, Schiff M, Valente R, et al. · Arthritis Rheum · 2013 · Derived
    PubMed: PMID 23169319 · NCT00929864 · Arthritis, Rheumatoid
  3. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease.
    Steenholdt C, Al-khalaf M, Brynskov J, et al. · Inflamm Bowel Dis · 2013 · Derived
    PubMed: PMID 22344964 · NCT00055497 (CLASSICII) · Crohn Disease
  4. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate.
    Smolen JS, van der Heijde DM, Keystone EC, et al. · Ann Rheum Dis · 2013 · Derived
    PubMed: PMID 22915617 · NCT00195663 (PREMIER) · Arthritis, Rheumatoid
  5. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).
    Sieper J, van der Heijde D, Dougados M, et al. · Ann Rheum Dis · 2013 · Derived
    PubMed: PMID 22772328 · NCT00939003 · Axial Spondyloarthritis
  6. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease.
    Schreiber S, Reinisch W, Colombel JF, et al. · J Crohns Colitis · 2013 · Derived
    PubMed: PMID 22704916 · NCT00195715 · Crohn Disease
  7. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.
    Sandborn WJ, Colombel JF, D'Haens G, et al. · Aliment Pharmacol Ther · 2013 · Derived
    PubMed: PMID 23173821 · NCT00408629 · Colitis, Ulcerative
  8. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.
    Paul C, van de Kerkhof P, Puig L, et al. · Eur J Dermatol · 2013 · Derived
    PubMed: PMID 23178916 · NCT00574249 (BELIEVE) · Psoriasis
  9. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT.
    Mease PJ, Heckaman M, Kary S, et al. · J Rheumatol · 2013 · Derived
    PubMed: PMID 23504383 · NCT00646386 · Arthritis
  10. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial.
    Louis E, Löfberg R, Reinisch W, et al. · J Crohns Colitis · 2013 · Derived
    PubMed: PMID 22480772 · NCT00409617 · Crohn Disease
  11. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
    Kimball AB, Kerdel F, Adams D, et al. · Ann Intern Med · 2013 · Derived
    PubMed: PMID 23247938 · NCT00918255 · Hidradenitis Suppurativa
  12. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan.
    Imagawa T, Takei S, Umebayashi H, et al. · Clin Rheumatol · 2013 · Derived
    PubMed: PMID 23053683 · NCT00690573 · Arthritis, Juvenile
  13. Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare.
    Haibel H, Heldmann F, Braun J, et al. · Arthritis Rheum · 2013 · Derived
    PubMed: PMID 23686466 · NCT00235105 · Spondylitis, Ankylosing
  14. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.
    Gabay C, Emery P, van Vollenhoven R, et al. · Lancet · 2013 · Derived
    PubMed: PMID 23515142 · NCT01119859 · Arthritis, Rheumatoid
  15. Effects of the tumor necrosis factor-α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial.
    Bissonnette R, Tardif JC, Harel F, et al. · Circ Cardiovasc Imaging · 2013 · Derived
    PubMed: PMID 23204039 · NCT00940862 · Psoriasis
  16. Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis.
    Zeng Z, Duan Z, Zhang T, et al. · Mod Rheumatol · 2013 · Background
    PubMed: PMID 22760475 · NCT02878161 · Arthritis, Rheumatoid
  17. Platelets in thrombosis and hemostasis: old topic with new mechanisms.
    Wang Y, Andrews M, Yang Y, et al. · Cardiovasc Hematol Disord Drug Targets · 2013 · Background
    PubMed: PMID 23030445 · NCT05313620 · Colitis, Ulcerative
  18. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.
    van Schouwenburg PA, van de Stadt LA, de Jong RN, et al. · Ann Rheum Dis · 2013 · Background
    PubMed: PMID 22759910 · NCT05172817 (ACT) · Arthritis, Rheumatoid
  19. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.
    Van Rompaey L, Galien R, van der Aar EM, et al. · J Immunol · 2013 · Background
    PubMed: PMID 24006460 · NCT05502731 (JAKAR) · Arthritis, Rheumatoid
  20. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis.
    Umiċeviċ Mirkov M, Cui J, Vermeulen SH, et al. · Ann Rheum Dis · 2013 · Background
    PubMed: PMID 23233654 · NCT02878161 · Arthritis, Rheumatoid
  21. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease.
    Panés J, López-Sanromán A, Bermejo F, et al. · Gastroenterology · 2013 · Background
    PubMed: PMID 23770132 · NCT02852694 (RCT) · Crohn Disease
  22. Ulcerative colitis.
    Ordás I, Eckmann L, Talamini M, et al. · Lancet · 2013 · Background
    PubMed: PMID 22914296 · NCT05313620 · Colitis, Ulcerative
  23. Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy.
    Molnár T, Lakatos PL, Farkas K, et al. · Aliment Pharmacol Ther · 2013 · Background
    PubMed: PMID 23181359 · NCT02994836 · Crohn Disease
  24. Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation.
    Lu C, Waugh A, Bailey RJ, et al. · World J Gastroenterol · 2013 · Background
    PubMed: PMID 23049214 · NCT02994836 · Crohn Disease
  25. Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis.
    Kerkman PF, Rombouts Y, van der Voort EI, et al. · Ann Rheum Dis · 2013 · Background
    PubMed: PMID 23625975 · NCT05502731 (JAKAR) · Arthritis, Rheumatoid
  26. Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis.
    Kapoor SR, Filer A, Fitzpatrick MA, et al. · Arthritis Rheum · 2013 · Background
    PubMed: PMID 23460124 · NCT02878161 · Arthritis, Rheumatoid
  27. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study.
    Høivik ML, Moum B, Solberg IC, et al. · Gut · 2013 · Background
    PubMed: PMID 22717453 · NCT05313620 · Colitis, Ulcerative
  28. Label-free quantification for discovering novel biomarkers in the diagnosis and assessment of disease activity in inflammatory bowel disease.
    Han NY, Choi W, Park JM, et al. · J Dig Dis · 2013 · Background
    PubMed: PMID 23320753 · NCT03885713 (BioIBD) · Crohn Disease
  29. Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.
    D'Haens G, Feagan B, Colombel JF, et al. · Gastroenterology · 2013 · Background
    PubMed: PMID 23000597 · NCT03885713 (BioIBD) · Crohn Disease
  30. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis.
    Cui J, Stahl EA, Saevarsdottir S, et al. · PLoS Genet · 2013 · Background
    PubMed: PMID 23555300 · NCT02878161 · Arthritis, Rheumatoid
  31. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial.
    Cosnes J, Bourrier A, Laharie D, et al. · Gastroenterology · 2013 · Background
    PubMed: PMID 23644079 · NCT02852694 (RCT) · Crohn Disease
  32. Ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, or spondylarthritis: what's in a name?
    Claudepierre P, Wendling D, Breban M, et al. · Joint Bone Spine · 2013 · Background
    PubMed: PMID 22841580 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  33. Defective CD8+CD28+ regulatory T cell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy.
    Ceeraz S, Hall C, Choy EH, et al. · Clin Exp Immunol · 2013 · Background
    PubMed: PMID 23786396 · NCT02878161 · Arthritis, Rheumatoid
  34. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
    Baszis K, Garbutt J, Toib D, et al. · Arthritis Rheum · 2013 · Background
    PubMed: PMID 21702011 · NCT03816397 (ADJUST) · Uveitis

2012 (27 papers)

  1. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease.
    Watanabe M, Hibi T, Lomax KG, et al. · J Crohns Colitis · 2012 · Derived
    PubMed: PMID 22325170 · NCT00445432 · Crohn Disease
  2. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V, Rentz AM, Cifaldi MA, et al. · J Rheumatol · 2012 · Derived
    PubMed: PMID 22045836 · NCT00195663 (PREMIER) · Arthritis, Rheumatoid
  3. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover.
    Pedersen SJ, Sørensen IJ, Lambert RG, et al. · Arthritis Rheum · 2012 · Derived
    PubMed: PMID 22127697 · NCT00133315 · Spondylitis, Ankylosing
  4. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.
    Hyams JS, Griffiths A, Markowitz J, et al. · Gastroenterology · 2012 · Derived
    PubMed: PMID 22562021 · NCT00409682 · Crohn Disease
  5. Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study.
    Haraoui B, Cividino A, Stewart J, et al. · BMC Musculoskelet Disord · 2012 · Derived
    PubMed: PMID 22093579 · NCT00649545 (CanAct) · Arthritis, Rheumatoid
  6. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
    Gordon K, Papp K, Poulin Y, et al. · J Am Acad Dermatol · 2012 · Derived
    PubMed: PMID 21752491 · NCT00237887 · Psoriasis
  7. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
    Fleischmann R, Cutolo M, Genovese MC, et al. · Arthritis Rheum · 2012 · Derived
    PubMed: PMID 21952978 · NCT00550446 · Arthritis, Rheumatoid
  8. Six-transmembrane epithelial antigen of prostate 4 (STEAP4) is expressed on monocytes/neutrophils, and is regulated by TNF antagonist in patients with rheumatoid arthritis.
    Tanaka Y, Matsumoto I, Iwanami K, et al. · Clin Exp Rheumatol · 2012 · Background
    PubMed: PMID 22244520 · NCT02878161 · Arthritis, Rheumatoid
  9. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.
    Steenholdt C, Molazahi A, Ainsworth MA, et al. · Scand J Gastroenterol · 2012 · Background
    PubMed: PMID 22375898 · NCT02994836 · Crohn Disease
  10. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.
    Singh JA, Furst DE, Bharat A, et al. · Arthritis Care Res (Hoboken) · 2012 · Background
    PubMed: PMID 22473917 · NCT03172325
  11. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
    Rutgeerts P, Van Assche G, Sandborn WJ, et al. · Gastroenterology · 2012 · Background
    PubMed: PMID 22326435 · NCT01716039 · Colitis, Ulcerative
  12. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis.
    Rismo R, Olsen T, Cui G, et al. · Scand J Gastroenterol · 2012 · Background
    PubMed: PMID 22486187 · NCT03885713 (BioIBD) · Crohn Disease
  13. Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing.
    Rieder F, Karrasch T, Ben-Horin S, et al. · J Crohns Colitis · 2012 · Background
    PubMed: PMID 22405177 · NCT03885713 (BioIBD) · Crohn Disease
  14. Serological antibodies in inflammatory bowel disease: a systematic review.
    Prideaux L, De Cruz P, Ng SC, et al. · Inflamm Bowel Dis · 2012 · Background
    PubMed: PMID 22069240 · NCT02852694 (RCT) · Crohn Disease
  15. Host-microbe relationships in inflammatory bowel disease detected by bacterial and metaproteomic analysis of the mucosal-luminal interface.
    Presley LL, Ye J, Li X, et al. · Inflamm Bowel Dis · 2012 · Background
    PubMed: PMID 21698720 · NCT03885713 (BioIBD) · Crohn Disease
  16. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease.
    Peyrin-Biroulet L, Ferrante M, Magro F, et al. · J Crohns Colitis · 2012 · Background
    PubMed: PMID 21939925 · NCT03885713 (BioIBD) · Crohn Disease
  17. Mucosal healing in inflammatory bowel diseases: a systematic review.
    Neurath MF, Travis SP · Gut · 2012 · Background
    PubMed: PMID 22842618 · NCT03885713 (BioIBD) · Crohn Disease
  18. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
    Louis E, Mary JY, Vernier-Massouille G, et al. · Gastroenterology · 2012 · Background
    PubMed: PMID 21945953 · NCT02994836 · Crohn Disease
  19. CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis.
    Krintel SB, Essioux L, Wool A, et al. · PLoS One · 2012 · Background
    PubMed: PMID 22685579 · NCT02878161 · Arthritis, Rheumatoid
  20. CTLA4-Ig relieves inflammation in murine models of coxsackievirus B3-induced myocarditis.
    Han B, Jiang H, Liu Z, et al. · Can J Cardiol · 2012 · Background
    PubMed: PMID 22336520 · NCT03619876 (AMiRA) · Arthritis, Rheumatoid
  21. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.
    Gelfand JM, Wan J, Callis Duffin K, et al. · Arch Dermatol · 2012 · Background
    PubMed: PMID 22508874 · NCT02330380 · Psoriasis
  22. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study.
    Crombé V, Salleron J, Savoye G, et al. · Inflamm Bowel Dis · 2012 · Background
    PubMed: PMID 21287665 · NCT02994836 · Crohn Disease
  23. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission.
    Clarke K, Regueiro M · Inflamm Bowel Dis · 2012 · Background
    PubMed: PMID 21674731 · NCT02994836 · Crohn Disease
  24. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy.
    Chen DY, Chen YM, Chen HH, et al. · Arthritis Res Ther · 2012 · Background
    PubMed: PMID 21801431 · NCT02878161 · Arthritis, Rheumatoid
  25. Extracellular matrix proteins in hemostasis and thrombosis.
    Bergmeier W, Hynes RO · Cold Spring Harb Perspect Biol · 2012 · Background
    PubMed: PMID 21937733 · NCT05313620 · Colitis, Ulcerative
  26. A deep profiler's guide to cytometry.
    Bendall SC, Nolan GP, Roederer M, et al. · Trends Immunol · 2012 · Background
    PubMed: PMID 22476049 · NCT03885713 (BioIBD) · Crohn Disease
  27. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
    Aaltonen KJ, Virkki LM, Malmivaara A, et al. · PLoS One · 2012 · Background
    PubMed: PMID 22272322 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing

2011 (43 papers)

  1. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial.
    van Vollenhoven RF, Kinnman N, Vincent E, et al. · Arthritis Rheum · 2011 · Derived
    PubMed: PMID 21452294 · NCT00595413 (AUGUST II) · Arthritis, Rheumatoid
  2. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
    Trachtman H, Vento S, Gipson D, et al. · BMC Nephrol · 2011 · Derived
    PubMed: PMID 21310077 · NCT00814255 (FONTII) · Glomerulosclerosis, Focal Segmental
  3. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study.
    Strober BE, Poulin Y, Kerdel FA, et al. · J Am Acad Dermatol · 2011 · Derived
    PubMed: PMID 21414495 · NCT00566722 · Psoriasis
  4. Psychometric characteristics of the short form 36 health survey and functional assessment of chronic illness Therapy-Fatigue subscale for patients with ankylosing spondylitis.
    Revicki DA, Rentz AM, Luo MP, et al. · Health Qual Life Outcomes · 2011 · Derived
    PubMed: PMID 21600054 · NCT00085644 (ATLAS) · Spondylitis, Ankylosing
  5. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
    Reinisch W, Sandborn WJ, Hommes DW, et al. · Gut · 2011 · Derived
    PubMed: PMID 21209123 · NCT00385736 · Colitis, Ulcerative
  6. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis.
    Reilly MC, Gooch KL, Wong RL, et al. · Rheumatology (Oxford) · 2011 · Derived
    PubMed: PMID 20100797 · NCT00085644 (ATLAS) · Spondylitis, Ankylosing
  7. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.
    Pedersen SJ, Sørensen IJ, Garnero P, et al. · Ann Rheum Dis · 2011 · Derived
    PubMed: PMID 21551511 · NCT00133315 · Spondylitis, Ankylosing
  8. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
    Papp K, Crowley J, Ortonne JP, et al. · Br J Dermatol · 2011 · Derived
    PubMed: PMID 21083543 · NCT00195676 · Psoriasis
  9. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.
    Lichtiger S, Binion DG, Wolf DC, et al. · Aliment Pharmacol Ther · 2011 · Derived
    PubMed: PMID 20955442 · NCT00338650 · Crohn Disease
  10. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.
    Leonardi C, Langley RG, Papp K, et al. · Arch Dermatol · 2011 · Derived
    PubMed: PMID 21173304 · NCT00735787 · Psoriasis
  11. Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis.
    Kimel M, Revicki D, Rao S, et al. · Clin Exp Rheumatol · 2011 · Derived
    PubMed: PMID 21813060 · NCT00085644 (ATLAS) · Spondylitis, Ankylosing
  12. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis.
    Keystone EC, Kavanaugh A, Weinblatt ME, et al. · J Rheumatol · 2011 · Derived
    PubMed: PMID 21285171 · NCT00195702 · Arthritis, Rheumatoid
  13. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease.
    Kamm MA, Hanauer SB, Panaccione R, et al. · Aliment Pharmacol Ther · 2011 · Derived
    PubMed: PMID 21645018 · NCT00077779 (CHARM) · Crohn Disease
  14. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study.
    Gladman DD, ACCLAIM Study Investigators, Sampalis JS, et al. · J Rheumatol · 2011 · Derived
    PubMed: PMID 20595284 · NCT00427362 · Arthritis, Psoriatic
  15. Number and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept.
    Blache C, Lequerré T, Roucheux A, et al. · Rheumatology (Oxford) · 2011 · Derived
    PubMed: PMID 21791546 · NCT00234234 · Arthritis, Rheumatoid
  16. intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group.
    Wu L, Hernandez-Bogantes E, Roca JA, et al. · Retina · 2011 · Background
    PubMed: PMID 21099452 · NCT02706704 (IVAS) · Uveitis
  17. A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis.
    Wiens A, Correr CJ, Venson R, et al. · Rheumatol Int · 2011 · Background
    PubMed: PMID 19707765 · NCT03273192
  18. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort.
    Waugh AW, Garg S, Matic K, et al. · Aliment Pharmacol Ther · 2011 · Background
    PubMed: PMID 20807218 · NCT02994836 · Crohn Disease
  19. Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study.
    Visvanathan S, Rahman MU, Keystone E, et al. · Arthritis Res Ther · 2011 · Background
    PubMed: PMID 21083889 · NCT02878161 · Arthritis, Rheumatoid
  20. Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis).
    Tugal-Tutkun I, Herbort CP, Khairallah M, et al. · Int Ophthalmol · 2011 · Background
    PubMed: PMID 18795232 · NCT05015335 · Uveitis, Anterior
  21. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man.
    Skyler JS, Ricordi C · Diabetes · 2011 · Background
    PubMed: PMID 21193733 · NCT02586831 (DIPIT) · Autoimmune Diseases
  22. Predicting response to Anti-TNF Agents for the treatment of crohn's disease.
    Siegel CA, Melmed GY · Ther Adv Gastroenterol · 2011 · Background
    PubMed: PMID 21180547 · NCT03885713 (BioIBD) · Crohn Disease
  23. Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study.
    Nunes T, Barreiro-de Acosta M, Nos P, et al. · J Crohns Colitis · 2011 · Background
    PubMed: PMID 21122572 · NCT05313620 · Colitis, Ulcerative
  24. Improving the measurement of self-reported medication nonadherence: response to authors.
    Morisky DE, DiMatteo MR · J Clin Epidemiol · 2011 · Background
    PubMed: PMID 21144706 · NCT02750800 (VALUE) · Arthritis, Rheumatoid
  25. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.
    Miossec P, Verweij CL, Klareskog L, et al. · Ann Rheum Dis · 2011 · Background
    PubMed: PMID 21784723 · NCT02878161 · Arthritis, Rheumatoid
  26. Gene expression profiling in peripheral blood cells of patients with rheumatoid arthritis in response to anti-TNF-alpha treatments.
    Meugnier E, Coury F, Tebib J, et al. · Physiol Genomics · 2011 · Background
    PubMed: PMID 21266503 · NCT02878161 · Arthritis, Rheumatoid
  27. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study.
    Mehta NN, Yu Y, Saboury B, et al. · Arch Dermatol · 2011 · Background
    PubMed: PMID 21576552 · NCT02330380 · Psoriasis
  28. The pathogenesis of rheumatoid arthritis.
    McInnes IB, Schett G · N Engl J Med · 2011 · Background
    PubMed: PMID 22150039 · NCT03172325
  29. Toxicity of high-dose intravitreal adalimumab (Humira) in the rabbit.
    Manzano RP, Peyman GA, Carvounis PE, et al. · J Ocul Pharmacol Ther · 2011 · Background
    PubMed: PMID 21668348 · NCT02706704 (IVAS) · Uveitis
  30. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.
    Machado P, Landewé R, Lie E, et al. · Ann Rheum Dis · 2011 · Background
    PubMed: PMID 21068095 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  31. Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides.
    M'Koma AE, Seeley EH, Washington MK, et al. · Inflamm Bowel Dis · 2011 · Background
    PubMed: PMID 20806340 · NCT03885713 (BioIBD) · Crohn Disease
  32. Magnetic resonance enterocolonography is useful for simultaneous evaluation of small and large intestinal lesions in Crohn's disease.
    Hyun SB, Kitazume Y, Nagahori M, et al. · Inflamm Bowel Dis · 2011 · Background
    PubMed: PMID 21484957 · NCT02332356 · Crohn Disease
  33. Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy.
    Hennigan S, Ackermann C, Kavanaugh A, et al. · Core Evid · 2011 · Background
    PubMed: PMID 21221193 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  34. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort.
    Gies N, Kroeker KI, Wong K, et al. · Aliment Pharmacol Ther · 2011 · Background
    PubMed: PMID 20500733 · NCT06269185 · Colitis, Ulcerative
  35. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.
    Ford AC, Sandborn WJ, Khan KJ, et al. · Am J Gastroenterol · 2011 · Background
    PubMed: PMID 21407183 · NCT03885713 (BioIBD) · Crohn Disease
  36. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
    D'Haens GR, Panaccione R, Higgins PD, et al. · Am J Gastroenterol · 2011 · Background
    PubMed: PMID 21045814 · NCT03885713 (BioIBD) · Crohn Disease
  37. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients.
    Coulthard LR, Taylor JC, Eyre S, et al. · Ann Rheum Dis · 2011 · Background
    PubMed: PMID 20805296 · NCT02878161 · Arthritis, Rheumatoid
  38. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
    Colombel JF, Rutgeerts P, Reinisch W, et al. · Gastroenterology · 2011 · Background
    PubMed: PMID 21723220 · NCT03885713 (BioIBD) · Crohn Disease
  39. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response.
    Chaparro M, Panes J, García V, et al. · J Clin Gastroenterol · 2011 · Background
    PubMed: PMID 21242747 · NCT02994836 · Crohn Disease
  40. Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.
    Brophy DF, Martin EJ, Christian Barrett J, et al. · Haemophilia · 2011 · Background
    PubMed: PMID 21362113 · NCT05313620 · Colitis, Ulcerative
  41. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases.
    Baillet A, Trocmé C, Berthier S, et al. · Rheumatology (Oxford) · 2011 · Background
    PubMed: PMID 20100792 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  42. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.
    Arijs I, Quintens R, Van Lommel L, et al. · Inflamm Bowel Dis · 2011 · Background
    PubMed: PMID 20848504 · NCT03885713 (BioIBD) · Crohn Disease
  43. Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study.
    Ahlehoff O, Gislason GH, Lindhardsen J, et al. · J Intern Med · 2011 · Background
    PubMed: PMID 21362070 · NCT01722214 · Psoriasis

2010 (30 papers)

  1. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
    Rudwaleit M, Van den Bosch F, Kron M, et al. · Arthritis Res Ther · 2010 · Derived
    PubMed: PMID 20553600 · NCT00235885 (STEREO) · Arthritis, Psoriatic
  2. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis.
    Rudwaleit M, Claudepierre P, Kron M, et al. · Arthritis Res Ther · 2010 · Derived
    PubMed: PMID 20230622 · NCT00478660 (RHAPSODY) · Spondylitis, Ankylosing
  3. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ, Sørensen IJ, Hermann KG, et al. · Ann Rheum Dis · 2010 · Derived
    PubMed: PMID 19740906 · NCT00133315 · Spondylitis, Ankylosing
  4. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.
    Joy MS, Gipson DS, Powell L, et al. · Am J Kidney Dis · 2010 · Derived
    PubMed: PMID 19932542 · NCT00814255 (FONTII) · Glomerulosclerosis, Focal Segmental
  5. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT.
    Gladman DD, Mease PJ, Choy EH, et al. · Arthritis Res Ther · 2010 · Derived
    PubMed: PMID 20537151 · NCT00195689 · Arthritis, Psoriatic
  6. Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trial.
    Genevay S, Viatte S, Finckh A, et al. · Arthritis Rheum · 2010 · Derived
    PubMed: PMID 20506391 · NCT00470509 (ASAS) · Sciatica
  7. To switch or to change class-the biologic dilemma in rheumatoid arthritis.
    Villeneuve E, Haraoui B · Nat Rev Rheumatol · 2010 · Background
    PubMed: PMID 20386564 · NCT00796705 · Arthritis, Rheumatoid
  8. Validation of the Spanish Work Productivity and Activity impairment questionnaire: Crohn's disease version.
    Vergara M, Montserrat A, Casellas F, et al. · Eur J Gastroenterol Hepatol · 2010 · Background
    PubMed: PMID 19404204 · NCT02994836 · Crohn Disease
  9. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment.
    Tan RJ, Gibbons LJ, Potter C, et al. · Ann Rheum Dis · 2010 · Background
    PubMed: PMID 20444755 · NCT02878161 · Arthritis, Rheumatoid
  10. CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis.
    Stuhlmüller B, Häupl T, Hernandez MM, et al. · Clin Pharmacol Ther · 2010 · Background
    PubMed: PMID 20032971 · NCT02878161 · Arthritis, Rheumatoid
  11. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
    Potter C, Cordell HJ, Barton A, et al. · Ann Rheum Dis · 2010 · Background
    PubMed: PMID 20448286 · NCT02878161 · Arthritis, Rheumatoid
  12. Natural history of Crohn's disease: comparison between childhood- and adult-onset disease.
    Pigneur B, Seksik P, Viola S, et al. · Inflamm Bowel Dis · 2010 · Background
    PubMed: PMID 19834970 · NCT02852694 (RCT) · Crohn Disease
  13. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions.
    Nishimoto N, Ito K, Takagi N, et al. · Mod Rheumatol · 2010 · Background
    PubMed: PMID 20221663 · NCT04115423 · Arthritis, Rheumatoid
  14. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort.
    Mavragani CP, La DT, Stohl W, et al. · Arthritis Rheum · 2010 · Background
    PubMed: PMID 20112385 · NCT02878161 · Arthritis, Rheumatoid
  15. Anti-TNF and Crohn's disease: when should we stop?
    Louis E, Belaiche J, Reenaers C, et al. · Curr Drug Targets · 2010 · Background
    PubMed: PMID 20210763 · NCT02994836 · Crohn Disease
  16. The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis.
    Lindberg J, Wijbrandts CA, van Baarsen LG, et al. · PLoS One · 2010 · Background
    PubMed: PMID 20593016 · NCT02878161 · Arthritis, Rheumatoid
  17. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.
    Li Z, Arijs I, De Hertogh G, et al. · Inflamm Bowel Dis · 2010 · Background
    PubMed: PMID 20196149 · NCT03885713 (BioIBD) · Crohn Disease
  18. Risk assessment for recurrent venous thrombosis.
    Kyrle PA, Rosendaal FR, Eichinger S, et al. · Lancet · 2010 · Background
    PubMed: PMID 21131039 · NCT05313620 · Colitis, Ulcerative
  19. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee.
    Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology, et al. · Am J Gastroenterol · 2010 · Background
    PubMed: PMID 20068560 · NCT05313620 · Colitis, Ulcerative
  20. An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis.
    Julià A, Erra A, Palacio C, et al. · PLoS One · 2010 · Background
    PubMed: PMID 19847310 · NCT02878161 · Arthritis, Rheumatoid
  21. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis.
    Hueber W, Tomooka BH, Batliwalla F, et al. · Arthritis Res Ther · 2010 · Background
    PubMed: PMID 19460157 · NCT02878161 · Arthritis, Rheumatoid
  22. Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life.
    Ho SG, Yeung CK, Chan HH, et al. · Clin Exp Dermatol · 2010 · Background
    PubMed: PMID 19925489 · NCT02330380 · Psoriasis
  23. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions.
    Davidovici BB, Sattar N, Prinz J, et al. · J Invest Dermatol · 2010 · Background
    PubMed: PMID 20445552 · NCT01722214 · Psoriasis
  24. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy.
    Cui J, Saevarsdottir S, Thomson B, et al. · Arthritis Rheum · 2010 · Background
    PubMed: PMID 20309874 · NCT02878161 · Arthritis, Rheumatoid
  25. Infliximab, azathioprine, or combination therapy for Crohn's disease.
    Colombel JF, Sandborn WJ, Reinisch W, et al. · N Engl J Med · 2010 · Background
    PubMed: PMID 20393175 · NCT03885713 (BioIBD) · Crohn Disease
  26. Systematic review: the costs of ulcerative colitis in Western countries.
    Cohen RD, Yu AP, Wu EQ, et al. · Aliment Pharmacol Ther · 2010 · Background
    PubMed: PMID 20064142 · NCT05313620 · Colitis, Ulcerative
  27. Chronic nonbacterial osteomyelitis in childhood: prospective follow-up during the first year of anti-inflammatory treatment.
    Beck C, Morbach H, Beer M, et al. · Arthritis Res Ther · 2010 · Background
    PubMed: PMID 20433730 · NCT04725422 (CHOIR) · Chronic recurrent multifocal osteomyelitis
  28. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.
    Atteno M, Peluso R, Costa L, et al. · Clin Rheumatol · 2010 · Background
    PubMed: PMID 20066450 · NCT02330380 · Psoriasis
  29. Intravitreal adalimumab for refractory uveitis-related macular edema.
    Androudi S, Tsironi E, Kalogeropoulos C, et al. · Ophthalmology · 2010 · Background
    PubMed: PMID 20378179 · NCT02706704 (IVAS) · Uveitis
  30. A cost-effectiveness comparison of liquor carbonis distillate solution and calcipotriol cream in the treatment of moderate chronic plaque psoriasis.
    Alora-Palli MB, Brouda I, Green B, et al. · Arch Dermatol · 2010 · Background
    PubMed: PMID 20713833 · NCT02330380 · Psoriasis

2009 (29 papers)

  1. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration.
    Theodossiadis PG, Liarakos VS, Sfikakis PP, et al. · Am J Ophthalmol · 2009 · Trial result
    PubMed: PMID 19211094 · NCT00855608 (ADA01) · Uveitis
  2. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.
    Joy MS, Gipson DS, Dike M, et al. · Clin J Am Soc Nephrol · 2009 · Trial result
    PubMed: PMID 19073787 · NCT00814255 (FONTII) · Glomerulosclerosis, Focal Segmental
  3. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.
    Afif W, Leighton JA, Hanauer SB, et al. · Inflamm Bowel Dis · 2009 · Trial result
    PubMed: PMID 19408340 · NCT00421642 · Colitis, Ulcerative
  4. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis.
    van der Heijde DM, Revicki DA, Gooch KL, et al. · Arthritis Res Ther · 2009 · Derived
    PubMed: PMID 19686597 · NCT00085644 (ATLAS) · Spondylitis, Ankylosing
  5. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.
    van der Heijde D, Schiff MH, Sieper J, et al. · Ann Rheum Dis · 2009 · Derived
    PubMed: PMID 18701556 · NCT00085644 (ATLAS) · Spondylitis, Ankylosing
  6. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.
    van der Heijde D, Salonen D, Weissman BN, et al. · Arthritis Res Ther · 2009 · Derived
    PubMed: PMID 19703304 · NCT00085644 (ATLAS) · Spondylitis, Ankylosing
  7. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study.
    Rudwaleit M, Rødevand E, Holck P, et al. · Ann Rheum Dis · 2009 · Derived
    PubMed: PMID 18662932 · NCT00478660 (RHAPSODY) · Spondylitis, Ankylosing
  8. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
    Rudwaleit M, Claudepierre P, Wordsworth P, et al. · J Rheumatol · 2009 · Derived
    PubMed: PMID 19273449 · NCT00478660 (RHAPSODY) · Spondylitis, Ankylosing
  9. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).
    Mease PJ, Ory P, Sharp JT, et al. · Ann Rheum Dis · 2009 · Derived
    PubMed: PMID 18684743 · NCT00195689 · Arthritis, Psoriatic
  10. Adalimumab for the treatment of fistulas in patients with Crohn's disease.
    Colombel JF, Schwartz DA, Sandborn WJ, et al. · Gut · 2009 · Derived
    PubMed: PMID 19201775 · NCT00195715 · Crohn Disease
  11. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study.
    Westhovens R, Kremer JM, Moreland LW, et al. · J Rheumatol · 2009 · Background
    PubMed: PMID 19273451 · NCT03172325
  12. Evaluation of potential retinal toxicity of adalimumab (Humira).
    Tsilimbaris M, Diakonis VF, Naoumidi I, et al. · Graefes Arch Clin Exp Ophthalmol · 2009 · Background
    PubMed: PMID 19296122 · NCT02706704 (IVAS) · Uveitis
  13. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis.
    Trocmé C, Marotte H, Baillet A, et al. · Ann Rheum Dis · 2009 · Background
    PubMed: PMID 18664547 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  14. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy.
    Ruemmele FM, Lachaux A, Cézard JP, et al. · Inflamm Bowel Dis · 2009 · Background
    PubMed: PMID 19023899 · NCT02852694 (RCT) · Crohn Disease
  15. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review.
    Rubbert-Roth A, Finckh A · Arthritis Res Ther · 2009 · Background
    PubMed: PMID 19368701 · NCT00796705 · Arthritis, Rheumatoid
  16. Infliximab prevents Crohn's disease recurrence after ileal resection.
    Regueiro M, Schraut W, Baidoo L, et al. · Gastroenterology · 2009 · Background
    PubMed: PMID 19109962 · NCT01629628 (POPART) · Crohn Disease
  17. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis.
    Radstake TR, Svenson M, Eijsbouts AM, et al. · Ann Rheum Dis · 2009 · Background
    PubMed: PMID 19019895 · NCT02878161 · Arthritis, Rheumatoid
  18. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality.
    Prodanovich S, Kirsner RS, Kravetz JD, et al. · Arch Dermatol · 2009 · Background
    PubMed: PMID 19528427 · NCT01722214 · Psoriasis
  19. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.
    Potter C, Hyrich KL, Tracey A, et al. · Ann Rheum Dis · 2009 · Background
    PubMed: PMID 18375541 · NCT02878161 · Arthritis, Rheumatoid
  20. [TNF inhibitors for treatment of rheumatoid arthritis].
    Otomo K, Koike T · Nihon Naika Gakkai Zasshi · 2009 · Background
    PubMed: PMID 19149036 · NCT00837434 · Arthritis, Rheumatoid
  21. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
    Olsen T, Goll R, Cui G, et al. · Cytokine · 2009 · Background
    PubMed: PMID 19286392 · NCT03885713 (BioIBD) · Crohn Disease
  22. Psoriasis.
    Nestle FO, Kaplan DH, Barker J, et al. · N Engl J Med · 2009 · Background
    PubMed: PMID 19641206 · NCT01237262 (ELIDACE) · Psoriasis
  23. Differential proteomic analysis of HT29 Cl.16E and intestinal epithelial cells by LC ESI/QTOF mass spectrometry.
    Nanni P, Mezzanotte L, Roda G, et al. · J Proteomics · 2009 · Background
    PubMed: PMID 19168159 · NCT03885713 (BioIBD) · Crohn Disease
  24. Pathological and protective roles of glia in chronic pain.
    Milligan ED, Watkins LR · Nat Rev Neurosci · 2009 · Background
    PubMed: PMID 19096368 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  25. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
    Karmiris K, Paintaud G, Noman M, et al. · Gastroenterology · 2009 · Background
    PubMed: PMID 19664627 · NCT02256462 · Crohn Disease
  26. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.
    Gisbert JP, Panés J · Am J Gastroenterol · 2009 · Background
    PubMed: PMID 19174781 · NCT02994836 · Crohn Disease
  27. The risk of stroke in patients with psoriasis.
    Gelfand JM, Dommasch ED, Shin DB, et al. · J Invest Dermatol · 2009 · Background
    PubMed: PMID 19458634 · NCT01722214 · Psoriasis
  28. Emerging therapeutics for rheumatoid arthritis.
    Bingham CO · Bull NYU Hosp Jt Dis · 2009 · Background
    PubMed: PMID 18937634 · NCT00837434 · Arthritis, Rheumatoid
  29. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.
    Arijs I, Li K, Toedter G, et al. · Gut · 2009 · Background
    PubMed: PMID 19700435 · NCT03885713 (BioIBD) · Crohn Disease

2008 (42 papers)

  1. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
    Saurat JH, Stingl G, Dubertret L, et al. · Br J Dermatol · 2008 · Trial result
    PubMed: PMID 18047523 · NCT00932113 (MOA) · Psoriasis
  2. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.
    van der Heijde D, Pangan AL, Schiff MH, et al. · Ann Rheum Dis · 2008 · Derived
    PubMed: PMID 18056755 · NCT00085644 (ATLAS) · Spondylitis, Ankylosing
  3. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study.
    Revicki DA, Menter A, Feldman S, et al. · Health Qual Life Outcomes · 2008 · Derived
    PubMed: PMID 18831744 · NCT00237887 · Psoriasis
  4. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
    Menter A, Tyring SK, Gordon K, et al. · J Am Acad Dermatol · 2008 · Derived
    PubMed: PMID 17936411 · NCT00237887 · Psoriasis
  5. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.
    Lovell DJ, Ruperto N, Goodman S, et al. · N Engl J Med · 2008 · Derived
    PubMed: PMID 18716298 · NCT00048542 · Arthritis, Juvenile
  6. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Lambert RG, Salonen D, Rahman P, et al. · Arthritis Rheum · 2008 · Derived
    PubMed: PMID 18050198 · NCT00195819 · Spondylitis, Ankylosing
  7. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two.
    Haibel H, Rudwaleit M, Listing J, et al. · Arthritis Rheum · 2008 · Derived
    PubMed: PMID 18576337 · NCT00235105 · Spondylitis, Ankylosing
  8. Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial.
    Dougados M, Luo MP, Maksymowych WP, et al. · Arthritis Rheum · 2008 · Derived
    PubMed: PMID 18383418 · NCT00085644 (ATLAS) · Spondylitis, Ankylosing
  9. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.
    Burmester GR, Ferraccioli G, Flipo RM, et al. · Arthritis Rheum · 2008 · Derived
    PubMed: PMID 18163417 · NCT00448383 (ReAct) · Arthritis, Rheumatoid
  10. Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis.
    Yount S, Sorensen MV, Cella D, et al. · Clin Exp Rheumatol · 2008 · Background
    PubMed: PMID 18173917 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  11. 12-month follow-up after successful infliximab therapy in pediatric crohn disease.
    Wynands J, Belbouab R, Candon S, et al. · J Pediatr Gastroenterol Nutr · 2008 · Background
    PubMed: PMID 18376247 · NCT02994836 · Crohn Disease
  12. TNFalpha blockade in human diseases: mechanisms and future directions.
    Wong M, Ziring D, Korin Y, et al. · Clin Immunol · 2008 · Background
    PubMed: PMID 17916444 · NCT03273192
  13. Natural history of pediatric Crohn's disease: a population-based cohort study.
    Vernier-Massouille G, Balde M, Salleron J, et al. · Gastroenterology · 2008 · Background
    PubMed: PMID 18692056 · NCT02852694 (RCT) · Crohn Disease
  14. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease.
    Van Limbergen J, Russell RK, Drummond HE, et al. · Gastroenterology · 2008 · Background
    PubMed: PMID 18725221 · NCT02852694 (RCT) · Crohn Disease
  15. Systemic inflammation as a risk factor for atherothrombosis.
    van Leuven SI, Franssen R, Kastelein JJ, et al. · Rheumatology (Oxford) · 2008 · Background
    PubMed: PMID 17702769 · NCT01722214 · Psoriasis
  16. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease.
    Turner D, Grossman AB, Rosh J, et al. · Am J Gastroenterol · 2008 · Background
    PubMed: PMID 18042110 · NCT02852694 (RCT) · Crohn Disease
  17. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study.
    Solberg IC, Vatn MH, Høie O, et al. · Clin Gastroenterol Hepatol · 2008 · Background
    PubMed: PMID 18054751 · NCT02994836 · Crohn Disease
  18. [Daily practice using the guidelines for prevention and treatment of osteoporosis. The effects of anti-TNF therapy on bone and joint manifestations in rheumatoid arthritis].
    Soen S · Clin Calcium · 2008 · Background
    PubMed: PMID 18677056 · NCT00837434 · Arthritis, Rheumatoid
  19. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N, Kawauchi S, Furuya T, et al. · Rheumatology (Oxford) · 2008 · Background
    PubMed: PMID 18388148 · NCT02878161 · Arthritis, Rheumatoid
  20. Investigation into the neural correlates of emotional augmentation of clinical pain.
    Schweinhardt P, Kalk N, Wartolowska K, et al. · Neuroimage · 2008 · Background
    PubMed: PMID 18221890 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  21. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
    Reich K, Sinclair R, Roberts G, et al. · Curr Med Res Opin · 2008 · Background
    PubMed: PMID 18355421 · NCT02330380 · Psoriasis
  22. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response.
    Pachot A, Arnaud B, Marrote H, et al. · J Rheumatol · 2008 · Background
    PubMed: PMID 17896807 · NCT02878161 · Arthritis, Rheumatoid
  23. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis.
    Nanni P, Parisi D, Roda G, et al. · Rapid Commun Mass Spectrom · 2008 · Background
    PubMed: PMID 18022963 · NCT03885713 (BioIBD) · Crohn Disease
  24. Anti-inflammatory drugs and atherosclerosis.
    Moubayed SP, Heinonen TM, Tardif JC, et al. · Curr Opin Lipidol · 2008 · Background
    PubMed: PMID 17993809 · NCT01722214 · Psoriasis
  25. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a community-based cohort.
    Miyasaka Y, Barnes ME, Petersen RC, et al. · Eur Heart J · 2008 · Background
    PubMed: PMID 17459900 · NCT01722214 · Psoriasis
  26. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis.
    Miceli-Richard C, Comets E, Verstuyft C, et al. · Ann Rheum Dis · 2008 · Background
    PubMed: PMID 17673491 · NCT02878161 · Arthritis, Rheumatoid
  27. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study.
    Meuwis MA, Fillet M, Lutteri L, et al. · Clin Biochem · 2008 · Background
    PubMed: PMID 18489908 · NCT03885713 (BioIBD) · Crohn Disease
  28. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
    Mathsson L, Mullazehi M, Wick MC, et al. · Arthritis Rheum · 2008 · Background
    PubMed: PMID 18163519 · NCT02878161 · Arthritis, Rheumatoid
  29. S100 proteins calprotectin and S100A12 are related to radiographic changes rather than disease activity in psoriatic arthritis with low disease activity.
    Madland TM, Larsen A, Brun JG, et al. · J Rheumatol · 2008 · Background
    PubMed: PMID 17787039 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  30. Triggers, targets and treatments for thrombosis.
    Mackman N · Nature · 2008 · Background
    PubMed: PMID 18288180 · NCT05313620 · Colitis, Ulcerative
  31. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis.
    Liu C, Batliwalla F, Li W, et al. · Mol Med · 2008 · Background
    PubMed: PMID 18615156 · NCT02878161 · Arthritis, Rheumatoid
  32. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II.
    Lawrence RC, Felson DT, Helmick CG, et al. · Arthritis Rheum · 2008 · Background
    PubMed: PMID 18163497 · NCT01793519 (STARA) · Arthritis, Rheumatoid
  33. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram.
    Lak M, Scharling B, Blemings A, et al. · Haemophilia · 2008 · Background
    PubMed: PMID 18070065 · NCT05313620 · Colitis, Ulcerative
  34. Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate.
    Kavanaugh A, Klareskog L, van der Heijde D, et al. · Ann Rheum Dis · 2008 · Background
    PubMed: PMID 18535115 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  35. Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade.
    Inglis JJ, Notley CA, Essex D, et al. · Arthritis Rheum · 2008 · Background
    PubMed: PMID 18050216 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  36. Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience.
    Guidi L, Ratto C, Semeraro S, et al. · Tech Coloproctol · 2008 · Background
    PubMed: PMID 18545878 · NCT02994836 · Crohn Disease
  37. Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI).
    Gal E, Geller A, Fraser G, et al. · Dig Dis Sci · 2008 · Background
    PubMed: PMID 18034304 · NCT01144156 · Crohn Disease
  38. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial.
    Flytström I, Stenberg B, Svensson A, et al. · Br J Dermatol · 2008 · Background
    PubMed: PMID 17986302 · NCT02330380 · Psoriasis
  39. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis.
    Fabre S, Dupuy AM, Dossat N, et al. · Clin Exp Immunol · 2008 · Background
    PubMed: PMID 18549443 · NCT02878161 · Arthritis, Rheumatoid
  40. Adalimumab therapy for refractory uveitis: a pilot study.
    Diaz-Llopis M, García-Delpech S, Salom D, et al. · J Ocul Pharmacol Ther · 2008 · Background
    PubMed: PMID 18476805 · NCT02706704 (IVAS) · Uveitis
  41. WHO-ILAR COPCORD Study (Stage 1, Urban Study) in Iran.
    Davatchi F, Jamshidi AR, Banihashemi AT, et al. · J Rheumatol · 2008 · Background
    PubMed: PMID 18464299 · NCT03273192
  42. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
    D'Haens G, Baert F, van Assche G, et al. · Lancet · 2008 · Background
    PubMed: PMID 18295023 · NCT02852694 (RCT) · Crohn Disease

2007 (37 papers)

  1. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
    Sandborn WJ, Rutgeerts P, Enns R, et al. · Ann Intern Med · 2007 · Derived
    PubMed: PMID 17470824 · NCT00105300 · Crohn Disease
  2. Unravelling the pathogenesis of inflammatory bowel disease.
    Xavier RJ, Podolsky DK · Nature · 2007 · Background
    PubMed: PMID 17653185 · NCT07495644 · Crohn Disease
  3. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue.
    van Vollenhoven RF · Ann Rheum Dis · 2007 · Background
    PubMed: PMID 17576784 · NCT02878161 · Arthritis, Rheumatoid
  4. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study.
    Uhlen S, Belbouab R, Narebski K, et al. · Inflamm Bowel Dis · 2007 · Background
    PubMed: PMID 17075346 · NCT02852694 (RCT) · Crohn Disease
  5. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis.
    Turesson C, McClelland RL, Christianson TJ, et al. · Ann Rheum Dis · 2007 · Background
    PubMed: PMID 16877533 · NCT01722214 · Psoriasis
  6. Mechanisms of action of etanercept in psoriasis.
    Tan JK, Aphale A, Malaviya R, et al. · J Investig Dermatol Symp Proc · 2007 · Background
    PubMed: PMID 17502868 · NCT00932113 (MOA) · Psoriasis
  7. Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease.
    Shkoda A, Werner T, Daniel H, et al. · J Proteome Res · 2007 · Background
    PubMed: PMID 17330946 · NCT03885713 (BioIBD) · Crohn Disease
  8. Role of methotrexate in the management of Crohn disease.
    Ravikumara M, Hinsberger A, Spray CH, et al. · J Pediatr Gastroenterol Nutr · 2007 · Background
    PubMed: PMID 17414138 · NCT02852694 (RCT) · Crohn Disease
  9. Characterization of non-calcified coronary atherosclerotic plaque by multi-detector row CT: comparison to IVUS.
    Pohle K, Achenbach S, Macneill B, et al. · Atherosclerosis · 2007 · Background
    PubMed: PMID 16494883 · NCT00940862 · Psoriasis
  10. Infliximab in fistulizing Crohn's disease.
    Osterman MT, Lichtenstein GR · Gastroenterol Clin North Am · 2007 · Background
    PubMed: PMID 17129814 · NCT07495644 · Crohn Disease
  11. Detection of significant coronary artery stenosis with 64-section MDCT angiography.
    Oncel D, Oncel G, Tastan A, et al. · Eur J Radiol · 2007 · Background
    PubMed: PMID 17306490 · NCT00940862 · Psoriasis
  12. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
    North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition, Colitis Foundation of America, Bousvaros A, et al. · J Pediatr Gastroenterol Nutr · 2007 · Background
    PubMed: PMID 17460505 · NCT02852694 (RCT) · Crohn Disease
  13. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis.
    Morozzi G, Fabbroni M, Bellisai F, et al. · Clin Rheumatol · 2007 · Background
    PubMed: PMID 17285224 · NCT02878161 · Arthritis, Rheumatoid
  14. Adalimumab in the therapy of uveitis in childhood.
    Mansour AM · Br J Ophthalmol · 2007 · Background
    PubMed: PMID 17322463 · NCT02706704 (IVAS) · Uveitis
  15. Arthritic pain is processed in brain areas concerned with emotions and fear.
    Kulkarni B, Bentley DE, Elliott R, et al. · Arthritis Rheum · 2007 · Background
    PubMed: PMID 17393440 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  16. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
    Kramer G, Mitteregger D, Marberger M, et al. · Eur Urol · 2007 · Background
    PubMed: PMID 17182170 · NCT06062875 · Prostatic Hyperplasia
  17. Technology insight: confocal laser endoscopy for in vivo diagnosis of colorectal cancer.
    Kiesslich R, Goetz M, Vieth M, et al. · Nat Clin Pract Oncol · 2007 · Background
    PubMed: PMID 17657253 · NCT01275508 (FA-Crohn) · Crohn Disease
  18. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
    Kamm MA, Sandborn WJ, Gassull M, et al. · Gastroenterology · 2007 · Background
    PubMed: PMID 17241860 · NCT05313620 · Colitis, Ulcerative
  19. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, et al. · Gastroenterology · 2007 · Background
    PubMed: PMID 17324398 · NCT02852694 (RCT) · Crohn Disease
  20. Soft and intermediate plaques in coronary arteries: how accurately can we measure CT attenuation using 64-MDCT?
    Horiguchi J, Fujioka C, Kiguchi M, et al. · AJR Am J Roentgenol · 2007 · Background
    PubMed: PMID 17885074 · NCT00940862 · Psoriasis
  21. Positron emission tomography in coronary artery disease.
    Gould KL · Curr Opin Cardiol · 2007 · Background
    PubMed: PMID 17762543 · NCT00940862 · Psoriasis
  22. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists.
    González-Alvaro I, Ortiz AM, Tomero EG, et al. · Ann Rheum Dis · 2007 · Background
    PubMed: PMID 17666448 · NCT02878161 · Arthritis, Rheumatoid
  23. Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis.
    Goldstein RS, Bruchfeld A, Yang L, et al. · Mol Med · 2007 · Background
    PubMed: PMID 17597834 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  24. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort.
    Frøslie KF, Jahnsen J, Moum BA, et al. · Gastroenterology · 2007 · Background
    PubMed: PMID 17681162 · NCT02852694 (RCT) · Crohn Disease
  25. Medical therapy for refractory pediatric Crohn's disease.
    Faubion WA, Bousvaros A · Clin Gastroenterol Hepatol · 2007 · Background
    PubMed: PMID 16872913 · NCT02852694 (RCT) · Crohn Disease
  26. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG, Watson KD, Lunt M, et al. · Arthritis Rheum · 2007 · Background
    PubMed: PMID 17763428 · NCT00940862 · Psoriasis
  27. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.
    Dixon WG, Symmons DP · Ann Rheum Dis · 2007 · Background
    PubMed: PMID 17251223 · NCT01722214 · Psoriasis
  28. New technology for noninvasive evaluation of coronary artery disease.
    Di Carli MF, Hachamovitch R · Circulation · 2007 · Background
    PubMed: PMID 17372188 · NCT00940862 · Psoriasis
  29. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.
    D'Haens G, Sandborn WJ, Feagan BG, et al. · Gastroenterology · 2007 · Background
    PubMed: PMID 17258735 · NCT03885713 (BioIBD) · Crohn Disease
  30. Advances in biologic therapy for ulcerative colitis and Crohn's disease.
    D'Haens G, Daperno M · Curr Gastroenterol Rep · 2007 · Background
    PubMed: PMID 17105690 · NCT00514982 · Colitis
  31. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. · Gastroenterology · 2007 · Background
    PubMed: PMID 17241859 · NCT01275508 (FA-Crohn) · Crohn Disease
  32. Emerging approaches for imaging vulnerable plaques in patients.
    Choi SH, Chae A, Chen CH, et al. · Curr Opin Biotechnol · 2007 · Background
    PubMed: PMID 17234398 · NCT00940862 · Psoriasis
  33. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up.
    Caviglia R, Ribolsi M, Rizzi M, et al. · World J Gastroenterol · 2007 · Background
    PubMed: PMID 17876895 · NCT02994836 · Crohn Disease
  34. Trends in hospitalization rates for inflammatory bowel disease in the United States.
    Bewtra M, Su C, Lewis JD, et al. · Clin Gastroenterol Hepatol · 2007 · Background
    PubMed: PMID 17382602 · NCT03885713 (BioIBD) · Crohn Disease
  35. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
    Bedini C, Nasorri F, Girolomoni G, et al. · Br J Dermatol · 2007 · Background
    PubMed: PMID 17489975 · NCT01237262 (ELIDACE) · Psoriasis
  36. Cytokine patterns in fibromyalgia and their correlation with clinical manifestations.
    Bazzichi L, Rossi A, Massimetti G, et al. · Clin Exp Rheumatol · 2007 · Background
    PubMed: PMID 17543146 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  37. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review.
    Alamanos Y, Voulgari PV, Drosos AA, et al. · Semin Arthritis Rheum · 2007 · Background
    PubMed: PMID 17045630 · NCT03172325

2006 (22 papers)

  1. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study.
    Weinblatt ME, Keystone EC, Furst DE, et al. · Ann Rheum Dis · 2006 · Background
    PubMed: PMID 16308341 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  2. Adalimumab therapy for childhood uveitis.
    Vazquez-Cobian LB, Flynn T, Lehman TJ, et al. · J Pediatr · 2006 · Background
    PubMed: PMID 17011337 · NCT03816397 (ADJUST) · Uveitis
  3. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
    Van Assche G, Sandborn WJ, Feagan BG, et al. · Gut · 2006 · Background
    PubMed: PMID 16603634 · NCT03885713 (BioIBD) · Crohn Disease
  4. Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain.
    Uçeyler N, Valenza R, Stock M, et al. · Arthritis Rheum · 2006 · Background
    PubMed: PMID 16871547 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  5. Vascular biomarkers and surrogates in cardiovascular disease.
    Tardif JC, Heinonen T, Orloff D, et al. · Circulation · 2006 · Background
    PubMed: PMID 16801474 · NCT00940862 · Psoriasis
  6. Patterns of cardiovascular risk in rheumatoid arthritis.
    Solomon DH, Goodson NJ, Katz JN, et al. · Ann Rheum Dis · 2006 · Background
    PubMed: PMID 16793844 · NCT03619876 (AMiRA) · Arthritis, Rheumatoid
  7. Neural correlates of individual differences in pain-related fear and anxiety.
    Ochsner KN, Ludlow DH, Knierim K, et al. · Pain · 2006 · Background
    PubMed: PMID 16364548 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  8. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients.
    Malaviya R, Sun Y, Tan JK, et al. · J Am Acad Dermatol · 2006 · Background
    PubMed: PMID 17010737 · NCT00932113 (MOA) · Psoriasis
  9. Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis.
    Malaviya R, Sun Y, Tan JK, et al. · J Drugs Dermatol · 2006 · Background
    PubMed: PMID 17039656 · NCT00932113 (MOA) · Psoriasis
  10. Effects of adenovirus-mediated gene transfer of ICOSIg and CTLA4Ig fusion protein on experimental autoimmune myocarditis.
    Liu W, Gao C, Zhou BG, et al. · Autoimmunity · 2006 · Background
    PubMed: PMID 16698663 · NCT03619876 (AMiRA) · Arthritis, Rheumatoid
  11. Biologic therapies for inflammatory eye disease.
    Lim L, Suhler EB, Smith JR, et al. · Clin Exp Ophthalmol · 2006 · Background
    PubMed: PMID 16764659 · NCT00348153 · Uveitis
  12. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.
    Langley RG, Ho V, Lynde C, et al. · J Cutan Med Surg · 2006 · Background
    PubMed: PMID 16633860 · NCT00940862 · Psoriasis
  13. Comparative proteomic studies on the pathogenesis of human ulcerative colitis.
    Hsieh SY, Shih TC, Yeh CY, et al. · Proteomics · 2006 · Background
    PubMed: PMID 16947118 · NCT03885713 (BioIBD) · Crohn Disease
  14. Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients.
    Holtmann MH, Krummenauer F, Claas C, et al. · Dig Dis Sci · 2006 · Background
    PubMed: PMID 16927148 · NCT02852694 (RCT) · Crohn Disease
  15. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. · Gastroenterology · 2006 · Background
    PubMed: PMID 16472588 · NCT02256462 · Crohn Disease
  16. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial.
    Haibel H, Rudwaleit M, Brandt HC, et al. · Arthritis Rheum · 2006 · Background
    PubMed: PMID 16447247 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  17. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.
    Guenther L, Langley RG, Shear NH, et al. · J Cutan Med Surg · 2006 · Background
    PubMed: PMID 15868311 · NCT00940862 · Psoriasis
  18. Risk of myocardial infarction in patients with psoriasis.
    Gelfand JM, Neimann AL, Shin DB, et al. · JAMA · 2006 · Background
    PubMed: PMID 17032986 · NCT01722214 · Psoriasis
  19. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
    Domènech E, Hinojosa J, Nos P, et al. · Aliment Pharmacol Ther · 2006 · Background
    PubMed: PMID 16305724 · NCT02994836 · Crohn Disease
  20. Systematic review: the use of mesalazine in inflammatory bowel disease.
    Bergman R, Parkes M · Aliment Pharmacol Ther · 2006 · Background
    PubMed: PMID 16573787 · NCT00514982 · Colitis
  21. Chronic pain and the emotional brain: specific brain activity associated with spontaneous fluctuations of intensity of chronic back pain.
    Baliki MN, Chialvo DR, Geha PY, et al. · J Neurosci · 2006 · Background
    PubMed: PMID 17122041 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  22. Prevention of experimental autoimmune myocarditis by hydrodynamics-based naked plasmid DNA encoding CTLA4-Ig gene delivery.
    Abe S, Hanawa H, Hayashi M, et al. · J Card Fail · 2006 · Background
    PubMed: PMID 16198253 · NCT03619876 (AMiRA) · Arthritis, Rheumatoid

2005 (20 papers)

  1. Immune regulation of central nervous system functions: from sickness responses to pathological pain.
    Watkins LR, Maier SF · J Intern Med · 2005 · Background
    PubMed: PMID 15656873 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  2. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
    Suhler EB, Smith JR, Wertheim MS, et al. · Arch Ophthalmol · 2005 · Background
    PubMed: PMID 16009830 · NCT00348153 · Uveitis
  3. Infliximab for induction and maintenance therapy for ulcerative colitis.
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. · N Engl J Med · 2005 · Background
    PubMed: PMID 16339095 · NCT01716039 · Colitis, Ulcerative
  4. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA, Tyring S, Lahfa M, et al. · Br J Dermatol · 2005 · Background
    PubMed: PMID 15948997 · NCT00940862 · Psoriasis
  5. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
    Nussenblatt RB, Peterson JS, Foster CS, et al. · Ophthalmology · 2005 · Background
    PubMed: PMID 15878055 · NCT05015335 · Uveitis, Anterior
  6. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.
    Maradit-Kremers H, Crowson CS, Nicola PJ, et al. · Arthritis Rheum · 2005 · Background
    PubMed: PMID 15693010 · NCT00940862 · Psoriasis
  7. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept.
    Lizzul PF, Aphale A, Malaviya R, et al. · J Invest Dermatol · 2005 · Background
    PubMed: PMID 15955104 · NCT00932113 (MOA) · Psoriasis
  8. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease.
    Lichtenstein GR, Yan S, Bala M, et al. · Gastroenterology · 2005 · Background
    PubMed: PMID 15825070 · NCT02994836 · Crohn Disease
  9. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine.
    Lémann M, Mary JY, Colombel JF, et al. · Gastroenterology · 2005 · Background
    PubMed: PMID 15940616 · NCT02852694 (RCT) · Crohn Disease
  10. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis.
    Kang CP, Lee KW, Yoo DH, et al. · Rheumatology (Oxford) · 2005 · Background
    PubMed: PMID 15695296 · NCT02878161 · Arthritis, Rheumatoid
  11. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.
    Jacobsson LT, Turesson C, Gülfe A, et al. · J Rheumatol · 2005 · Background
    PubMed: PMID 15996054 · NCT00940862 · Psoriasis
  12. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.
    Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. · Am J Ophthalmol · 2005 · Background
    PubMed: PMID 16196117 · NCT02706704 (IVAS) · Uveitis
  13. Inflammation, atherosclerosis, and coronary artery disease.
    Hansson GK · N Engl J Med · 2005 · Background
    PubMed: PMID 15843671 · NCT00940862 · Psoriasis
  14. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques.
    Gottlieb AB, Chamian F, Masud S, et al. · J Immunol · 2005 · Background
    PubMed: PMID 16081850 · NCT00932113 (MOA) · Psoriasis
  15. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s.
    Goodson N, Marks J, Lunt M, et al. · Ann Rheum Dis · 2005 · Background
    PubMed: PMID 15843450 · NCT00940862 · Psoriasis
  16. Determinants of quality of life in patients with psoriasis: a study from the US population.
    Gelfand JM, Feldman SR, Stern RS, et al. · J Am Acad Dermatol · 2005 · Background
    PubMed: PMID 15523347 · NCT00940862 · Psoriasis
  17. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.
    Daperno M, D'Haens G, Van Assche G, et al. · Gastrointest Endosc · 2005 · Background
    PubMed: PMID 15472670 · NCT02994836 · Crohn Disease
  18. Management of sight-threatening uveitis: new therapeutic options.
    Becker MD, Smith JR, Max R, et al. · Drugs · 2005 · Background
    PubMed: PMID 15733012 · NCT00348153 · Uveitis
  19. Human brain mechanisms of pain perception and regulation in health and disease.
    Apkarian AV, Bushnell MC, Treede RD, et al. · Eur J Pain · 2005 · Background
    PubMed: PMID 15979027 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  20. Methotrexate for induction of remission in refractory Crohn's disease.
    Alfadhli AA, McDonald JW, Feagan BG, et al. · Cochrane Database Syst Rev · 2005 · Background
    PubMed: PMID 15674908 · NCT02852694 (RCT) · Crohn Disease

2004 (20 papers)

  1. Inflammatory bowel disease (ulcerative colitis and Crohn's disease): diagnostic criteria and differential diagnosis.
    Winther KV, Føgh P, Thomsen OØ, et al. · Drugs Today (Barc) · 2004 · Background
    PubMed: PMID 14743262 · NCT02852694 (RCT) · Crohn Disease
  2. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study.
    Sihvonen S, Korpela M, Laippala P, et al. · Scand J Rheumatol · 2004 · Background
    PubMed: PMID 15370716 · NCT03619876 (AMiRA) · Arthritis, Rheumatoid
  3. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
    Roehrborn CG, Bruskewitz R, Nickel JC, et al. · J Urol · 2004 · Background
    PubMed: PMID 14767299 · NCT06062875 · Prostatic Hyperplasia
  4. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27.
    Pérez-Guijo V, Santos-Lacomba M, Sánchez-Hernández M, et al. · Curr Med Res Opin · 2004 · Background
    PubMed: PMID 15006008 · NCT02706704 (IVAS) · Uveitis
  5. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences.
    Loftus EV · Gastroenterology · 2004 · Background
    PubMed: PMID 15168363 · NCT03885713 (BioIBD) · Crohn Disease
  6. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo.
    Kiesslich R, Burg J, Vieth M, et al. · Gastroenterology · 2004 · Background
    PubMed: PMID 15362025 · NCT01275508 (FA-Crohn) · Crohn Disease
  7. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC, Kavanaugh AF, Sharp JT, et al. · Arthritis Rheum · 2004 · Background
    PubMed: PMID 15146409 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  8. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine.
    Johnston IN, Milligan ED, Wieseler-Frank J, et al. · J Neurosci · 2004 · Background
    PubMed: PMID 15317861 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  9. Proteomic analysis of the intestinal epithelial cell response to enteropathogenic Escherichia coli.
    Hardwidge PR, Rodriguez-Escudero I, Goode D, et al. · J Biol Chem · 2004 · Background
    PubMed: PMID 14988394 · NCT03885713 (BioIBD) · Crohn Disease
  10. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study.
    Genevay S, Stingelin S, Gabay C, et al. · Ann Rheum Dis · 2004 · Background
    PubMed: PMID 15115710 · NCT01510548 · Pain
  11. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE, Schiff MH, Fleischmann RM, et al. · J Rheumatol · 2004 · Background
    PubMed: PMID 14719195 · NCT03172325
  12. Heart rate variability in patients with rheumatoid arthritis.
    Evrengül H, Dursunoglu D, Cobankara V, et al. · Rheumatol Int · 2004 · Background
    PubMed: PMID 14523570 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  13. Inflammatory bowel disease: the role of environmental factors.
    Danese S, Sans M, Fiocchi C, et al. · Autoimmun Rev · 2004 · Background
    PubMed: PMID 15288007 · NCT05313620 · Colitis, Ulcerative
  14. Role of TNF-alpha in sensitization of nociceptive dorsal horn neurons induced by application of nucleus pulposus to L5 dorsal root ganglion in rats.
    Cuellar MJ, Montesano XP, Carstens E, et al. · Pain · 2004 · Background
    PubMed: PMID 15288398 · NCT01510548 · Pain
  15. TNF-alpha blockade for herniated intervertebral disc-induced sciatica: a way forward at last?
    Cooper RG, Freemont AJ · Rheumatology (Oxford) · 2004 · Background
    PubMed: PMID 13130150 · NCT01510548 · Pain
  16. Quality of life issues in psoriasis.
    Choi J, Koo JY · J Am Acad Dermatol · 2004 · Background
    PubMed: PMID 12894127 · NCT00940862 · Psoriasis
  17. Biological therapies in the spondyloarthritides--the current state.
    Braun J, Sieper J · Rheumatology (Oxford) · 2004 · Background
    PubMed: PMID 15187239 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  18. Etanercept for the treatment of rheumatoid arthritis.
    Blumenauer B, Judd M, Cranney A, et al. · Cochrane Database Syst Rev · 2004 · Background
    PubMed: PMID 14584021 · NCT03172325
  19. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study.
    Ardizzone S, Bollani S, Manzionna G, et al. · Dig Liver Dis · 2004 · Background
    PubMed: PMID 14563183 · NCT02852694 (RCT) · Crohn Disease
  20. Shortened questionnaire on quality of life for inflammatory bowel disease.
    Alcalá MJ, Casellas F, Fontanet G, et al. · Inflamm Bowel Dis · 2004 · Background
    PubMed: PMID 15475746 · NCT02994836 · Crohn Disease

2003 (19 papers)

  1. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis.
    Wolfe F, Freundlich B, Straus WL, et al. · J Rheumatol · 2003 · Background
    PubMed: PMID 12508387 · NCT03619876 (AMiRA) · Arthritis, Rheumatoid
  2. [Therapeutic use of anti-TNF-alpha agents in spondyloarthropathies].
    Wendling D, Claudepierre P, Lohse A, et al. · Presse Med · 2003 · Background
    PubMed: PMID 14534471 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  3. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
    Weinblatt ME, Keystone EC, Furst DE, et al. · Arthritis Rheum · 2003 · Background
    PubMed: PMID 12528101 · NCT03172325
  4. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database.
    Watson DJ, Rhodes T, Guess HA, et al. · J Rheumatol · 2003 · Background
    PubMed: PMID 12784389 · NCT00940862 · Psoriasis
  5. The inflammatory reflex.
    Tracey KJ · Nature · 2003 · Background
    PubMed: PMID 12490958 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  6. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.
    Solomon DH, Karlson EW, Rimm EB, et al. · Circulation · 2003 · Background
    PubMed: PMID 12628952 · NCT03619876 (AMiRA) · Arthritis, Rheumatoid
  7. Detection of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia.
    Salemi S, Rethage J, Wollina U, et al. · J Rheumatol · 2003 · Background
    PubMed: PMID 12508404 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  8. Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group.
    Pham T, van der Heijde D, Calin A, et al. · Ann Rheum Dis · 2003 · Background
    PubMed: PMID 12922951 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  9. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis.
    Padyukov L, Lampa J, Heimbürger M, et al. · Ann Rheum Dis · 2003 · Background
    PubMed: PMID 12759288 · NCT02878161 · Arthritis, Rheumatoid
  10. Epidemiology of fibromyalgia.
    Neumann L, Buskila D · Curr Pain Headache Rep · 2003 · Background
    PubMed: PMID 12946289 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  11. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    McConnell JD, Roehrborn CG, Bautista OM, et al. · N Engl J Med · 2003 · Background
    PubMed: PMID 14681504 · NCT06062875 · Prostatic Hyperplasia
  12. Etanercept as monotherapy in patients with psoriasis.
    Leonardi CL, Powers JL, Matheson RT, et al. · N Engl J Med · 2003 · Background
    PubMed: PMID 14627786 · NCT00940862 · Psoriasis
  13. Fluorescence endoscopy using a fluorescein-labeled monoclonal antibody against carcinoembryonic antigen in patients with colorectal carcinoma and adenoma.
    Keller R, Winde G, Terpe HJ, et al. · Endoscopy · 2003 · Background
    PubMed: PMID 12244502 · NCT01275508 (FA-Crohn) · Crohn Disease
  14. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
    Heydendael VM, Spuls PI, Opmeer BC, et al. · N Engl J Med · 2003 · Background
    PubMed: PMID 12917302 · NCT02330380 · Psoriasis
  15. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.
    den Broeder A, van de Putte L, Rau R, et al. · J Rheumatol · 2003 · Background
    PubMed: PMID 12415583 · NCT03172325
  16. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.
    Braun J, Pham T, Sieper J, et al. · Ann Rheum Dis · 2003 · Background
    PubMed: PMID 12922952 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  17. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J, Khariouzov A, Listing J, et al. · Arthritis Rheum · 2003 · Background
    PubMed: PMID 12794835 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  18. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?
    Baeten D, Kruithof E, Van den Bosch F, et al. · Ann Rheum Dis · 2003 · Background
    PubMed: PMID 12922954 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  19. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F, Noman M, Vermeire S, et al. · N Engl J Med · 2003 · Background
    PubMed: PMID 12584368 · NCT01716039 · Colitis, Ulcerative

2002 (10 papers)

  1. Quantifying the harmful effect of psoriasis on health-related quality of life.
    Weiss SC, Kimball AB, Liewehr DJ, et al. · J Am Acad Dermatol · 2002 · Background
    PubMed: PMID 12271293 · NCT00940862 · Psoriasis
  2. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.
    Van Den Bosch F, Kruithof E, Baeten D, et al. · Arthritis Rheum · 2002 · Background
    PubMed: PMID 11920412 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  3. Topical agents for the treatment of psoriasis, past, present and future.
    Tremblay JF, Bissonnette R · J Cutan Med Surg · 2002 · Background
    PubMed: PMID 11976984 · NCT00940862 · Psoriasis
  4. Binding and functional comparisons of two types of tumor necrosis factor antagonists.
    Scallon B, Cai A, Solowski N, et al. · J Pharmacol Exp Ther · 2002 · Background
    PubMed: PMID 11961039 · NCT03172325
  5. Platelets and thrombin generation.
    Monroe DM, Hoffman M, Roberts HR, et al. · Arterioscler Thromb Vasc Biol · 2002 · Background
    PubMed: PMID 12231555 · NCT05313620 · Colitis, Ulcerative
  6. Blockade of T cell costimulatory signals using adenovirus vectors prevents both the induction and the progression of experimental autoimmune myocarditis.
    Matsui Y, Inobe M, Okamoto H, et al. · J Mol Cell Cardiol · 2002 · Background
    PubMed: PMID 11945021 · NCT03619876 (AMiRA) · Arthritis, Rheumatoid
  7. Somatosensory perception and function of diffuse noxious inhibitory controls (DNIC) in patients suffering from rheumatoid arthritis.
    Leffler AS, Kosek E, Lerndal T, et al. · Eur J Pain · 2002 · Background
    PubMed: PMID 11900476 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  8. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.
    Braun J, Brandt J, Listing J, et al. · Lancet · 2002 · Background
    PubMed: PMID 11955536 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  9. Control of synaptic strength by glial TNFalpha.
    Beattie EC, Stellwagen D, Morishita W, et al. · Science · 2002 · Background
    PubMed: PMID 11910117 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  10. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases.
    Barceló-Batllori S, André M, Servis C, et al. · Proteomics · 2002 · Background
    PubMed: PMID 11987129 · NCT03885713 (BioIBD) · Crohn Disease

2001 (6 papers)

  1. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.
    Smith JR, Levinson RD, Holland GN, et al. · Arthritis Rheum · 2001 · Background
    PubMed: PMID 11409666 · NCT00348153 · Uveitis
  2. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis.
    Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, et al. · Ophthalmic Res · 2001 · Background
    PubMed: PMID 11586057 · NCT02706704 (IVAS) · Uveitis
  3. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice.
    International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. · J Postgrad Med · 2001 · Background
    PubMed: PMID 11590294 · NCT06291948 · Arthritis, Rheumatoid
  4. Autonomic nervous system derangement in fibromyalgia syndrome and related disorders.
    Cohen H, Neumann L, Kotler M, et al. · Isr Med Assoc J · 2001 · Background
    PubMed: PMID 11692551 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  5. Cytokine pathways and joint inflammation in rheumatoid arthritis.
    Choy EH, Panayi GS · N Engl J Med · 2001 · Background
    PubMed: PMID 11259725 · NCT01793519 (STARA) · Arthritis, Rheumatoid
  6. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy.
    Braun J, de Keyser F, Brandt J, et al. · Curr Opin Rheumatol · 2001 · Background
    PubMed: PMID 11555723 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing

2000 (4 papers)

  1. Azathioprine for maintaining remission of Crohn's disease.
    Pearson DC, May GR, Fick G, et al. · Cochrane Database Syst Rev · 2000 · Background
    PubMed: PMID 10796482 · NCT02852694 (RCT) · Crohn Disease
  2. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.
    Markowitz J, Grancher K, Kohn N, et al. · Gastroenterology · 2000 · Background
    PubMed: PMID 11040176 · NCT02852694 (RCT) · Crohn Disease
  3. Methotrexate in Crohn's disease: long-term efficacy and toxicity.
    Lémann M, Zenjari T, Bouhnik Y, et al. · Am J Gastroenterol · 2000 · Background
    PubMed: PMID 10925976 · NCT02852694 (RCT) · Crohn Disease
  4. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.
    Feagan BG, Fedorak RN, Irvine EJ, et al. · N Engl J Med · 2000 · Background
    PubMed: PMID 10833208 · NCT02852694 (RCT) · Crohn Disease

1999 (2 papers)

  1. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline.
    Yelin E, Wanke LA · Arthritis Rheum · 1999 · Background
    PubMed: PMID 10366114 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  2. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine.
    D'Haens G, Geboes K, Rutgeerts P, et al. · Gastrointest Endosc · 1999 · Background
    PubMed: PMID 10536324 · NCT02852694 (RCT) · Crohn Disease

1998 (8 papers)

  1. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts.
    van Gestel AM, Haagsma CJ, van Riel PL, et al. · Arthritis Rheum · 1998 · Background
    PubMed: PMID 9778226 · NCT00796705 · Arthritis, Rheumatoid
  2. Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9.
    Trocmé C, Gaudin P, Berthier S, et al. · J Biol Chem · 1998 · Background
    PubMed: PMID 9685427 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  3. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well.
    Symmons DP, Jones MA, Scott DL, et al. · J Rheumatol · 1998 · Background
    PubMed: PMID 9632066 · NCT03619876 (AMiRA) · Arthritis, Rheumatoid
  4. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
    McConnell JD, Bruskewitz R, Walsh P, et al. · N Engl J Med · 1998 · Background
    PubMed: PMID 9475762 · NCT06062875 · Prostatic Hyperplasia
  5. Methotrexate in patients with Crohn's disease after 6-mercaptopurine.
    Mack DR, Young R, Kaufman SS, et al. · J Pediatr · 1998 · Background
    PubMed: PMID 9602195 · NCT02852694 (RCT) · Crohn Disease
  6. The heart in rheumatoid arthritis (rheumatoid disease). A clinical and pathological study of sixty-two cases.
    LEBOWITZ WB · Ann Intern Med · 1998 · Background
    PubMed: PMID 13928929 · NCT03619876 (AMiRA) · Arthritis, Rheumatoid
  7. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States.
    Lawrence RC, Helmick CG, Arnett FC, et al. · Arthritis Rheum · 1998 · Background
    PubMed: PMID 9588729 · NCT01793519 (STARA) · Arthritis, Rheumatoid
  8. Rheumatoid heart disease. A study of the incidence and nature of cardiac lesions in rheumatoid arthritis.
    CATHCART ES, SPODICK DH · N Engl J Med · 1998 · Background
    PubMed: PMID 13877345 · NCT03619876 (AMiRA) · Arthritis, Rheumatoid

1997 (3 papers)

  1. Pain in the rheumatic diseases.
    Thompson PW, Carr AJ · Ann Rheum Dis · 1997 · Background
    PubMed: PMID 9227173 · NCT01197144 (PARADE) · Arthritis, Rheumatoid
  2. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial.
    Oren R, Moshkowitz M, Odes S, et al. · Am J Gastroenterol · 1997 · Background
    PubMed: PMID 9399753 · NCT02852694 (RCT) · Crohn Disease
  3. Food control surveys of polychlorinated dibenzo-p-dioxins and dibenzofurans and intake estimates.
    Hallikainen A, Vartiainen T · Food Addit Contam · 1997 · Background
    PubMed: PMID 9205564 · NCT03172325

1996 (4 papers)

  1. CARDIAC INVOLVEMENT IN RHEUMATOID ARTHRITIS AND ALLIED DISORDERS: CURRENT CONCEPTS.
    SOKOLOFF L · Mod Concepts Cardiovasc Dis · 1996 · Background
    PubMed: PMID 14144874 · NCT03619876 (AMiRA) · Arthritis, Rheumatoid
  2. The cost of rheumatoid arthritis.
    McIntosh E · Br J Rheumatol · 1996 · Background
    PubMed: PMID 8761194 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing
  3. Gastrointestinal endoscopy in high-risk patients.
    Cappell MS · Dig Dis · 1996 · Background
    PubMed: PMID 8843979 · NCT00514982 · Colitis
  4. A controlled double blind study of azathioprine in the management of Crohn's disease.
    Candy S, Wright J, Gerber M, et al. · Gut · 1996 · Background
    PubMed: PMID 8549944 · NCT02852694 (RCT) · Crohn Disease

1995 (2 papers)

  1. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.
    Felson DT, Anderson JJ, Boers M, et al. · Arthritis Rheum · 1995 · Background
    PubMed: PMID 7779114 · NCT03172325
  2. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.
    Feagan BG, Rochon J, Fedorak RN, et al. · N Engl J Med · 1995 · Background
    PubMed: PMID 7816064 · NCT02852694 (RCT) · Crohn Disease

1994 (1 paper)

  1. Elderly rheumatoid arthritis patients on steroid treatment tolerate physical training without an increase in disease activity.
    Lyngberg KK, Harreby M, Bentzen H, et al. · Arch Phys Med Rehabil · 1994 · Background
    PubMed: PMID 7979927 · NCT03561649 (PRESHUM) · Spondylitis, Ankylosing

1990 (1 paper)

  1. A patient education program to improve adherence rates with antituberculosis drug regimens.
    Morisky DE, Malotte CK, Choi P, et al. · Health Educ Q · 1990 · Background
    PubMed: PMID 2228629 · NCT02750800 (VALUE) · Arthritis, Rheumatoid

1989 (2 papers)

  1. Assessment of disease progress in psoriasis.
    Marks R, Barton SP, Shuttleworth D, et al. · Arch Dermatol · 1989 · Background
    PubMed: PMID 2643928 · NCT01722214 · Psoriasis
  2. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.
    Kozarek RA, Patterson DJ, Gelfand MD, et al. · Ann Intern Med · 1989 · Background
    PubMed: PMID 2492786 · NCT02852694 (RCT) · Crohn Disease

1986 (1 paper)

  1. Concurrent and predictive validity of a self-reported measure of medication adherence.
    Morisky DE, Green LW, Levine DM, et al. · Med Care · 1986 · Background
    PubMed: PMID 3945130 · NCT02750800 (VALUE) · Arthritis, Rheumatoid

1978 (1 paper)

  1. Severe psoriasis--oral therapy with a new retinoid.
    Fredriksson T, Pettersson U · Dermatologica · 1978 · Background
    PubMed: PMID 357213 · NCT01722214 · Psoriasis

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).